

# First-Line Crizotinib versus Chemotherapy in *ALK*

New England Journal of Medicine

371, 2167-2177

DOI: 10.1056/nejmoa1408440

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of prostaglandin E2 in contractile abnormality induced by calcium ionophore, A23187. <i>Neurology</i> , 1984, 34, 91-91.	1.5	3
2	Cancer-Drug Discovery "Let's Get Ready for the Next Period. <i>New England Journal of Medicine</i> , 2014, 371, 2227-2228.	13.9	9
3	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
5	EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1546-1552.	0.5	34
6	Towards manageable toxicities from targeted lung cancer treatment. <i>Lung Cancer Management</i> , 2015, 4, 279-287.	1.5	0
7	Clinical significance of expanded Foxp3+ Helios <sup>+</sup> regulatory T cells in patients with non-small cell lung cancer. <i>International Journal of Oncology</i> , 2015, 47, 2082-2090.	1.4	22
8	Developing ALK Immunohistochemistry and In Situ Hybridization Proficiency Testing for Non-Small Cell Lung Cancer in Canada. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 677-681.	0.6	8
11	Novel targeted agents for the treatment of lung cancer in China. <i>Cancer</i> , 2015, 121, 3089-3096.	2.0	10
12	Complex renal cysts associated with crizotinib treatment. <i>Cancer Medicine</i> , 2015, 4, 887-896.	1.3	47
13	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. <i>Journal of Internal Medicine</i> , 2015, 278, 545-570.	2.7	46
14	Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1148-1155.	0.5	48
15	Varicella zoster virus infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15016.	18.1	435
16	Current challenges in clinical development of "targeted therapies": the case of acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2461-2466.	0.6	71
18	Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma. <i>Internal Medicine</i> , 2015, 54, 3185-3188.	0.3	7
19	Response to alectinib after one year of discontinuation of crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2015, 3, 889-891.	0.4	1
20	EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer. <i>Oncology Letters</i> , 2015, 10, 3385-3392.	0.8	5
21	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <i>Cell Death Discovery</i> , 2015, 1, 15049.	2.0	37
22	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1337-1346.	2.3	23

#	ARTICLE	IF	CITATIONS
23	Non-Small Cell Lung Cancer, Version 6.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 515-524.	2.3	323
24	More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds. Biomarker Insights, 2015, 10s3, BMI.S22436.	1.0	7
25	Pathological complete response of a patient with ALK-translocated adenocarcinoma of the lung upon treatment with crizotinib followed by alectinib. Cancer Treatment Communications, 2015, 4, 131-133.	0.4	2
28	Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib. Investigational New Drugs, 2015, 33, 1148-1150.	1.2	16
29	SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clinical and Translational Oncology, 2015, 17, 1020-1029.	1.2	43
30	Global efforts in conquering lung cancer in China. Chinese Journal of Cancer, 2015, 34, 320-2.	4.9	9
31	Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chinese Journal of Cancer, 2015, 34, 310-9.	4.9	13
32	Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Research Notes, 2015, 8, 800.	0.6	38
33	Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors. Biomarker Insights, 2015, 10s3, BMI.S22430.	1.0	29
34	Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2015, 21, 404-412.	1.0	23
35	Darkness before dawn, but will the sun always rise?. Cancer, 2015, 121, 2514-2516.	2.0	0
36	ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients. Diagnostic Cytopathology, 2015, 43, 941-946.	0.5	51
37	What have we learned from exceptional tumour responses?. Current Opinion in Oncology, 2015, 27, 267-275.	1.1	8
38	Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer. Cancer Journal (Sudbury, Mass ), 2015, 21, 378-382.	1.0	20
39	The Evolution of Therapies in Non-Small Cell Lung Cancer. Cancers, 2015, 7, 1815-1846.	1.7	107
40	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2015, 6, 35.	1.3	2
41	The distinctive nature of adenocarcinoma of the lung. OncoTargets and Therapy, 2015, 8, 2399.	1.0	16
42	Clinical development of nintedanib for advanced non-small-cell lung cancer. Therapeutics and Clinical Risk Management, 2015, 11, 1701.	0.9	10

#	ARTICLE	IF	CITATIONS
43	Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. <i>OncoTargets and Therapy</i> , 2015, 8, 999.	1.0	11
44	Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 145.	0.4	15
45	Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature. <i>American Journal of Case Reports</i> , 2015, 16, 782-789.	0.3	10
46	Combating Acquired Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e165-e173.	1.8	16
47	Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. <i>Cancers</i> , 2015, 7, 763-783.	1.7	59
48	Epiregulin as a therapeutic target in non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 91.	1.3	24
49	Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5491.	2.0	1
50	First-line treatment of advanced ALK-positive non-small-cell lung cancer. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 71.	1.3	5
51	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211.	1.1	16
52	Crizotinib-Induced Abnormal Signal Processing in the Retina. <i>PLoS ONE</i> , 2015, 10, e0135521.	1.1	17
53	Molecular Markers in the Diagnosis and Treatment of Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	2
54	Ready or Not? Lung Cancer Diagnosis in 2015. <i>Current Oncology</i> , 2015, 22, 239-242.	0.9	2
55	Crizotinib-induced pancreatic pseudocyst: a novel adverse event. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015211556.	0.2	2
56	Best Lung Cancer Research of 2014. <i>Oncology Times</i> , 2015, 37, 1.	0.1	0
57	Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity?. <i>Neuro-Oncology</i> , 2015, 17, 1365-1373.	0.6	44
58	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.4	30
59	Non-small-cell lung cancer. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15009.	18.1	653
60	Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. <i>Lung Cancer</i> , 2015, 89, 104-109.	0.9	69

#	ARTICLE	IF	CITATIONS
61	Nivolumab for advanced squamous cell lung cancer: what are the next steps?. <i>Lancet Oncology</i> , The, 2015, 16, 234-235.	5.1	16
62	Crizotinib in the management of advanced-stage non-small-cell lung cancer. <i>Future Oncology</i> , 2015, 11, 735-745.	1.1	16
63	Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine. <i>Clinical Cancer Research</i> , 2015, 21, 2227-2235.	3.2	236
64	Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4014-4021.	3.2	392
65	Necitumumab for non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1231-1239.	1.4	14
66	New insights into the molecular profile of lung adenocarcinoma and implications for therapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 361-364.	1.1	1
67	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	3.2	104
68	Anaplastic lymphoma kinase: Role in cancer and therapy perspective. <i>Cancer Biology and Therapy</i> , 2015, 16, 1691-1701.	1.5	32
69	Cross-over- it's a feature, not a bug. <i>Annals of Oncology</i> , 2015, 26, 2000-2002.	0.6	1
70	Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 1456-1462.	0.5	20
71	Efficacy of pemetrexed in a patient with brain metastases during crizotinib treatment. <i>Personalized Medicine</i> , 2015, 12, 549-553.	0.8	1
72	First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 614-616.	0.9	16
73	Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9296-9308.	2.9	34
74	Cancers bronchiques non À petites cellules mutés ou réarrangés : de la première à la dernière ligne. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 497-505.	0.0	0
75	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1396-1403.	0.5	76
76	Traitement de 1re ligne des cancers bronchopulmonaires non À petites cellules de stade IV en l'absence d'addiction oncogénique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 404-413.	0.0	0
77	Clinical potential of gene mutations in lung cancer. <i>Clinical and Translational Medicine</i> , 2015, 4, 33.	1.7	36
79	Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. <i>Oncology Research and Treatment</i> , 2015, 38, 291-298.	0.8	82

#	ARTICLE	IF	CITATIONS
80	Future options for ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, 211-219.	0.9	50
81	New standard for ALK-positive NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 66-66.	12.5	0
82	Detecting and targetting oncogenic fusion proteins in the genomic era. <i>Biology of the Cell</i> , 2015, 107, 111-129.	0.7	29
83	Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1035-1036.	0.6	10
84	Innovative Clinical Trials: The LUNGâ€MAP Study. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 488-491.	2.3	56
85	Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. <i>Lung Cancer</i> , 2015, 87, 207-209.	0.9	21
86	Nit-Picking around second line inEGFR NSCLC: just an academic effort. <i>Annals of Oncology</i> , 2015, 26, 448-450.	0.6	0
87	Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2015, 16, e83-e89.	1.1	40
88	Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2015, 754, 82-91.	1.7	31
89	Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 461-477.	1.3	31
90	Advances in target therapy in lung cancer. <i>European Respiratory Review</i> , 2015, 24, 23-29.	3.0	28
91	Cancer bronchique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 138-145.	0.0	0
92	What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 306-317.	2.0	27
93	Successful treatment with alectinib after crizotinib-induced esophageal ulceration. <i>Lung Cancer</i> , 2015, 88, 349-351.	0.9	6
94	Using large-scale genomics data to identify driver mutations in lung cancer: methods and challenges. <i>Pharmacogenomics</i> , 2015, 16, 1149-1160.	0.6	15
95	Alectinib Induces a Durable (&gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. <i>Oncologist</i> , 2015, 20, 224-226.	1.9	48
96	Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy. <i>Clinical Oncology</i> , 2015, 27, 561-569.	0.6	52
97	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1415-1421.	0.6	187

#	ARTICLE	IF	CITATIONS
99	Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer. <i>Molecular Aspects of Medicine</i> , 2015, 45, 55-66.	2.7	26
100	Similitude and evolution of treatment algorithms. <i>Current Medical Research and Opinion</i> , 2015, 31, 1583-1585.	0.9	0
101	Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 871-873.	1.3	11
102	Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. <i>Cancer Research</i> , 2015, 75, 2916-2927.	0.4	40
103	Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2015, 75, 1059-1070.	4.9	17
104	PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. <i>Cancer Cell</i> , 2015, 28, 70-81.	7.7	389
105	Stereotactic Body Radiotherapy for Oligometastatic Disease. <i>Clinical Oncology</i> , 2015, 27, 290-297.	0.6	27
107	Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2015, 16, 325-333.	1.1	65
108	Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2015, 27, 36-48.	0.4	8
109	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
110	Targeting oncogenic drivers in lung cancer: celebrating a decade of progress. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 81-83.	0.3	1
111	Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case. <i>World Journal of Surgical Oncology</i> , 2015, 13, 74.	0.8	6
112	Addressing the unmet need in lung cancer: The potential of immuno-oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 465-475.	3.4	30
113	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
114	Emerging paradigms in targeted treatments for Asian patients with NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1167-1176.	0.9	16
115	Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 255-268.	1.0	24
116	Therapeutic management of ALK+nonsmall cell lung cancer patients. <i>European Respiratory Journal</i> , 2015, 46, 230-242.	3.1	21
117	ALK FISH and IHC: You Cannot Have One without the Other. <i>Journal of Thoracic Oncology</i> , 2015, 10, 548-550.	0.5	41

#	ARTICLE	IF	CITATIONS
118	Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report. <i>Cancer Treatment Communications</i> , 2015, 4, 6-9.	0.4	5
119	Validating <i>ROS1</i> Rearrangements As a Therapeutic Target in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 972-974.	0.8	16
120	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. <i>Pharmacological Research</i> , 2015, 102, 90-106.	3.1	4
121	Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 263-273.	1.4	47
122	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1630-1638.	5.1	75
123	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 538-545.	0.8	14
124	Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 797-805.	2.7	86
126	Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations. <i>Oncologist</i> , 2015, 20, 1175-1181.	1.9	26
127	Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 375-385.	1.1	0
128	The efficacy of ceritinib in patients with <i>ALK</i> -positive non-small cell lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 236-241.	1.0	3
129	First-Line Crizotinib in <i>ALK</i> -Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 781-782.	13.9	22
130	Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. <i>Future Oncology</i> , 2015, 11, 2043-2048.	1.1	35
131	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015, 90, 1-7.	0.9	14
133	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1284-1291.	0.7	7
134	Are We Making Progress in Lung Cancer Using Progression-Free Survival as a Surrogate End Point?. <i>JAMA Oncology</i> , 2015, 1, 202.	3.4	3
135	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
136	Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis. <i>Lung Cancer</i> , 2015, 90, 255-260.	0.9	43
137	Cost-effectiveness of Lung Cancer Screening in Canada. <i>JAMA Oncology</i> , 2015, 1, 807.	3.4	90



#	ARTICLE	IF	CITATIONS
139	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK <sup>+</sup> positive lung cancer. <i>Nature Medicine</i> , 2015, 21, 1038-1047.	15.2	245
140	The impact of the Cancer Genome Atlas on lung cancer. <i>Translational Research</i> , 2015, 166, 568-585.	2.2	83
141	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606
142	Practical Value of Molecular Pathology in Stage III Lung Cancer: Implications for the Clinical Surgeon. <i>Annals of Surgical Oncology</i> , 2015, 22, 3459-3465.	0.7	5
143	Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy. <i>Endocrine-Related Cancer</i> , 2015, 22, L19-L22.	1.6	1
144	Management of Dermatologic Complications of Lung Cancer Therapies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 50.	1.3	13
145	New Treatment Options for ALK-Rearranged Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 49.	1.3	28
146	Treating patients with ALK <sup>+</sup> -positive non-small cell lung cancer: latest evidence and management strategy. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 274-290.	1.4	20
147	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	1.4	22
148	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 366-373.	1.1	23
149	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. <i>Journal of Genetics and Genomics</i> , 2015, 42, 579-587.	1.7	3
150	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015, 90, 369-374.	0.9	70
151	Crizotinib: an orphan drug for treating non-small-cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1209-1218.	0.5	1
152	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. <i>British Journal of Health Care Management</i> , 2016, 22, 486-487.	0.1	0
153	The steady progress of targeted therapies, promising advances for lung cancer. <i>Ecancermedalscience</i> , 2016, 10, 638.	0.6	6
154	Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 1066-1075.	0.8	172
155	ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues. <i>Oncology Reports</i> , 2016, 36, 1427-1434.	1.2	9
156	New treatment options for ALK <sup>+</sup> advanced non-small-cell lung cancer: critical appraisal of ceritinib. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 735.	0.9	13

#	ARTICLE	IF	CITATIONS
157	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. Reviews on Recent Clinical Trials, 2016, 11, 87-92.	0.4	3
158	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer: Targets and Therapy, 2016, 7, 83.	1.3	6
159	Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Case Reports in Oncology, 2016, 9, 212-215.	0.3	12
160	Bilateral breast adenocarcinomas with EML4&mdash;ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site?. OncoTargets and Therapy, 2016, 9, 3589.	1.0	3
161	Canadian Consensus: Inhibition of Alk-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. Current Oncology, 2016, 23, 196-200.	0.9	12
162	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?. Journal of Cancer, 2016, 7, 633-649.	1.2	28
163	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 7275-7283.	1.0	49
164	Precision medicine in lung cancer: the battle continues. Journal of Thoracic Disease, 2016, 8, 2991-2993.	0.6	4
165	Treatment Pathways and Associated Costs of Advanced or Metastatic ALK <sup>+</sup> Non-Small Cell Lung Cancer in Greece. Pharmacoeconomics Open Access, 2016, 01, .	0.1	0
166	ASCENDING the anaplastic lymphoma kinase ladder: a tale of two C-nibs. Journal of Thoracic Disease, 2016, 8, E1514-E1516.	0.6	1
167	Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalsecience, 2016, 10, 648.	0.6	29
168	New targeted treatments for non-small-cell lung cancer &ndash; role of nivolumab. Biologics: Targets and Therapy, 2016, Volume 10, 103-117.	3.0	23
169	Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients. OncoTargets and Therapy, 2016, Volume 9, 4671-4679.	1.0	2
170	The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and Therapy, 2016, 9, 833.	1.0	38
171	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e577-e583.	1.8	2
172	Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. Translational Lung Cancer Research, 2016, 5, 579-587.	1.3	7
173	High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma. Journal of Thoracic Disease, 2016, 8, 1103-1111.	0.6	15
174	Ceritinib in second and further lines of therapy in advanced ALK mutant adenocarcinoma. Journal of Thoracic Disease, 2016, 8, E584-E585.	0.6	0

#	ARTICLE	IF	CITATIONS
175	B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up. <i>Translational Lung Cancer Research</i> , 2016, 5, 367-369.	1.3	8
176	Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. <i>Translational Lung Cancer Research</i> , 2016, 5, 401-412.	1.3	56
177	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC? – current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15
178	ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 660-664.	1.3	0
179	Non-Small-Cell Lung Cancer Treatment. <i>Juntendo Medical Journal</i> , 2016, 62, 7-12.	0.1	1
180	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1517-E1519.	0.6	1
181	Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. <i>Translational Lung Cancer Research</i> , 2016, 5, 301-321.	1.3	37
182	Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.. <i>Journal of Thoracic Disease</i> , 2016, 8, 2997-3002.	0.6	5
183	Second-generation anaplastic lymphoma kinase inhibitors: revolutionary or evolutionary?. <i>Journal of Thoracic Disease</i> , 2016, 8, 1425-1427.	0.6	0
184	Systemic therapy for echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase non-small cell lung cancer brain metastases. <i>Journal of Thoracic Disease</i> , 2016, 8, E1028-E1031.	0.6	0
185	Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 2369-2371.	0.6	3
186	Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial” • <i>Journal of Thoracic Disease</i> , 2016, 8, E1287-E1292.	0.6	2
187	Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation. <i>Journal of Thoracic Disease</i> , 2016, 8, E1311-E1316.	0.6	2
188	Alectinib – a new chapter in the management of ALK-positive lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 343-346.	1.3	3
189	ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. <i>Oncotarget</i> , 2016, 7, 12289-12304.	0.8	22
190	Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice. <i>Oncotarget</i> , 2016, 7, 28748-28760.	0.8	95
191	Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer. <i>Tumori</i> , 2016, 102, S46-S49.	0.6	7
192	Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. <i>Disease Markers</i> , 2016, 2016, 1-14.	0.6	13

#	ARTICLE	IF	CITATIONS
193	Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1186.	1.8	20
194	Epidemiological profile and prognostic factors in patients with lung cancer. <i>Revista Da Associação Médica Brasileira</i> , 2016, 62, 428-433.	0.3	6
195	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6361-6376.	1.0	21
196	Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer. <i>Veterinary Sciences</i> , 2016, 3, 4.	0.6	15
197	Non-small cell lung cancer: current treatment and future advances. <i>Translational Lung Cancer Research</i> , 2016, 5, 288-300.	1.3	1,256
198	Cytostatic Agents – Tyrosine Kinase Inhibitors Utilized in the Treatment of Solid Malignancies. <i>Side Effects of Drugs Annual</i> , 2016, 38, 479-491.	0.6	1
199	Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 65.	1.2	8
200	Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 112.	1.3	23
201	Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1074.	1.8	26
202	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. <i>Respiratory Research</i> , 2016, 17, 105.	1.4	10
203	ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country. <i>PLoS ONE</i> , 2016, 11, e0160752.	1.1	28
204	Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0161081.	1.1	34
205	Oligometastatic non-small-cell lung cancer: current treatment strategies. <i>Lung Cancer: Targets and Therapy</i> , 2016, Volume 7, 129-140.	1.3	11
206	Fatal Haemoptysis Associated with Dramatic Response to Crizotinib in an ALK-Rearranged Lung Adenocarcinoma. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2016, 10, XD01-XD03.	0.8	1
207	Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 308-311.	0.3	32
208	Personalized Therapy in Action. <i>Obstetrics and Gynecology</i> , 2016, 127, 202-203.	1.2	0
209	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	1.9	64
212	Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma. <i>Lung Cancer</i> , 2016, 98, 118-121.	0.9	10

#	ARTICLE	IF	CITATIONS
213	Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (Wrest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf_50 742 T trial. <i>Cancer</i> , 2016, 122, 1050-1059.	2.0	35
214	Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor. <i>Obstetrics and Gynecology</i> , 2016, 127, 222-225.	1.2	4
215	Targeted therapies for treatment of non-small cell lung cancer—Recent advances and future perspectives. <i>International Journal of Cancer</i> , 2016, 138, 2549-2561.	2.3	155
216	Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 559-566.	1.0	41
217	RESPONSE OF UVEAL METASTASES TO ALK INHIBITORS IN ALK-POSITIVE NON-SMALL-CELL LUNG CANCER. <i>Retinal Cases and Brief Reports</i> , 2016, 10, 37-40.	0.3	1
218	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
219	Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1693-1701.	0.9	16
220	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
221	The pharmacogenomics of drug resistance to protein kinase inhibitors. <i>Drug Resistance Updates</i> , 2016, 28, 28-42.	6.5	24
222	Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges. <i>Clinical Lung Cancer</i> , 2016, 17, 507-516.	1.1	43
223	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. <i>Clinical Lung Cancer</i> , 2016, 17, 466-469.	1.1	16
225	Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill. <i>Anti-Cancer Drugs</i> , 2016, 27, 573-575.	0.7	15
226	Reply to J. Jürgens et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1962-1963.	0.8	0
227	BRAF Inhibition in <i>BRAF</i> <sup>V600E</sup> -Positive Anaplastic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 249-254.	2.3	38
228	NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , 2016, 1, e000023.	2.0	444
229	Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors. <i>Lung Cancer</i> , 2016, 102, 38-41.	0.9	58
230	Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review. <i>Internal Medicine</i> , 2016, 55, 507-509.	0.3	7
231	Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 755-761.	1.9	21

#	ARTICLE	IF	CITATIONS
232	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. <i>DMM Disease Models and Mechanisms</i> , 2016, 9, 749-57.	1.2	25
233	Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. <i>Scientific Reports</i> , 2016, 6, 23893.	1.6	92
234	Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed. <i>BMC Cancer</i> , 2016, 16, 417.	1.1	17
235	A convex optimization approach to cancer treatment to address tumor heterogeneity and imperfect drug penetration in physiological compartments. , 2016, , .		11
236	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
237	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. <i>Scientific Reports</i> , 2016, 6, 25952.	1.6	36
238	A Decade of Nilotinib and Dasatinib: From <i>In Vitro</i> Studies to First-Line Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2016, 76, 5911-5913.	0.4	7
241	Genomic Alterationâ€“Driven Clinical Trial Designs in Oncology. <i>Annals of Internal Medicine</i> , 2016, 165, 270.	2.0	40
242	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 837-851.	1.0	14
243	Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational study. <i>Cancer Treatment Communications</i> , 2016, 5, 1-10.	0.4	1
245	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i> -Positive Nonâ€“Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	0.8	216
246	Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit. <i>Clinical Lung Cancer</i> , 2016, 17, 523-527.	1.1	21
247	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€“Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	3.2	977
248	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With <i>EML4-ALK</i> -Positive Nonâ€“Small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2016, 17, e173-e177.	1.1	22
249	Progression-Free Survival, Response Rate, and Disease Control Rate as Predictors of Overall Survival in Phase III Randomized Controlled Trials Evaluating the First-Line Chemotherapy for Advanced, Locally Advanced, and Recurrent Nonâ€“Small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1574-1585.	0.5	22
250	Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. <i>Modern Pathology</i> , 2016, 29, 824-831.	2.9	68
251	miR-29b Mediates NF- $\kappa$ B Signaling in KRAS-Induced Nonâ€“Small Cell Lung Cancers. <i>Cancer Research</i> , 2016, 76, 4160-4169.	0.4	56
252	Specialty pharmacy services for patients receiving oral medications for solid tumors. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 775-796.	0.5	14

#	ARTICLE	IF	CITATIONS
253	Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib. <i>Clinical Lung Cancer</i> , 2016, 17, 528-534.	1.1	39
254	New oncogenes drivers in lung cancer—new therapeutic targets. <i>Current Pulmonology Reports</i> , 2016, 5, 49-56.	0.5	0
255	Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study. <i>Lung Cancer</i> , 2016, 95, 39-43.	0.9	13
256	Management of lung cancer. <i>Medicine</i> , 2016, 44, 244-248.	0.2	2
257	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. <i>Tumor Biology</i> , 2016, 37, 8515-8528.	0.8	47
258	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	0.6	92
259	EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1 $\alpha$ and STAT3. <i>Oncolmmunology</i> , 2016, 5, e1108514.	2.1	124
260	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 25.	1.3	15
261	Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. <i>Cancer Cell</i> , 2016, 29, 508-522.	7.7	226
262	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 32-39.	2.0	15
263	Emerging treatment for ALK-positive lung cancer. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 147-155.	1.0	4
264	Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. <i>Clinical Lung Cancer</i> , 2016, 17, e77-e94.	1.1	27
265	No impact on long-term survival of prolonged ICU stay and re-admission for patients undergoing cytoreductive surgery with HIPEC. <i>European Journal of Surgical Oncology</i> , 2016, 42, 855-860.	0.5	6
266	Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 4948-4964.	2.9	277
267	Emerging agents for the prevention of treatment induced neutropenia in adult cancer patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 157-166.	1.0	6
268	Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 737-749.	1.5	24
269	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 822-835.	5.1	390
272	Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2016, 12, 141-150.	1.0	40

#	ARTICLE	IF	CITATIONS
273	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
274	Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 615-623.	1.1	21
275	The role of the ALK receptor in cancer biology. <i>Annals of Oncology</i> , 2016, 27, iii4-iii15.	0.6	250
276	Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1287-1292.	0.8	11
277	The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options – an overview. <i>Annals of Oncology</i> , 2016, 27, iii1-iii3.	0.6	8
278	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2016, 22, 5772-5782.	3.2	279
279	Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. <i>Cancer Medicine</i> , 2016, 5, 2694-2700.	1.3	26
281	A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. <i>British Journal of Cancer</i> , 2016, 115, 784-788.	2.9	18
282	Resisting Resistance: Targeted Therapies in Lung Cancer. <i>Trends in Cancer</i> , 2016, 2, 350-364.	3.8	162
283	Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. <i>Cell Research</i> , 2016, 26, 1149-1164.	5.7	26
284	The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1229-1241.	1.0	9
285	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2253-2266.	0.9	26
286	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2016, 115, 549-552.	2.9	11
287	Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 4079-4085.	0.8	171
288	Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?. <i>Oncologist</i> , 2016, 21, 662-663.	1.9	26
289	Clinical outcome of reflex EGFR mutation and ALK fusion testing in patients with non-squamous non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 75-80.	0.7	0
290	Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1892-1893.	13.9	17
291	Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer. <i>World Neurosurgery</i> , 2016, 95, 399-405.	0.7	6



#	ARTICLE	IF	CITATIONS
292	Prognostic and Predictive Value of KRAS Mutation in NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, e128-e129.	0.5	1
293	A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. <i>Journal of Thoracic Oncology</i> , 2016, 11, e126-e128.	0.5	9
294	Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. <i>Lung Cancer</i> , 2016, 99, 166-171.	0.9	49
295	Differential Sensitivity to Crizotinib: Does <i>EML4-ALK</i> Fusion Variant Matter?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3363-3365.	0.8	23
296	The renal effects of ALK inhibitors. <i>Investigational New Drugs</i> , 2016, 34, 643-649.	1.2	34
297	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 221-233.	0.4	15
298	Common Fluorescence In Situ Hybridization Applications in Cytology. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1323-1330.	1.2	38
299	Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials ( <i>PROFILE</i> 1005 and 1007). <i>Cancer Medicine</i> , 2016, 5, 617-622.	1.3	46
300	Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in <i>ALK</i> -positive advanced lung adenocarcinoma? A retrospective study of Chinese patients. <i>Cancer Medicine</i> , 2016, 5, 1013-1021.	1.3	20
301	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
302	Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma. <i>Thoracic Cancer</i> , 2016, 7, 3-8.	0.8	14
303	Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2016, 7, 452-458.	0.8	8
304	Sufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib. <i>Clinical and Translational Science</i> , 2016, 9, 63-73.	1.5	14
305	Immunotherapy for lung cancer. <i>Respirology</i> , 2016, 21, 821-833.	1.3	268
306	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. <i>Future Oncology</i> , 2016, 12, 2713-2727.	1.1	18
307	Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2027-2032.	0.5	85
308	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
309	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet</i> , 2016, 388, 1002-1011.	6.3	132

#	ARTICLE	IF	CITATIONS
310	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016, 388, 1012-1024.	6.3	381
311	Patients with <i>ROS1</i> rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 2688-2693.	1.3	35
312	Management of Lung Cancer in the Elderly. <i>Cancer Treatment and Research</i> , 2016, 170, 251-284.	0.2	10
313	Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 54.	1.3	18
314	Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report. <i>Lung Cancer</i> , 2016, 99, 66-68.	0.9	15
315	Testing for <i>ROS1</i> in non-small cell lung cancer: a review with recommendations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 489-503.	1.4	190
316	Targeted Therapies for Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 165-182.	0.2	10
317	Resistance to Therapy. <i>Cancer Treatment and Research</i> , 2016, 170, 183-202.	0.2	10
318	How might treatment of <i>ALK</i> -positive non-small cell lung cancer change in the near future?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 997-999.	1.1	2
319	Stratified Treatment in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 760-766.	0.8	13
320	QSAR-based targeting anaplastic lymphoma kinase (ALK) variants with noncognate inhibitors in pediatric acute lymphoblastic leukemia. <i>Journal of Chemometrics</i> , 2016, 30, 759-765.	0.7	3
321	Next-generation sequencing facilitates detection of the classic E13-A20 <i>EML4-ALK</i> fusion in an <i>ALK-FISH/IHC</i> inconclusive biopsy of a stage IV lung cancer patient: a case report. <i>Diagnostic Pathology</i> , 2016, 11, 133.	0.9	8
322	Crizotinib: from discovery to accelerated development to front-line treatment. <i>Annals of Oncology</i> , 2016, 27, iii35-iii41.	0.6	36
323	Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with <i>ABCB1</i> polymorphism. <i>Cancer Science</i> , 2016, 107, 1117-1123.	1.7	20
324	Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer. <i>Oncologist</i> , 2016, 21, 964-973.	1.9	45
325	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 460-473.	1.4	30
326	Novel therapeutic targets on the horizon for lung cancer. <i>Lancet Oncology, The</i> , 2016, 17, e347-e362.	5.1	156
327	Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the <i>EML4-ALK</i> Fusion Gene ( <i>ALRIGHT/OLCSG1405</i> ). <i>Clinical Lung Cancer</i> , 2016, 17, 602-605.	1.1	10

#	ARTICLE	IF	CITATIONS
328	Treatment of Stage IIIA Non-Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist. <i>Journal of Oncology Practice</i> , 2016, 12, 601-606.	2.5	13
329	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1974-1982.	0.8	49
330	Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. <i>Oncogenesis</i> , 2016, 5, e241-e241.	2.1	49
331	FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib. <i>Clinical Cancer Research</i> , 2016, 22, 5171-5176.	3.2	90
332	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
333	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	0.8	316
334	Testicular metastasis from ALK-rearranged non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 32-34.	0.7	0
335	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
337	Novel kinase fusion transcripts found in endometrial cancer. <i>Scientific Reports</i> , 2016, 5, 18657.	1.6	11
338	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. <i>Forum of Clinical Oncology</i> , 2016, 7, 17-27.	0.1	0
339	The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. <i>Clinical Cancer Research</i> , 2016, 22, 5527-5538.	3.2	263
340	The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis. <i>Scientific Reports</i> , 2016, 6, 35770.	1.6	15
341	Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2016, 17, 1653-1660.	5.1	365
342	Microfluidic enrichment for the single cell analysis of circulating tumor cells. <i>Scientific Reports</i> , 2016, 6, 22076.	1.6	109
343	The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database. <i>Lung Cancer</i> , 2016, 102, 96-100.	0.9	4
345	Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1683-1696.	5.1	298
346	Drug selection for anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, 1627-1628.	5.1	0
347	Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. <i>Lung Cancer</i> , 2016, 102, 89-95.	0.9	223

#	ARTICLE	IF	CITATIONS
348	miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1. <i>Molecular Medicine Reports</i> , 2016, 14, 4135-4143.	1.1	25
349	The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1227-1233.	1.1	6
350	Crizotinib resistance: implications for therapeutic strategies. <i>Annals of Oncology</i> , 2016, 27, iii42-iii50.	0.6	109
351	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in <i>ALK</i>-rearranged lung cancer. <i>Cell Cycle</i> , 2016, 15, 3413-3418.	1.3	49
352	Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5399-5402.	1.0	5
353	A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. <i>Scientific Reports</i> , 2016, 6, 22338.	1.6	49
354	SUV<sub>max</sub> and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 681-686.	0.8	6
355	Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet. <i>Tumori</i> , 2016, 102, 223-225.	0.6	7
357	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v1-v27.	0.6	1,351
358	Post ASCO update 2016â€™lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 215-218.	0.3	0
359	Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 603.	1.1	33
360	Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments. <i>SpringerPlus</i> , 2016, 5, 2083.	1.2	3
361	Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma. <i>Medicine (United States)</i> , 2016, 95, e5077.	0.4	1
362	Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis. <i>Medicine (United States)</i> , 2016, 95, e4221.	0.4	4
363	Best Practices in Treatment Selection for Patients with Advanced NSCLC. <i>Cancer Control</i> , 2016, 23, 2-14.	0.7	7
364	Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Nonâ€™Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5722-5728.	3.2	22
365	ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy. <i>World Journal of Surgical Oncology</i> , 2016, 14, 139.	0.8	7
366	Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms. <i>JAMA Oncology</i> , 2016, 2, 1452.	3.4	279

#	ARTICLE	IF	CITATIONS
367	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 984-993.	5.1	689
368	Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. <i>Journal of Neuro-Oncology</i> , 2016, 129, 355-361.	1.4	25
369	Targeting EGFR and ALK in NSCLC: current evidence and future perspective. <i>Lung Cancer Management</i> , 2016, 5, 79-90.	1.5	1
370	Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer. <i>American Journal of Pathology</i> , 2016, 186, 2162-2170.	1.9	18
371	Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1550-1557.	0.5	39
372	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1627-1643.	0.5	67
373	Alectinib for ALK-positive non-small-cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1005-1013.	1.3	17
374	Use of big data in drug development for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 245-253.	0.4	28
375	Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 319-328.	1.2	77
376	The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. <i>Clinical and Translational Oncology</i> , 2016, 18, 915-924.	1.2	10
377	Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3713-3717.	3.2	62
378	Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib. <i>Journal of Thoracic Oncology</i> , 2016, 11, 256-260.	0.5	59
379	Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 474-482.	1.1	19
380	Phlegmasia cerulea dolens and multiple recurrent thrombotic events as the presenting feature of EML4-ALK translocated non-small cell lung cancer. <i>Cancer Treatment Communications</i> , 2016, 6, 4-7.	0.4	0
381	The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1503-1510.	0.5	61
382	Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 176-187.	1.4	25
383	A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. <i>Gynecologic Oncology</i> , 2016, 142, 144-149.	0.6	13
384	Targeted Therapy and Immunotherapy for Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 601-609.	0.6	99

#	ARTICLE	IF	CITATIONS
385	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
386	Second- and third-generation <i>ALK</i> inhibitors for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 19.	6.9	116
387	First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral <i>ALK</i> inhibitor ASP3026 in patients with advanced solid tumors. <i>Journal of Hematology and Oncology</i> , 2016, 9, 23.	6.9	23
388	Management of Brain Metastases in <i>ALK</i> -Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2814-2819.	0.8	37
389	Stratification in advanced non-small cell lung cancer: precision medicine in practice. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 279-287.	0.4	1
390	Outcomes of chemotherapies and <i>HER2</i> directed therapies in advanced <i>HER2</i> -mutant lung cancers. <i>Lung Cancer</i> , 2016, 99, 53-56.	0.9	45
391	Economic analysis of <i>ALK</i> testing and crizotinib therapy for advanced non-small-cell lung cancer. <i>Pharmacogenomics</i> , 2016, 17, 985-994.	0.6	22
392	Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 877-883.	1.1	2
393	Inflammatory myofibroblastic tumour-like dedifferentiation of anaplastic lymphoma kinase-rearranged lung adenocarcinoma. <i>Histopathology</i> , 2016, 69, 510-515.	1.6	2
394	Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). <i>Surgery Today</i> , 2016, 46, 25-37.	0.7	30
395	Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy – A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. <i>Clinical Oncology</i> , 2016, 28, 327-333.	0.6	4
396	Transformation to SCLC after Treatment with the <i>ALK</i> Inhibitor Alectinib. <i>Journal of Thoracic Oncology</i> , 2016, 11, e67-e72.	0.5	106
397	Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 223-234.	1.1	3
398	Targeted therapy in cancer. <i>Medicine</i> , 2016, 44, 34-38.	0.2	23
399	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. <i>Journal of Clinical Oncology</i> , 2016, 34, 91-101.	0.8	146
400	Alectinib in <i>ALK</i> -positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 234-242.	5.1	574
401	Alectinib in crizotinib-resistant, <i>ALK</i> -positive NSCLC. <i>Lancet Oncology</i> , The, 2016, 17, 134-135.	5.1	2
402	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372

#	ARTICLE	IF	CITATIONS
403	Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment. <i>Cancer Letters</i> , 2016, 380, 216-226.	3.2	42
404	An update of ALK inhibitors in human clinical trials. <i>Future Oncology</i> , 2016, 12, 71-81.	1.1	9
405	Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 113-129.	1.0	125
406	CNS Metastases in Patients With Non-Small-Cell Lung Cancer and <i>ALK</i> Gene Rearrangement. <i>Journal of Clinical Oncology</i> , 2016, 34, 107-109.	0.8	29
407	Alectinib in Crizotinib-Refractory <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	0.8	548
408	Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 203-214.	1.3	6
409	ALK inhibitors: plateauing systemic and intracranial activity?. <i>Lancet Oncology</i> , The, 2016, 17, 404-406.	5.1	7
410	Activity and safety of ceritinib in patients with <i>ALK</i> -rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 452-463.	5.1	418
411	The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 139-162.	3.4	187
412	Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 199-207.	1.2	32
414	2015 and human cancer: back to overall survival. <i>Future Oncology</i> , 2016, 12, 1751-1754.	1.1	0
415	Clinical characteristics associated with non-small-cell lung cancer harboring <i>ALK</i> rearrangements in Chinese patients. <i>Future Oncology</i> , 2016, 12, 1243-1249.	1.1	6
416	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 351-354.	1.2	12
417	Durable brain response with pulse-dose crizotinib and ceritinib in <i>ALK</i> -positive non-small cell lung cancer compared with brain radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2016, 26, 46-49.	0.8	12
418	Treatment modalities for advanced <i>ALK</i> -rearranged non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 945-961.	1.1	17
419	Antitumor activity of alectinib, a selective <i>ALK</i> inhibitor, in an <i>ALK</i> -positive NSCLC cell line harboring G1269A mutation. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 623-628.	1.1	23
420	Crizotinib-induced fatal fulminant liver failure. <i>Lung Cancer</i> , 2016, 93, 17-19.	0.9	22
421	Feasibility of cytological specimens for <i>ALK</i> fusion detection in patients with advanced NSCLC using the method of RT-PCR. <i>Lung Cancer</i> , 2016, 94, 28-34.	0.9	12

#	ARTICLE	IF	CITATIONS
425	Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. Targeted Oncology, 2016, 11, 263-275.	1.7	17
427	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of <i>DDR2</i> . Clinical Cancer Research, 2016, 22, 3663-3671.	3.2	14
428	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. Cancer and Metastasis Reviews, 2016, 35, 141-150.	2.7	25
429	Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling. International Journal of Oncology, 2016, 48, 945-952.	1.4	26
431	Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer, 2016, 16, 143.	1.1	55
432	Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations. Journal of Thoracic Oncology, 2016, 11, 281-283.	0.5	1
433	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. Journal of Thoracic Oncology, 2016, 11, 737-747.	0.5	54
434	Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. Cellular and Molecular Life Sciences, 2016, 73, 1209-1224.	2.4	80
435	Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature Reviews Clinical Oncology, 2016, 13, 209-227.	12.5	177
436	Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib. Expert Review of Anticancer Therapy, 2016, 16, 147-157.	1.1	33
437	Gender, Sex Hormones and Respiratory Disease. Respiratory Medicine, 2016, , .	0.1	5
438	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine, 2016, 3, 54-66.	2.7	123
439	<i>ALK</i> inhibitors in non-small cell lung cancer: the latest evidence and developments. Therapeutic Advances in Medical Oncology, 2016, 8, 32-47.	1.4	106
440	Emerging Options After Progression During Crizotinib Therapy. Journal of Clinical Oncology, 2016, 34, 643-645.	0.8	5
441	Sex-Specific Differences in Lung Cancer. Respiratory Medicine, 2016, , 147-171.	0.1	2
442	Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 590-599.	0.6	35
443	TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value. Critical Reviews in Oncology/Hematology, 2016, 99, 63-73.	2.0	65
444	Characterization of anaplastic lymphoma kinase-positive medulloblastomas. Journal of Clinical Neuroscience, 2016, 23, 120-122.	0.8	3



#	ARTICLE	IF	CITATIONS
445	Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. <i>Lung Cancer</i> , 2016, 91, 23-28.	0.9	112
446	Adult systemic anaplastic large-cell lymphoma: recommendations for diagnosis and management. <i>Expert Review of Hematology</i> , 2016, 9, 137-150.	1.0	20
447	Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents. <i>Annals of Oncology</i> , 2016, 27, 373-378.	0.6	50
448	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 143-155.	1.3	1
449	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. <i>European Radiology</i> , 2016, 26, 2798-2807.	2.3	33
450	Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. <i>Annals of Oncology</i> , 2016, 27, 281-286.	0.6	254
451	MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 778-788.	2.7	23
452	Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. <i>Gastroenterology</i> , 2016, 150, 513-525.e10.	0.6	78
453	ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression. <i>Lung Cancer</i> , 2016, 91, 70-72.	0.9	46
454	Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2016, 17, 223-231.	1.1	57
455	Extended Survival and Prognostic Factors for Patients With <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. <i>Journal of Clinical Oncology</i> , 2016, 34, 123-129.	0.8	284
456	Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). <i>Clinical and Translational Oncology</i> , 2017, 19, 31-43.	1.2	19
457	Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. <i>Lung Cancer</i> , 2017, 107, 100-107.	0.9	128
458	Principles of Kinase Inhibitor Therapy for Solid Tumors. <i>Annals of Surgery</i> , 2017, 265, 311-319.	2.1	10
459	Amphiregulin triggered epidermal growth factor receptor activation confers <i>in vivo</i> crizotinib-resistance of <i>EML4-ALK</i> lung cancer and circumvention by epidermal growth factor receptor inhibitors. <i>Cancer Science</i> , 2017, 108, 53-60.	1.7	28
460	First-line ceritinib versus platinum-based chemotherapy in advanced <i>ALK</i> -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. <i>Lancet</i> , 2017, 389, 917-929.	6.3	919
461	First-line treatment options for <i>ALK</i> -rearranged lung cancer. <i>Lancet</i> , 2017, 389, 884-886.	6.3	7
462	<i>ALK</i> : a tyrosine kinase target for cancer therapy. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001115.	0.5	131

#	ARTICLE	IF	CITATIONS
463	Comparable clinical outcomes in patients with HER2 <sup>+</sup> mutant and EGFR <sup>+</sup> mutant lung adenocarcinomas. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 373-381.	1.5	17
464	ALK -Rearranged Non <sup>+</sup> Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017, 18, 156-161.	1.1	78
465	Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. <i>Clinical Lung Cancer</i> , 2017, 18, 388-395.e4.	1.1	23
466	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
467	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. <i>Cancer Treatment Reviews</i> , 2017, 53, 128-137.	3.4	146
468	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 151-163.	0.9	10
469	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 295-304.	0.9	12
470	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non <sup>+</sup> Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	1.5	62
471	STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3442-3452.	3.2	15
472	CT characteristics of non-small cell lung cancer with epidermal growth factor receptor mutation: a systematic review and meta-analysis. <i>BMC Medical Imaging</i> , 2017, 17, 5.	1.4	43
473	<i>ALK</i> gene alterations in cancer: biological aspects and therapeutic implications. <i>Pharmacogenomics</i> , 2017, 18, 277-292.	0.6	8
474	Targeting ALK: Precision Medicine Takes on Drug Resistance. <i>Cancer Discovery</i> , 2017, 7, 137-155.	7.7	405
475	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , 2017, 66, 1166-1172.	1.8	178
476	Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution. <i>Cancer Imaging</i> , 2017, 17, 7.	1.2	19
477	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2017, 25, 1713-1739.	1.0	125
479	Optimal management of ALK -positive NSCLC progressing on crizotinib. <i>Lung Cancer</i> , 2017, 106, 58-66.	0.9	33
480	<i>Ex Vivo</i> Explant Cultures of Non <sup>+</sup> Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. <i>Cancer Research</i> , 2017, 77, 2029-2039.	0.4	64
481	Safety of alectinib for the treatment of metastatic <i>ALK</i> -rearranged non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 509-514.	1.0	10

#	ARTICLE	IF	CITATIONS
483	Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. <i>Cancer Treatment Reviews</i> , 2017, 55, 83-95.	3.4	58
484	Looking back and to the future: Are we improving "cure"™ in non-small cell lung cancer?. <i>European Journal of Cancer</i> , 2017, 75, 192-194.	1.3	13
485	Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry. <i>Clinical Lung Cancer</i> , 2017, 18, 535-542.	1.1	8
486	Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu A1401). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1161-1166.	0.5	42
487	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	1.9	8
488	Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1372-1379.	0.5	29
489	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>TJ ETQq0 0,0,rgBT /Overlock 10</i>	0.7	34
490	Optimizing Treatment for Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 625-633.	2.3	24
491	Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. <i>Scientific Reports</i> , 2017, 7, 42259.	1.6	49
492	Checkpoint Blockade in Lung Cancer and Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 274-282.	2.5	59
493	Biological therapies in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601520.	3.1	37
494	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , 2017, 7, 400-409.	7.7	647
495	Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer. , 2017, 177, 1-8.		30
496	The changing landscape of clinical trial and approval processes in China. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 577-583.	12.5	46
497	A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 804-813.	0.5	46
498	Layered double hydroxide bio-composites toward excellent systematic anticancer therapy. <i>Journal of Materials Chemistry B</i> , 2017, 5, 3212-3216.	2.9	20
500	Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review. <i>Cancer Biology and Therapy</i> , 2017, 18, 279-284.	1.5	9
501	Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. <i>Advances in Therapy</i> , 2017, 34, 1145-1156.	1.3	15

#	ARTICLE	IF	CITATIONS
502	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <i>European Journal of Cancer</i> , 2017, 78, 16-23.	1.3	108
503	EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. <i>Cancer Research</i> , 2017, 77, 3551-3563.	0.4	65
504	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , 2017, 6, 139-151.	1.2	12
505	Characteristics and outcomes of <i>ALK</i> + non-small cell lung cancer patients in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e239-e245.	0.7	6
506	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017, 2, e000174.	2.0	3
507	Alectinib versus crizotinib in patients with <i>ALK</i> -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet, The</i> , 2017, 390, 29-39.	6.3	753
508	Treatment of <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1835.	3.8	12
509	J-ALEX: alectinib versus crizotinib in <i>ALK</i> -positive lung cancer. <i>Lancet, The</i> , 2017, 390, 3-4.	6.3	11
510	Hypopharyngeal and upper esophageal ulceration after cervical spine radiotherapy concurrent with crizotinib. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 589-592.	1.0	5
511	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Patients. <i>Cancer Research</i> , 2017, 77, 2222-2230.	0.4	64
512	<i>AJRCCM</i> : 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1150-1160.	2.5	75
513	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 713-722.	1.9	17
514	Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. <i>Medical Oncology</i> , 2017, 34, 105.	1.2	47
515	Immunotherapy in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 131-141.	0.9	31
516	Systemic Treatment of Brain Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 157-176.	0.9	8
517	Lung Cancer Biomarkers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 13-29.	0.9	180
518	Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 31-44.	0.9	6
519	Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 101-111.	0.9	32

#	ARTICLE	IF	CITATIONS
520	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <i>Respiration</i> , 2017, 93, 1-14.	1.2	7
521	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials. <i>JAMA Oncology</i> , 2017, 3, e171029.	3.4	70
522	Small Molecule Inhibitors of ALK. <i>Topics in Medicinal Chemistry</i> , 2017, , 435-467.	0.4	4
523	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , 2017, 111, 30-37.	0.9	27
524	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 563-569.	1.7	71
525	A Case of Metastatic Atypical Neuroendocrine Tumor with <i>ALK</i> Translocation and Diffuse Brain Metastases. <i>Oncologist</i> , 2017, 22, 768-773.	1.9	33
526	Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 3527-3539.	0.4	42
527	Flexible 19-Gauge Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Needle: First Experience. <i>Respiration</i> , 2017, 94, 52-57.	1.2	48
528	Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2017, 18, 692-697.	1.1	49
529	Mechanisms of Primary Drug Resistance in <i>FGFR1</i> -Amplified Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5527-5536.	3.2	44
530	Identifying "super responders" in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 300-311.	0.8	19
531	Complete remission of intrathecal metastases with lorlatinib therapy in a heavily pretreated ALK-positive lung cancer patient. <i>Anti-Cancer Drugs</i> , 2017, 28, 928-930.	0.7	17
532	Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory non-small cell lung cancer patient with a poor performance status. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 927-930.	0.2	5
533	Lung cancer samples preserved in liquid medium: One step beyond cytology. <i>Diagnostic Cytopathology</i> , 2017, 45, 915-921.	0.5	1
534	Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients. <i>Advances in Therapy</i> , 2017, 34, 1673-1685.	1.3	5
535	Involvement of glycogen debranching enzyme in bladder cancer. <i>Biomedical Reports</i> , 2017, 6, 595-598.	0.9	3
536	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 874-886.	5.1	453
537	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 36.	1.3	14

#	ARTICLE	IF	CITATIONS
538	Self-Assembled ZnO Nanoparticle Capsules for Carrying and Delivering Isotretinoin to Cancer Cells. ACS Applied Materials & Interfaces, 2017, 9, 18474-18481.	4.0	38
539	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. Personalized Medicine, 2017, 14, 309-325.	0.8	22
540	Ascending role of next-generation ALK inhibitors. Lancet Oncology, The, 2017, 18, 837-839.	5.1	5
541	Scientific Advances in Thoracic Oncology 2016. Journal of Thoracic Oncology, 2017, 12, 1183-1209.	0.5	40
542	Impact of <sc>MET</sc> inhibition on smallâ€cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/<sc>MET</sc> pathway. Cancer Science, 2017, 108, 1378-1385.	1.7	20
543	Management of ceritinib therapy and adverse events in patients with ALK -rearranged non-small cell lung cancer. Lung Cancer, 2017, 111, 51-58.	0.9	15
544	Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma. Laboratory Investigation, 2017, 97, 1332-1342.	1.7	23
545	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	5.8	55
546	Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 405-414.	1.4	35
547	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews, 2017, 55, 181-189.	3.4	12
548	Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset. Japanese Journal of Clinical Oncology, 2017, 47, 618-624.	0.6	14
549	A large, singleâ€center, realâ€world study of clinicopathological characteristics and treatment in advanced <sc>ALK</sc>-positive nonâ€smallâ€cell lung cancer. Cancer Medicine, 2017, 6, 953-961.	1.3	15
550	Milestones in the systemic treatment of lung cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 22-26.	0.3	8
551	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
552	Targeted Treatment of Brain Metastases. Current Neurology and Neuroscience Reports, 2017, 17, 37.	2.0	28
553	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	7.7	490
554	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. BMC Medicine, 2017, 15, 55.	2.3	65
555	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. Handbook of Experimental Pharmacology, 2017, 249, 63-89.	0.9	10

#	ARTICLE	IF	CITATIONS
556	Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opinion on Biological Therapy, 2017, 17, 781-789.	1.4	13
557	Clinical features of <i>Bim</i> deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with <i>ALK</i> / <i>ROS1</i> fusion-positive non-small cell lung cancer. Cancer, 2017, 123, 2927-2935.	2.0	36
558	Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and Tj ETQq0 0 Origt/Ovcrlock 10 Tf		
559	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. Drugs, 2017, 77, 713-719.	4.9	33
560	Molecular biomarkers for lung adenocarcinoma. European Respiratory Journal, 2017, 49, 1601734.	3.1	110
561	Spatiotemporal diversification of inpatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. Drug Discovery Today, 2017, 22, 1148-1164.	3.2	30
562	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. Radiotherapy and Oncology, 2017, 123, 195-202.	0.3	43
563	Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy. Lung Cancer, 2017, 109, 147-148.	0.9	1
564	The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib. Journal of Medical Economics, 2017, 20, 671-677.	1.0	28
565	Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 909-919.	1.7	5
566	Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clinical Lung Cancer, 2017, 18, 472-479.	1.1	44
567	SBRT for oligoprogressive oncogene addicted NSCLC. Lung Cancer, 2017, 106, 50-57.	0.9	49
568	Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemotherapy and Pharmacology, 2017, 79, 559-568.	1.1	30
569	First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemotherapy and Pharmacology, 2017, 79, 181-187.	1.1	28
570	Clinicopathological Features and Therapeutic Responses of Chinese Patients with Advanced Lung Adenocarcinoma Harboring an Anaplastic Lymphoma Kinase Rearrangement. Oncology Research and Treatment, 2017, 40, 27-33.	0.8	1
571	Intrahepatic cholangiocarcinoma: current management and emerging therapies. Expert Review of Gastroenterology and Hepatology, 2017, 11, 439-449.	1.4	58
572	Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Journal of Thoracic Oncology, 2017, 12, 681-688.	0.5	58
573	Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clinical Lung Cancer, 2017, 18, e233-e241.	1.1	30

#	ARTICLE	IF	CITATIONS
574	A Histologic Basis for the Efficacy of SBRT to the lung. <i>Journal of Thoracic Oncology</i> , 2017, 12, 510-519.	0.5	82
575	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
576	Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, e251-e258.	1.1	15
577	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 1-12.	2.0	67
578	Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 791-797.	0.6	178
579	Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. <i>Clinical and Translational Oncology</i> , 2017, 19, 658-666.	1.2	21
580	The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking. <i>Histopathology</i> , 2017, 70, 889-895.	1.6	3
581	Understanding and targeting resistance mechanisms in NSCLC. <i>Nature Reviews Cancer</i> , 2017, 17, 637-658.	12.8	679
583	Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. <i>Scientific Reports</i> , 2017, 7, 12277.	1.6	21
584	Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. <i>Scientific Reports</i> , 2017, 7, 12510.	1.6	81
585	Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 378-383.	2.5	90
586	A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 84-89.	1.2	8
588	Molecular Tumor Boards: current practice and future needs. <i>Annals of Oncology</i> , 2017, 28, 3070-3075.	0.6	112
589	Current chemotherapeutic regimens for brain metastases treatment. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 391-399.	1.7	6
590	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	5.1	535
591	ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. <i>Lancet Oncology</i> , The, 2017, 18, 1555-1556.	5.1	2
592	ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. <i>Scientific Reports</i> , 2017, 7, 13955.	1.6	22
593	Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1089-1096.	1.5	16



#	ARTICLE	IF	CITATIONS
594	Targeted Therapy and Imaging Findings. <i>Journal of Thoracic Imaging</i> , 2017, 32, 313-322.	0.8	10
595	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 933-942.	1.5	5
596	The changing diagnostic pathway for lung cancer patients in Shanghai, China. <i>European Journal of Cancer</i> , 2017, 84, 168-172.	1.3	8
597	Fast, Food and Ceritinib in ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1341-1343.	0.5	2
598	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 849-861.	13.9	578
599	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 735-748.	12.5	234
600	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. <i>Targeted Oncology</i> , 2017, 12, 709-718.	1.7	17
601	Who treats lung cancer? Results from a global survey. <i>Respiratory Investigation</i> , 2017, 55, 308-313.	0.9	4
602	Nucleobase-modified polyamidoamine-mediated miR-23b delivery to inhibit the proliferation and migration of lung cancer. <i>Biomaterials Science</i> , 2017, 5, 2268-2275.	2.6	22
604	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1307-1316.	5.1	889
605	An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). <i>Lung Cancer</i> , 2017, 113, 30-36.	0.9	27
606	Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. <i>Future Oncology</i> , 2017, 13, 2629-2644.	1.1	8
607	Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer. <i>Medical Oncology</i> , 2017, 34, 169.	1.2	7
608	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209.	1.7	16
609	Future Clinical Trials. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 791-797.	0.6	4
610	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. <i>Molecular and Clinical Oncology</i> , 2017, 7, 604-608.	0.4	21
611	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 213-222.	1.0	6
612	Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 744-751.	2.9	66

#	ARTICLE	IF	CITATIONS
613	Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer, 2017, 111, 182-189.	0.9	30
614	Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 221-233.	1.4	14
615	Survival Patterns of 5750 Stereotactic Radiosurgeryâ€”Treated Patients with Brain Metastasis as a Function of the Number of Lesions. World Neurosurgery, 2017, 107, 944-951.e1.	0.7	30
617	Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions. Journal of the National Cancer Institute, 2017, 109, .	3.0	6
618	Anaplastic lymphoma kinase rearrangements in non-small-cell lung cancer: novel applications in diagnostics and treatment. Pharmacogenomics, 2017, 18, 1179-1192.	0.6	4
619	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02â€”14 Study). Targeted Oncology, 2017, 12, 833-838.	1.7	8
620	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor ( EGFR ) mutations and anaplastic lymphoma kinase ( ALK ) translocations â€” Still a daily challenge. European Journal of Cancer, 2017, 83, 266-278.	1.3	22
621	Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis. Lung Cancer, 2017, 112, 1-9.	0.9	14
622	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. ESMO Open, 2017, 2, e000200.	2.0	31
623	TRIM59 is a novel potential prognostic biomarker in patients with non-small cell lung cancer: A research based on bioinformatics analysis. Oncology Letters, 2017, 14, 2153-2164.	0.8	21
624	Lung cancer as a cardiotoxic state: a review. Medical Oncology, 2017, 34, 159.	1.2	12
625	Recent Advances in Targeting ROS1 in Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1611-1625.	0.5	194
626	Treatment of <i>ALK</i>-rearranged nonâ€”small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 3-13.	0.7	11
627	Successful oral desensitization with crizotinib after crizotinibâ€”induced hepatitis in an anaplastic lymphoma kinaseâ€”rearranged nonâ€”smallâ€”cell lung cancer patient: A case report. Molecular and Clinical Oncology, 2017, 7, 295-297.	0.4	8
628	Current Landscape of Targeted Therapy in Lung Cancer. Clinical Pharmacology and Therapeutics, 2017, 102, 757-764.	2.3	134
629	Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones. Scientific Reports, 2017, 7, 17524.	1.6	14
630	Characterization of distinct types of KRAS mutation and its impact on firstâ€”line platinumâ€”based chemotherapy in Chinese patients with advanced nonâ€”small cell lung cancer. Oncology Letters, 2017, 14, 6525-6532.	0.8	32
631	Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer, 2017, 114, 90-95.	0.9	24

#	ARTICLE	IF	CITATIONS
632	Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS. Current Treatment Options in Oncology, 2017, 18, 71.	1.3	22
633	Personalised medicine for nonsmall cell lung cancer. European Respiratory Review, 2017, 26, 170066.	3.0	37
634	Crizotinib resistance overcome by ceritinib in an ALK-positive non-small cell lung cancer patient with brain metastases. Medicine (United States), 2017, 96, e8652.	0.4	8
636	What's new in chemotherapy for non-small cell lung cancer?. Memo - Magazine of European Medical Oncology, 2017, 10, 123-126.	0.3	0
637	Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report. Oncology Letters, 2017, 14, 7545-7548.	0.8	4
638	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncology, The, 2017, 18, 1600-1609.	5.1	282
639	Adherence to surveillance guidelines in resected NSCLC: Physician compliance and impact on outcomes. Lung Cancer, 2017, 112, 176-180.	0.9	3
640	Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I <sup>2</sup> Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation. ACS Central Science, 2017, 3, 1208-1220.	5.3	42
641	Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK -positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1552-1560.	0.5	75
642	Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study. Cancer Chemotherapy and Pharmacology, 2017, 80, 461-467.	1.1	9
643	Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK -positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. European Journal of Cancer, 2017, 82, 27-33.	1.3	25
644	Prognostic significance of ABCB1 in stage I lung adenocarcinoma. Oncology Letters, 2017, 14, 313-321.	0.8	10
645	ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack. Oncologist, 2017, 22, 759-761.	1.9	2
646	Desensitization to protein kinase inhibitors. Annals of Allergy, Asthma and Immunology, 2017, 119, 9-15.	0.5	2
648	Recent advances in targeted advanced lung cancer therapy in the elderly. Expert Review of Anticancer Therapy, 2017, 17, 787-797.	1.1	13
649	Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer. Scientific Reports, 2017, 7, 1232.	1.6	79
650	Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC. BMC Cancer, 2017, 17, 412.	1.1	24
651	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58

#	ARTICLE	IF	CITATIONS
652	Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?. <i>Cancer</i> , 2017, 123, 3872-3874.	2.0	4
653	Alectinib for treatment of <i>ALK</i> -positive non-small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 321-335.	1.1	12
654	Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 843-853.	1.4	51
655	Establishment of a Conditional Transgenic Mouse Model Recapitulating <i>EML4-ALK</i> -Positive Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 491-500.	0.5	21
656	Preclinical evaluation of the potential for cytochrome P450 inhibition and induction of the selective <i>ALK</i> inhibitor, alectinib. <i>Xenobiotica</i> , 2017, 47, 1042-1051.	0.5	9
657	Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 257-274.	2.3	4
658	Crizotinib for <i>ROS1</i> patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. <i>Lung Cancer</i> , 2017, 104, 131-133.	0.9	7
659	Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer. <i>International Journal of Cancer</i> , 2017, 140, 1945-1954.	2.3	19
660	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
661	Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 179-193.	0.5	82
662	Targeting <i>MET</i> in Lung Cancer: Will Expectations Finally Be <i>MET</i> ?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 15-26.	0.5	299
663	Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma. <i>Thoracic Cancer</i> , 2017, 8, 8-15.	0.8	13
664	Vandetanib in patients with previously treated <i>RET</i> -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 42-50.	5.2	252
665	Sequential Therapy with Crizotinib and Alectinib in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer: A Multicenter Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 390-396.	0.5	44
666	Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective <i>ALK</i> Inhibitor Alectinib. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 280-291.	0.8	38
667	Lung cancer: current therapies and new targeted treatments. <i>Lancet</i> , 2017, 389, 299-311.	6.3	2,267
669	High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with <i>ROS1</i> -Positive Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 54-64.	0.5	62
670	<i>MET</i> Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without <i>EGFR</i> Mutations. <i>Clinical Lung Cancer</i> , 2017, 18, 213-219.e2.	1.1	13

#	ARTICLE	IF	CITATIONS
671	Highlights of Recent Studies of Metastatic Non-Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 159.	3.4	1
672	Biomarker Development in COPD. Chest, 2017, 151, 455-467.	0.4	36
673	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Molecular Cancer Research, 2017, 15, 106-114.	1.5	54
674	Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro-Oncology, 2017, 19, 22-30.	0.6	32
675	ALK Into the Next Stage. Clinical Lung Cancer, 2017, 18, 122-126.	1.1	6
676	A consensus statement on the gender perspective in lung cancer. Clinical and Translational Oncology, 2017, 19, 527-535.	1.2	26
677	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. Annual Review of Medicine, 2017, 68, 153-168.	5.0	24
678	Epidemiology of Lung Cancer. , 2017, , 347-366.		1
679	ALK alterations and inhibition in lung cancer. Seminars in Cancer Biology, 2017, 42, 81-88.	4.3	33
680	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. The Cochrane Library, 2017, , .	1.5	0
681	Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 829-838.	13.9	1,858
682	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
684	Prise en charge des patients de stade avancé avec remaniement ALK : aujourd'hui et demain (qui sera) Tj ETQq0 0 0 ggBT /Over	0.0	0
686	Altérations moléculaires anciennes et émergentes : quand les rechercher ?. Revue Des Maladies Respiratoires Actualites, 2017, 9, 202-212.	0.0	1
688	Prise en charge du CBNPC chez les sujets âgés. Revue Des Maladies Respiratoires Actualites, 2017, 9, 299-307.	0.0	0
690	Ceritinib: an orphan drug for ALK positive non-small cell lung cancer with robust clinical evidence. Expert Opinion on Orphan Drugs, 2017, 5, 991-997.	0.5	0
691	Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment. Case Reports in Oncology, 2017, 10, 447-451.	0.3	1
692	An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Annals of Oncology, 2017, 28, 2874-2881.	0.6	45

#	ARTICLE	IF	CITATIONS
693	Phase I/II study of alectinib in lung cancer with <i>RET</i> fusion gene: study protocol. <i>Journal of Medical Investigation</i> , 2017, 64, 317-320.	0.2	16
695	Crizotinib may be effective for rheumatoid arthritis: a case report of a rheumatoid arthritis patient with lung cancer. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 49-53.	0.3	2
696	Family with sequence similarity 83, member A is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. <i>Oncology Letters</i> , 2017, 15, 1549-1558.	0.8	8
697	Liquid biopsy genotyping in lung cancer: ready for clinical utility?. <i>Oncotarget</i> , 2017, 8, 18590-18608.	0.8	52
698	Detection of somatic variants and <i>EGFR</i> mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion amplicon cancer hotspot panel and droplet digital polymerase chain reaction. <i>Oncotarget</i> , 2017, 8, 106901-106912.	0.8	20
699	3. Treatment Choice of ALK Inhibitor. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 1101-1107.	0.0	1
700	The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. <i>Oncotarget</i> , 2017, 8, 89194-89202.	0.8	21
701	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 619-629.	1.8	4
702	Ceritinib: a new first-line therapy against ALK-rearranged lung cancer?. <i>AME Medical Journal</i> , 2017, , 50-50.	0.4	0
703	Tyrosine kinase inhibitors: new molecules in non-small cell lung cancer (EGFR AND ALK). <i>ADMET and DMPK</i> , 2017, 5, 1.	1.1	0
704	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 223-236.	0.9	16
705	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. <i>E-cancermedicalscience</i> , 2017, 11, 787.	0.6	34
706	EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. <i>Cancers</i> , 2017, 9, 118.	1.7	147
707	Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells. <i>Frontiers in Pharmacology</i> , 2017, 08, 199.	1.6	45
708	Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2047-2063.	2.0	26
709	An UPLC-MS/MS method for the quantitation of alectinib in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 132, 227-231.	1.4	12
710	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	4.6	25
711	Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 75-82.	1.0	7

#	ARTICLE	IF	CITATIONS
712	Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2195.	1.8	116
714	Translocation Renal Cell Carcinoma: An Update on Clinicopathological and Molecular Features. <i>Cancers</i> , 2017, 9, 111.	1.7	39
715	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1374.	1.8	47
716	Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2017, 4, 39.	1.2	18
717	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38.	1.3	14
718	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43
719	Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	1.9	128
720	The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor. <i>Cancer Management and Research</i> , 2017, Volume 9, 801-811.	0.9	14
721	Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4869-4883.	1.0	26
722	The liquid biopsy in lung cancer. <i>Genes and Cancer</i> , 2017, 7, 355-367.	0.6	27
723	Patients harboring <em>ALK</em> rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3187-3192.	1.0	25
724	Targeting Autophagy in ALK-Associated Cancers. <i>Cancers</i> , 2017, 9, 161.	1.7	15
725	Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4535-4541.	1.0	27
726	Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 169-177.	1.3	8
727	Frequency and clinical relevance of EGFR mutations and EML4&ndash;ALK translocations in octogenarians with non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5179-5186.	1.0	7
728	Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. <i>Oncology Letters</i> , 2017, 15, 3295-3304.	0.8	9
729	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. <i>Journal of Thoracic Disease</i> , 2017, 9, 2560-2571.	0.6	25
730	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. <i>PLoS ONE</i> , 2017, 12, e0186106.	1.1	14

#	ARTICLE	IF	CITATIONS
731	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
732	ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. <i>BMC Cancer</i> , 2017, 17, 471.	1.1	23
734	Overall survival with crizotinib and next-generation ALK inhibitors in <i>ALK</i> -positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. <i>Oncotarget</i> , 2017, 8, 21903-21917.	0.8	140
735	Live, Learn, Pass It on. <i>Journal of Patient Experience</i> , 2017, 4, 162-168.	0.4	7
736	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017, 8, 109818-109835.	0.8	5
737	Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer. <i>American Journal of Case Reports</i> , 2017, 18, 890-893.	0.3	13
738	Targeted therapy for leptomeningeal metastases in non-small cell lung cancer – Changing treatment paradigms. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2017, 29, 535-542.	0.7	10
739	Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. <i>Oncotarget</i> , 2017, 8, 57680-57692.	0.8	62
740	Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2017, 6, 125-128.	1.5	2
741	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.5	15
742	Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with <i>ALK</i> rearrangement. <i>Oncotarget</i> , 2017, 8, 86066-86081.	0.8	11
743	5. New Development of the Lung Cancer Treatment. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 534-539.	0.0	0
744	The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung. <i>Oncology Reports</i> , 2017, 38, 2189-2196.	1.2	5
745	Preoperative serum carcinoembryonic antigen levels are associated with histologic subtype, EGFR mutations, and ALK fusion in patients with completely resected lung adenocarcinoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3345-3351.	1.0	10
746	Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. <i>Oncotarget</i> , 2017, 8, 9996-10006.	0.8	47
747	A Case Report Demonstrating the Potential Clinical Relevance of Liquid Tumor Biopsies in Lung Cancer. <i>Case Reports in Oncology</i> , 2017, 9, 714-717.	0.3	1
748	Molecular Testing of Lung Cancers. <i>Journal of Pathology and Translational Medicine</i> , 2017, 51, 242-254.	0.4	26
749	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 12-17.	1.8	3



#	ARTICLE	IF	CITATIONS
750	Managing Resistance to EGFR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 607-618.	1.8	16
751	Expanding the Roster of ROS1 Inhibitors. Journal of Clinical Oncology, 2017, 35, 2595-2597.	0.8	12
752	Combination of Arginine Depletion and Chemotherapy in Thoracic Malignancies. Journal of Clinical Oncology, 2017, 35, 1758-1759.	0.8	1
753	Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. Journal of Clinical Oncology, 2017, 35, 1515-1521.	0.8	63
754	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 2490-2498.	0.8	506
755	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. Journal of Clinical Oncology, 2017, 35, 2735-2736.	0.8	4
756	Impact of Reflex EGFR/ALK Testing on Time to Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Oncology Practice, 2017, 13, e130-e138.	2.5	45
757	ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm. JCO Precision Oncology, 2017, 1, 1-9.	1.5	9
758	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2017, 2017, 1-13.	1.5	158
759	Chart Review Versus an Automated Bioinformatic Approach to Assess Real-World Crizotinib Effectiveness in Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. JCO Clinical Cancer Informatics, 2017, 1, 1-6.	1.0	2
760	Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget, 2017, 8, 12417-12432.	0.8	24
761	Further Advances in the Management of Anaplastic Lymphoma Kinase-Mutated Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 2463-2466.	0.8	7
762	Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion. JCO Precision Oncology, 2017, 2017, 1-6.	1.5	103
763	Therapeutic management options for stage III non-small cell lung cancer. World Journal of Clinical Oncology, 2017, 8, 1.	0.9	188
764	Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases. Journal of Thoracic Disease, 2017, 9, E152-E154.	0.6	8
765	What is the optimal first-line treatment for advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer?. Journal of Thoracic Disease, 2017, 9, E447-E450.	0.6	0
766	The J-ALEX trial—is frontline alectinib a new standard of care?. Journal of Thoracic Disease, 2017, 9, 2242-2245.	0.6	1
767	A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay. Journal of Thoracic Disease, 2017, 9, 2311-2314.	0.6	0

#	ARTICLE	IF	CITATIONS
768	Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 4064-4069.	0.6	7
769	ASCEND-5: too little too late?. <i>Journal of Thoracic Disease</i> , 2017, 9, 3477-3479.	0.6	3
770	Biophysical technologies for understanding circulating tumor cell biology and metastasis. <i>Translational Lung Cancer Research</i> , 2017, 6, 473-485.	1.3	13
771	Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?. <i>Translational Lung Cancer Research</i> , 2017, 6, 444-453.	1.3	12
772	Pulmonary inflammatory myofibroblastic tumor with TPM4-ALK translocation. <i>Journal of Thoracic Disease</i> , 2017, 9, E1013-E1017.	0.6	0
773	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818.	0.6	1
774	ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases. <i>Journal of Thoracic Disease</i> , 2017, 9, 3919-3926.	0.6	24
775	Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 659-670.	1.1	18
776	Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger. <i>Clinical and Translational Oncology</i> , 2018, 20, 1168-1174.	1.2	18
777	Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting. <i>Clinical Lung Cancer</i> , 2018, 19, 360-370.	1.1	34
778	Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. <i>Cancer Science</i> , 2018, 109, 572-580.	1.7	49
779	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 353-361.	1.1	3
780	Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices. <i>Oncology</i> , 2018, 94, 297-305.	0.9	10
781	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1897-1908.	1.1	5
782	Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 577-586.	1.0	14
783	Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 367-375.	0.6	26
784	Alectinib for advanced ALK-positive non-small-cell lung cancer. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 515-522.	0.5	6
785	Clinicopathological features of younger (aged <math>\geq 50</math> years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene. <i>Thoracic Cancer</i> , 2018, 9, 563-570.	0.8	8

#	ARTICLE	IF	CITATIONS
786	Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2018, 36, 495-504.	1.7	24
787	Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma—a single center retrospective study. <i>Pathology Research and Practice</i> , 2018, 214, 572-578.	1.0	13
788	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517.	15.2	155
789	Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. <i>Cancer Research</i> , 2018, 78, 3350-3362.	0.4	42
790	A comprehensive review on Brigatinib — A wonder drug for targeted cancer therapy in non-small cell lung cancer. <i>Saudi Pharmaceutical Journal</i> , 2018, 26, 755-763.	1.2	30
791	Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (<i>ALK</i>+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e275-e282.	0.7	6
792	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. <i>Journal of Immunotherapy</i> , 2018, 41, 292-299.	1.2	30
793	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. <i>ESMO Open</i> , 2018, 3, e000344.	2.0	105
794	BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 796-797.	1.2	10
795	Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. <i>Medical Oncology</i> , 2018, 35, 72.	1.2	29
796	Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 119, 103-111.	0.9	27
797	Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. <i>JAMA Oncology</i> , 2018, 4, 874.	3.4	28
798	Monoclonal Antibody L <sub>1</sub> Mab-13 Detected Human PD-L1 in Lung Cancers. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2018, 37, 110-115.	0.8	45
799	Visual Disturbance in a Middle-aged Woman With Non-Small Cell Lung Cancer. <i>JAMA Ophthalmology</i> , 2018, 136, 702.	1.4	2
800	C-MET inhibitors for advanced non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 363-375.	1.9	94
801	Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. <i>Gene Reports</i> , 2018, 11, 196-204.	0.4	2
802	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	7.7	228
803	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 41-47.	2.0	32

#	ARTICLE	IF	CITATIONS
804	Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. <i>Annals of Oncology</i> , 2018, 29, 1409-1416.	0.6	238
805	Real-life experience of ceritinib in crizotinib-pretreated ALK <sup>+</sup> advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018, 4, 00058-2017.	1.1	8
807	Detection of ROS1 <sup>+</sup> non-small cell lung cancer on cytological specimens using immunocytochemistry. <i>Cancer Cytopathology</i> , 2018, 126, 421-429.	1.4	30
808	Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC. <i>Cancer Biology and Therapy</i> , 2018, 19, 359-363.	1.5	11
809	Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. <i>Lung Cancer</i> , 2018, 118, 128-133.	0.9	50
810	Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). <i>British Journal of Cancer</i> , 2018, 118, 654-661.	2.9	192
811	Leptomeningeal metastasis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 169-204.	1.0	55
812	Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. <i>ESMO Open</i> , 2018, 3, e000262.	2.0	69
813	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , 2018, 24, 2719-2731.	3.2	54
814	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
815	Bu-Fei decoction and modified Bu-Fei decoction inhibit the growth of non-small cell lung cancer, possibly via inhibition of apurinic/aprimidinic endonuclease 1. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2128-2138.	1.8	6
816	Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 4851-4863.	1.3	22
817	Long-term effects of crizotinib in ALK <sup>+</sup> positive tumors (excluding NSCLC): A phase 1b open-label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	2.0	75
818	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
819	Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 267-276.	1.1	14
821	Use of SuperARMS EGFR Mutation Detection Kit to Detect EGFR in Plasma Cell-free DNA of Patients With Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e313-e322.	1.1	21
822	Mind the Graph: Foregone Health Gains in Lung Cancer. <i>Seminars in Oncology</i> , 2018, 45, 316-317.	0.8	1
823	Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 211-220.	1.5	24

#	ARTICLE	IF	CITATIONS
824	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
825	Changing health care costs for NSCLC, what does it mean?. <i>Lung Cancer</i> , 2018, 117, 62-63.	0.9	2
826	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 15-24.	0.9	44
827	Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344.		0
828	Molecular pathology of lung cancer: current status and perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 69-76.	1.1	82
829	Treatment of ALK-positive nonsmall cell lung cancer: recent advances. <i>Current Opinion in Oncology</i> , 2018, 30, 84-91.	1.1	29
830	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. <i>Chemical Reviews</i> , 2018, 118, 1599-1663.	23.0	64
831	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501.	1.4	101
832	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 581-588.	1.4	5
833	A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 339-345.	1.1	3
834	Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib. <i>Journal of International Medical Research</i> , 2018, 46, 3491-3497.	0.4	8
835	A review of systemic anticancer therapy in disease palliation. <i>British Medical Bulletin</i> , 2018, 125, 43-53.	2.7	10
836	The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). <i>Molecular Cancer</i> , 2018, 17, 52.	7.9	157
837	Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. <i>Molecular Cancer</i> , 2018, 17, 60.	7.9	27
838	Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib. <i>Journal of Translational Medicine</i> , 2018, 16, 93.	1.8	10
839	Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry. <i>Diagnostic Pathology</i> , 2018, 13, 4.	0.9	16
840	Does ALK rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small cell lung cancer? Case report and literature review. <i>Clinical and Translational Medicine</i> , 2018, 7, 1.	1.7	27
841	Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung. <i>Surgical Case Reports</i> , 2018, 4, 19.	0.2	10

#	ARTICLE	IF	CITATIONS
842	NSCLC molecular testing in Central and Eastern European countries. <i>BMC Cancer</i> , 2018, 18, 269.	1.1	28
843	Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. <i>Cancer Medicine</i> , 2018, 7, 1211-1220.	1.3	22
844	Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis. <i>Journal of Drug Assessment</i> , 2018, 7, 21-27.	1.1	9
845	Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature. <i>Supportive Care in Cancer</i> , 2018, 26, 2945-2953.	1.0	51
846	Development of Complex Hepatic Cysts Is a Potential Side Effect of Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e62-e64.	0.5	2
847	Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors. <i>Molecular Pharmaceutics</i> , 2018, 15, 1892-1900.	2.3	15
848	Clinical Utility of Cell-Free DNA for the Detection of <i>ALK</i> Fusions and Genomic Mechanisms of <i>ALK</i> Inhibitor Resistance in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2758-2770.	3.2	143
849	Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876761.	1.0	64
850	National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e64-e65.	0.5	0
851	Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 253-258.	0.5	0
852	The Introduction and Clinical Application of Cell-Free Tumor DNA. <i>Methods in Molecular Biology</i> , 2018, 1754, 45-65.	0.4	2
853	Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). <i>Journal of Thoracic Oncology</i> , 2018, 13, 682-688.	0.5	182
854	Cetuximab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 483-493.	1.4	44
855	Cost-effectiveness of <i>KRAS</i> , <i>EGFR</i> and <i>ALK</i> testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. <i>European Respiratory Journal</i> , 2018, 51, 1701467.	3.1	16
856	Malignant Pleural Effusion from Lung Cancers with Driver Mutations. <i>Current Pulmonology Reports</i> , 2018, 7, 13-18.	0.5	1
857	Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). <i>European Journal of Medicinal Chemistry</i> , 2018, 151, 304-314.	2.6	165
858	Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 465-473.	1.2	4
859	Ensartinib (X-396) in <i>ALK</i> -Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	3.2	141

#	ARTICLE	IF	CITATIONS
860	Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1781-1787.	1.1	13
861	The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1875-1882.	1.1	5
862	Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer. <i>Investigational New Drugs</i> , 2018, 36, 45-52.	1.2	1
863	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018, 48, 37-44.	0.5	12
864	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 408-419.	1.2	70
865	ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 222-231.	1.9	38
866	Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings. <i>Clinical Lung Cancer</i> , 2018, 19, 139-147.	1.1	15
867	Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. <i>Clinical Lung Cancer</i> , 2018, 19, e151-e161.	1.1	50
868	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. <i>PET Clinics</i> , 2018, 13, 33-42.	1.5	2
869	Multifunctional, JNK-inhibiting nanotherapeutics for augmented elastic matrix regenerative repair in aortic aneurysms. <i>Drug Delivery and Translational Research</i> , 2018, 8, 964-984.	3.0	19
870	Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer. <i>Surgery Today</i> , 2018, 48, 380-387.	0.7	4
871	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
872	Pharmacogenomics in Lung Cancer. , 2018, , 466-478.e3.		0
873	New designs for basket clinical trials in oncology. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 245-255.	0.4	23
874	A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers. <i>International Journal of Cancer</i> , 2018, 142, 156-164.	2.3	2
875	Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience. <i>Journal of Thoracic Oncology</i> , 2018, 13, 63-72.	0.5	21
876	Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 151-167.	12.5	247
877	Value of <sup>18</sup> F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 735-750.	3.3	75

#	ARTICLE	IF	CITATIONS
878	Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 2307-2313.	7.2	36
879	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2018, 10, 93-105.	1.0	86
880	Lektion gelernt? Die molekularen Grundlagen von Kinase-gerichteten Therapien und Wirkstoffresistenz im nicht-kleinzelligen Lungenkrebs. <i>Angewandte Chemie</i> , 2018, 130, 2329-2335.	1.6	1
881	Molecular Diagnosis and Targeting for Lung Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 1-32.	0.1	0
883	MEK inhibitors under development for treatment of non-small-cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 17-30.	1.9	63
884	Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 71-80.	1.1	73
885	Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 123-136.	2.6	19
886	Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 27-45.	0.5	156
887	GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors. <i>Lung Cancer</i> , 2018, 115, 5-11.	0.9	23
888	Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial. <i>Clinical Oncology</i> , 2018, 30, 1-4.	0.6	18
889	Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing. <i>Clinical Lung Cancer</i> , 2018, 19, 163-169.e4.	1.1	11
890	Thromboembolism in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e71-e72.	1.1	14
891	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	1.5	24
892	Diagnosis and Management of Treatment-Related Pulmonary Complications. , 2018, , 221-241.		0
893	My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now? Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 696-707.	1.8	5
894	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
895	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	3
896	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 726-739.	1.8	13



#	ARTICLE	IF	CITATIONS
897	Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. <i>Journal of Clinical Oncology</i> , 2018, 36, 2571-2574.	0.8	6
898	CNS Metastases in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: Impact on Health Resource Utilization. <i>Journal of Oncology Practice</i> , 2018, 14, e612-e620.	2.5	8
899	Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1405-1411.	0.8	230
900	Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 2693-2701.	0.8	124
901	Reply to L. Zeng et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 3177-3178.	0.8	0
902	Moving From Mutation to Actionability. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 495-503.	1.8	4
903	Crizotinib-Induced Fulminant Hepatic Failure: A Rare Adverse Event. <i>Journal of Global Oncology</i> , 2018, 4, 1-4.	0.5	4
904	Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 23-31.	2.5	45
905	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
906	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	0.8	246
907	Broader indications for checkpoint inhibitors in NSCLC. <i>Journal of Thoracic Disease</i> , 2018, 10, 5190-5191.	0.6	0
908	Lung cancer in never smokers—the East Asian experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 450-463.	1.3	104
909	Immunotherapy in treatment naïve advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S412-S421.	0.6	13
910	BRAF inhibitors in metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 589-592.	0.6	27
911	Therapeutic bronchoscopy in the era of genotype directed lung cancer management. <i>Journal of Thoracic Disease</i> , 2018, 10, 6298-6309.	0.6	16
913	J-ALEX trial will crown alectinib as the standard choice for anaplastic lymphoma kinase positive untreated non-small cell lung cancer patients?. <i>Journal of Thoracic Disease</i> , 2018, 10, 106-108.	0.6	3
914	Utility of stereotactic ablative radiotherapy/stereotactic body radiation therapy in the setting of oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 657-660.	0.6	6
915	Oncogene-addicted non-small cell lung cancer and immunotherapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1547-S1555.	0.6	25

#	ARTICLE	IF	CITATIONS
916	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. <i>Journal of Thoracic Disease</i> , 2018, 10, 1386-1393.	0.6	4
917	Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens. <i>Journal of Thoracic Disease</i> , 2018, 10, 2631-2637.	0.6	37
918	TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. <i>Journal of Thoracic Disease</i> , 2018, 10, 2991-2998.	0.6	31
919	Emerging resistance pathways in lung cancer: what has ROS-1 taught us?. <i>Translational Lung Cancer Research</i> , 2018, 7, S9-S12.	1.3	3
920	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	0.8	308
921	ALK inhibitors and checkpoint blockade: a cautionary tale of mixing oil with water?. <i>Journal of Thoracic Disease</i> , 2018, 10, S2198-S2201.	0.6	13
922	The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 2948-2959.	0.6	2
923	An anaplastic lymphoma kinase (ALK) fusion oncogene positive metastatic sarcomatoid carcinoma of the lung with good response to crizotinib. <i>AME Case Reports</i> , 2018, 2, 2-2.	0.2	4
924	Development of biomarkers for real precision medicine. <i>Translational Lung Cancer Research</i> , 2018, 7, S228-S231.	1.3	0
925	Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011-2016. <i>Journal of Thoracic Disease</i> , 2018, 10, 5468-5475.	0.6	9
926	Management of Advanced Non-Small Cell Lung Cancer. , 2018, , 99-115.		1
927	Examining EML4-ALK variants in the clinical setting: the next frontier?. <i>Journal of Thoracic Disease</i> , 2018, 10, S4104-S4107.	0.6	7
928	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S290-S293.	1.3	2
929	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646.	1.3	98
930	Ginsenoside Rg3 promotes the antitumor activity of gefitinib in lung cancer cell lines. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 953-959.	0.8	14
931	Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review). <i>Oncology Letters</i> , 2019, 17, 2020-2030.	0.8	33
932	Discrepancies between ALK protein disruption and occurrence of ALK gene rearrangement in Polish NSCLC patients. <i>Journal of Thoracic Disease</i> , 2018, 10, 4994-5009.	0.6	7
933	Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples. <i>Frontiers in Public Health</i> , 2018, 6, 291.	1.3	3

#	ARTICLE	IF	CITATIONS
934	ALK Testing Trends and Patterns Among Community Practices in the United States. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	27
937	8. Molekularpathologie. , 2018, , 303-350.		0
939	Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3448.	1.8	45
940	Receptor Tyrosine Kinase-Targeted Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3491.	1.8	187
941	Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. <i>BMC Cancer</i> , 2018, 18, 1171.	1.1	22
942	Translocation-Related Sarcomas. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3784.	1.8	37
943	Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR. <i>BMC Cancer</i> , 2018, 18, 1136.	1.1	12
944	Canadian Perspectives: Update on Inhibition of ALK-Positive Tumours in Advanced Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 317-328.	0.9	14
945	Instrumental variable analysis with censored data in the presence of many weak instruments: Application to the effect of being sentenced to prison on time to employment. <i>Annals of Applied Statistics</i> , 2018, 12, .	0.5	6
946	Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint. <i>British Journal of Cancer</i> , 2018, 119, 1456-1463.	2.9	43
947	Precision oncology: separating the wheat from the chaff. <i>ESMO Open</i> , 2018, 3, e000446.	2.0	37
948	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1654-1667.	5.1	587
949	Lorlatinib: a new-generation drug for ALK-positive NSCLC. <i>Lancet Oncology</i> , The, 2018, 19, 1555-1557.	5.1	9
950	FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 1108-1116.	1.5	6
951	Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status. <i>OncoTargets and Therapy</i> , 2018, Volume 12, 15-19.	1.0	1
952	Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 6555-6561.	0.9	9
953	Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). <i>Journal of Thoracic Disease</i> , 2018, 10, 4858-4864.	0.6	2
954	Application of Ventana immunocytochemical analysis on ThinPrep cytology slides for detection of ALK rearrangement in patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2018, 18, 1277.	1.1	1

#	ARTICLE	IF	CITATIONS
955	Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance. <i>Cancers</i> , 2018, 10, 503.	1.7	44
956	Classification histomol�culaire des cancers pulmonaires. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 236-247.	0.0	0
959	Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 415-421.	0.3	3
960	Cystic brain metastases in ALK-rearranged non-small cell lung cancer. <i>Ecancermedicalsecience</i> , 2018, 12, 818.	0.6	3
961	Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1832-1841.	0.5	34
962	<i>CMTR1-ALK</i>: an <i>ALK</i> fusion in a patient with no response to ALK inhibitor crizotinib. <i>Cancer Biology and Therapy</i> , 2018, 19, 962-966.	1.5	20
963	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6189-6196.	1.0	47
964	A comprehensive review of protein kinase inhibitors for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1249-1270.	1.1	164
965	ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 147-155.	0.4	15
966	How Should We Treat Alectinib-Refractory ALK-Positive Non�Small Cell Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1438-1440.	0.5	1
967	Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2519-2529.	1.9	16
969	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
970	An expression signature model to predict lung adenocarcinoma-specific survival. <i>Cancer Management and Research</i> , 2018, Volume 10, 3717-3732.	0.9	38
971	ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question�to treat or not to treat?. <i>ESMO Open</i> , 2018, 3, e000419.	2.0	23
972	Brigatinib versus Crizotinib in <i>ALK</i>-Positive Non�Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	13.9	691
973	Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 231-241.	1.0	27
974	Prognostic Factors for Non-small Cell Lung Cancer Treated with Carboplatin, Paclitaxel, and Bevacizumab. <i>Journal of Cancer Science and Research</i> , 2018, 03, .	0.1	0
975	Diagnostic and Predictive Immunohistochemistry for Non�Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.	2.4	15

#	ARTICLE	IF	CITATIONS
976	ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria. <i>Folia Medica</i> , 2018, 60, 397-401.	0.2	0
977	Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients. <i>Medical Oncology</i> , 2018, 35, 154.	1.2	15
978	An expression quantitative trait locus variant for LKB1 gene predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer. <i>Cancer Genetics</i> , 2018, 228-229, 73-82.	0.2	3
979	Pharmacophore and molecular dynamics based activity profiling of natural products for kinases involved in lung cancer. <i>Journal of Molecular Modeling</i> , 2018, 24, 318.	0.8	7
981	Response to Cameron et al "Mind the graph" <i>Semin Oncol.</i> 2018. <i>Seminars in Oncology</i> , 2018, 45, 318-319.	0.8	0
982	Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China. <i>PLoS ONE</i> , 2018, 13, e0205827.	1.1	23
983	Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6287-6294.	1.0	17
984	Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3629-3636.	0.9	1
985	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	3.4	37
986	NTRK fusion-positive cancers and TRK inhibitor therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 731-747.	12.5	975
987	Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment. <i>Case Reports in Hepatology</i> , 2018, 2018, 1-5.	0.4	6
989	Biologie moléculaire des carcinomes bronchiques : standards actuels et perspectives. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 46-51.	0.0	1
990	Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 71, 59-67.	3.4	39
991	Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. <i>Targeted Oncology</i> , 2018, 13, 631-639.	1.7	2
992	Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results. <i>Japanese Journal of Radiology</i> , 2018, 36, 719-725.	1.0	17
993	The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 226.	3.5	107
994	Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylamino pyrimidine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 322-333.	2.6	16
995	New drugs in thoracic oncology: needs and knowledge " an online ERS Lung Cancer Assembly survey. <i>ERJ Open Research</i> , 2018, 4, 00040-2018.	1.1	2

#	ARTICLE	IF	CITATIONS
997	Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?. <i>Annals of Oncology</i> , 2018, 29, 2160-2162.	0.6	2
998	The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 4993-5005.	1.3	31
999	Design, synthesis and biological evaluation N2-(2-alkoxy-6-aliphatic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 667 Td (aminopyridin-3-yl)-2, inhibitors. <i>Bioorganic Chemistry</i> , 2018, 81, 689-699.	2.0	5
1000	Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. <i>Annals of Oncology</i> , 2018, 29, 2214-2222.	0.6	243
1001	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1717-1726.	0.5	119
1002	Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2018, 38, 4969-4975.	0.5	13
1003	Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. <i>Anticancer Research</i> , 2018, 38, 4987-4997.	0.5	63
1004	Patient-reported outcomes in a phase II study of alectinib. <i>ESMO Open</i> , 2018, 3, e000412.	2.0	0
1005	Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5093-5101.	1.0	43
1006	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
1008	Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 248-254.	0.9	61
1009	Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 2068-2075.	0.6	132
1010	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	5
1011	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. <i>CNS Drugs</i> , 2018, 32, 527-542.	2.7	10
1013	A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. <i>Investigational New Drugs</i> , 2018, 36, 886-894.	1.2	18
1014	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877281.	1.4	18
1015	A New Standard of Care for Advanced Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2135-2137.	13.9	18
1016	Management of co-existent tuberculosis and lung cancer. <i>Lung Cancer</i> , 2018, 122, 83-87.	0.9	56

#	ARTICLE	IF	CITATIONS
1017	Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 48, 1-4.	0.2	21
1018	Anticipating the Next Step in the Management of ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 595-597.	0.5	0
1019	Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer. <i>Value in Health</i> , 2018, 21, 1278-1285.	0.1	32
1020	Real-World Outcomes in Patients with Alk-Positive Non-Small Cell Lung Cancer Treated with Crizotinib. <i>Current Oncology</i> , 2018, 25, 40-49.	0.9	17
1021	Ventana ALK (D5F3) in the Detection of Patients Affected by Anaplastic Lymphoma Kinase-positive Non-Small-cell Lung Cancer: Clinical and Budget Effect. <i>Clinical Lung Cancer</i> , 2018, 19, e735-e743.	1.1	3
1022	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	24
1023	Stereotactic Body Radiotherapy. <i>Progress in Tumor Research</i> , 2018, , 67-88.	0.1	0
1024	Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer. <i>Current Oncology</i> , 2018, 25, 73-82.	0.9	24
1025	Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i> -Mutated Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 4650-4661.	3.2	63
1026	Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis. <i>Translational Oncology</i> , 2018, 11, 999-1006.	1.7	20
1027	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 68-76.	0.9	11
1028	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cancers</i> , 2018, 10, 245.	1.7	34
1029	The role of brigatinib in crizotinib-resistant non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 123-130.	0.9	14
1030	Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. <i>Journal of Clinical Medicine</i> , 2018, 7, 192.	1.0	27
1031	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , .	1.8	5
1032	Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with <i>ALK</i> / <i>ROS-1</i> mutations. <i>Journal of Cancer</i> , 2018, 9, 1863-1869.	1.2	8
1033	Crizotinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 57-65.	1.8	40
1034	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 937-945.	1.4	13

#	ARTICLE	IF	CITATIONS
1035	Brain Metastases in Non-Small-Cell Lung Cancer: Are Tyrosine Kinase Inhibitors and Checkpoint Inhibitors Now Viable Options?. <i>Current Oncology</i> , 2018, 25, 103-114.	0.9	42
1036	ALK Inhibitors, Resistance Development, Clinical Trials. <i>Current Oncology</i> , 2018, 25, 59-67.	0.9	35
1037	Review article: systemic treatment of hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 598-609.	1.9	131
1038	Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: <sc>ASCEND</sc>. <i>Cancer Science</i> , 2018, 109, 2863-2872.	1.7	42
1039	Overview of precision oncology trials: challenges and opportunities. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 797-804.	1.3	31
1040	Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. <i>Cancers</i> , 2018, 10, 35.	1.7	19
1041	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. <i>Lung Cancer</i> , 2018, 124, 31-39.	0.9	34
1042	Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer. <i>Yonsei Medical Journal</i> , 2018, 59, 202.	0.9	7
1043	Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2018, 15, 119-124.	0.1	6
1044	MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours. <i>Targeted Oncology</i> , 2018, 13, 423-436.	1.7	5
1045	Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations. <i>Scientific Reports</i> , 2018, 8, 10664.	1.6	13
1046	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. <i>Future Oncology</i> , 2018, 14, 3-17.	1.1	18
1047	Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers. <i>Cancers</i> , 2018, 10, 10.	1.7	39
1048	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
1049	ALK in Neuroblastoma: Biological and Therapeutic Implications. <i>Cancers</i> , 2018, 10, 113.	1.7	105
1050	Heterogeneous responses and resistant mechanisms to crizotinib in <i>ALK</i>-positive advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1093-1103.	0.8	18
1051	Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 129.	1.0	11
1052	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144.	1.0	54



#	ARTICLE	IF	CITATIONS
1053	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2018, 7, 153.	1.0	47
1054	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	2.3	394
1055	Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1964-1971.	0.6	16
1056	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	1.7	73
1057	Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	0.5	77
1058	Common cancer-driver mutations and their association with abnormally methylated genes in lung adenocarcinoma from never-smokers. <i>Lung Cancer</i> , 2018, 123, 99-106.	0.9	20
1059	FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium. <i>Oncogene</i> , 2018, 37, 6096-6104.	2.6	10
1060	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. <i>Pharmaceutical Research</i> , 2018, 35, 177.	1.7	53
1061	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. <i>Cancers</i> , 2018, 10, 236.	1.7	31
1062	A systematic review of targeted agents for non-small cell lung cancer. <i>Acta Oncologica</i> , 2018, 57, 176-186.	0.8	54
1063	Alectinib: A Review in Advanced, ALK-Positive NSCLC. <i>Drugs</i> , 2018, 78, 1247-1257.	4.9	30
1064	Emerging Trends in the Management of Brain Metastases from Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2018, 20, 54.	1.8	19
1066	Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment. <i>BMC Cancer</i> , 2018, 18, 10.	1.1	28
1067	Role and targeting of anaplastic lymphoma kinase in cancer. <i>Molecular Cancer</i> , 2018, 17, 30.	7.9	71
1068	Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 129-138.	1.1	25
1069	Xenograft tumors derived from malignant pleural effusion of the patients with non-small cell lung cancer as models to explore drug resistance. <i>Cancer Communications</i> , 2018, 38, 1-12.	3.7	14
1070	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 851-864.	0.9	6
1071	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27.	2.8	27

#	ARTICLE	IF	CITATIONS
1072	Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy. <i>Cancer</i> , 2018, 124, 3586-3595.	2.0	5
1073	Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review. <i>Current Cancer Drug Targets</i> , 2018, 18, 405-409.	0.8	4
1074	The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 311.	1.3	94
1075	Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy. <i>Current Pulmonology Reports</i> , 2018, 7, 79-91.	0.5	6
1076	Treatment of advanced non-small cell lung cancer in the elderly. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 783-792.	1.0	9
1077	Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1539-1548.	0.5	146
1078	Benefit of crizotinib in a lung cancer patient with discordant ALK testing results. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 13-16.	0.7	0
1079	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708.	12.5	255
1080	The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer. <i>Drugs and Aging</i> , 2018, 35, 819-834.	1.3	16
1081	Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2018, 9, 201-206.	0.4	18
1082	Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse. <i>Future Oncology</i> , 2018, 14, 2303-2317.	1.1	6
1083	Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538.	0.5	62
1084	Development of a high-throughput and sensitive assay of fusion genes in lung cancer by array-based MALDI-TOFMS. <i>RSC Advances</i> , 2018, 8, 27935-27945.	1.7	2
1085	Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878936.	1.4	26
1086	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). <i>Annals of Oncology</i> , 2018, 29, 1895-1902.	0.6	424
1087	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 120-136.	0.2	0
1088	Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. <i>Anticancer Research</i> , 2018, 38, 3559-3566.	0.5	14
1089	Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. <i>Journal of Hepatology</i> , 2018, 69, 826-839.	1.8	89

#	ARTICLE	IF	CITATIONS
1090	Calcitriol and cancer therapy: A missed opportunity. <i>Bone Reports</i> , 2018, 9, 110-119.	0.2	26
1091	Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib. <i>Internal Medicine</i> , 2018, 57, 713-716.	0.3	39
1092	Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 435-440.e1.	1.1	5
1093	A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Oncology Letters</i> , 2018, 15, 8703-8710.	0.8	19
1094	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1052-1059.	1.0	27
1095	Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1005-1011.	0.8	2
1096	Pulmonary Adenocarcinoma, Harboring Both an <i>EGFR</i> Mutation and <i>ALK</i> Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. <i>Internal Medicine</i> , 2018, 57, 2377-2382.	0.3	5
1097	Tissue sampling in the era of precision medicine: comparison of percutaneous biopsies performed for clinical trials or tumor genomics versus routine clinical care. <i>Abdominal Radiology</i> , 2019, 44, 2074-2080.	1.0	6
1098	Response to alectinib oil-based suspension in anaplastic lymphoma kinase-positive non-small cell lung cancer in a patient unable to swallow: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1722-1725.	0.5	4
1099	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
1100	<i>Precision oncology: lessons learned and challenges for the future</i> . <i>Cancer Management and Research</i> , 2019, Volume 11, 7525-7536.	0.9	10
1101	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019, 136, 109-114.	0.9	16
1102	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
1103	Ocular and orbital side effects of ALK inhibitors: a review article. <i>Future Oncology</i> , 2019, 15, 1939-1945.	1.1	13
1104	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. <i>Cancer</i> , 2019, 125, 4043-4051.	2.0	14
1105	Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031985507.	0.2	0
1106	Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 309-312.	0.4	4
1107	Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 199-219.	0.7	1

#	ARTICLE	IF	CITATIONS
1108	Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. <i>Cancer Medicine</i> , 2019, 8, 5823-5830.	1.3	9
1109	Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3939.	1.8	27
1110	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2019, 19, 495-509.	12.8	573
1111	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31
1112	Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. <i>Translational Lung Cancer Research</i> , 2019, 8, 286-301.	1.3	69
1113	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 617-630.	8.2	132
1114	ArtiFuse computational validation of fusion gene detection tools without relying on simulated reads. <i>Bioinformatics</i> , 2020, 36, 373-379.	1.8	3
1115	The alpha and beta in phase II trials hepatocellular carcinoma – A tale of more than radiological response?. <i>Liver International</i> , 2019, 39, 1391-1393.	1.9	0
1116	An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1551-1561.	0.9	2
1117	Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing. <i>Journal of Visualized Experiments</i> , 2019, .	0.2	9
1118	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
1119	Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment. <i>Clinical Lung Cancer</i> , 2019, 20, e631-e637.	1.1	7
1120	Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4567-4575.	1.0	14
1121	Prognostic value of site-specific metastases in lung cancer: A population based study. <i>Journal of Cancer</i> , 2019, 10, 3079-3086.	1.2	58
1122	Lung cancer in young adults aged 35 years or younger: A full-scale analysis and review. <i>Journal of Cancer</i> , 2019, 10, 3553-3559.	1.2	52
1123	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, .		0
1125	Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e555-e559.	1.1	21
1126	Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 432-438.	0.6	18

#	ARTICLE	IF	CITATIONS
1127	Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints. <i>BMC Medical Research Methodology</i> , 2019, 19, 159.	1.4	4
1128	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019, 10, 1505.	2.2	34
1129	Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells. <i>Frontiers in Oncology</i> , 2019, 9, 579.	1.3	24
1130	Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1628-1636.	1.9	18
1131	Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. <i>RSC Advances</i> , 2019, 9, 17921-17932.	1.7	2
1132	The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 218-224.	0.9	16
1133	Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM). <i>Tumori</i> , 2019, 105, 3-14.	0.6	9
1134	Reliable Gene Expression Profiling from Small and Hematoxylin and Eosinâ€Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 796-807.	1.2	19
1135	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	1.7	10
1136	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 179.	0.7	48
1137	ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. <i>Toxicology and Applied Pharmacology</i> , 2019, 383, 114768.	1.3	30
1138	The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4â€ALK Rearranged Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 880.	1.3	9
1139	Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 138, 79-87.	0.9	29
1140	Platycodon grandiflorus enhances the effect of DDP against lung cancer by down regulating PI3K/Akt signaling pathway. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109496.	2.5	14
1141	Precision medicine and companion diagnostics in drug development. , 2019, , 75-96.		0
1142	&lt;p&gt;Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 9195-9202.	0.9	20
1143	Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. <i>Pathology</i> , 2019, 51, 673-680.	0.3	8
1144	A Novel <i>ALK</i> Fusion in Pediatric Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1704-1707.	2.4	19

#	ARTICLE	IF	CITATIONS
1145	Pemetrexed Plus Platinum for Patients With Advanced Non-small Cell Lung Cancer and Interstitial Lung Disease. <i>In Vivo</i> , 2019, 33, 2059-2064.	0.6	13
1147	CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 113.	6.9	69
1148	Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100954.	0.2	1
1149	Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer. <i>Pathology Research and Practice</i> , 2019, 215, 152695.	1.0	7
1150	Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center. <i>Frontiers in Oncology</i> , 2019, 9, 1116.	1.3	18
1151	The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients. <i>Immunotherapy</i> , 2019, 11, 1481-1490.	1.0	14
1152	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. <i>Cancers</i> , 2019, 11, 1782.	1.7	53
1153	The Role of Pazopanib in Non-Clear Cell Renal Cell Carcinoma: A Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 419-424.	0.9	5
1154	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK “rearranged lung cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10581.	3.3	40
1155	A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 3909-3919.	0.6	2
1156	Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3864-3873.	0.6	11
1157	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. <i>Frontiers in Medicine</i> , 2019, 6, 233.	1.2	8
1158	<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8191-8200.	0.9	4
1159	A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance. <i>Precision Clinical Medicine</i> , 2019, 2, 1-5.	1.3	6
1160	The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase“positive non“small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2117-2123.	0.8	9
1161	ALK“positive lung cancer diagnosed with abdominal lymph nodes in a patient receiving hemodialysis. <i>Thoracic Cancer</i> , 2019, 10, 2188-2191.	0.8	3
1162	Front“line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. <i>Thoracic Cancer</i> , 2019, 10, 2274-2281.	0.8	4
1163	Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (<i><sc>ALK</sc></i>)“rearranged non“small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3382-3390.	1.7	26

#	ARTICLE	IF	CITATIONS
1164	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation. <i>Cancers</i> , 2019, 11, 1229.	1.7	23
1165	Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: a retrospective study. <i>International Journal of Hyperthermia</i> , 2019, 36, 826-833.	1.1	21
1166	Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review. <i>Frontiers in Oncology</i> , 2019, 9, 715.	1.3	13
1167	Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer. <i>Oncology Letters</i> , 2019, 18, 3017-3024.	0.8	7
1168	An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 115051.	1.4	8
1170	Crizotinib-Associated Renal Cysts: A Case Series. <i>Journal of Gastrointestinal and Abdominal Radiology</i> , 2019, 02, 130-134.	0.2	0
1171	<p>Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6535-6548.	1.0	26
1172	Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. <i>Current Treatment Options in Oncology</i> , 2019, 20, 79.	1.3	34
1173	Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 294.	1.8	45
1174	Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2019, 11, 2965-2972.	0.6	11
1175	Evolution of treatment strategies for oligometastatic NSCLC patients – A systematic review of the literature. <i>Cancer Treatment Reviews</i> , 2019, 80, 101892.	3.4	45
1176	Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer. <i>Oncology Research and Treatment</i> , 2019, 42, 599-606.	0.8	14
1177	<p>Chinese perspectives on clinical efficacy and safety of alectinib in patients with <em>ALK</em>-positive advanced non-small cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6481-6495.	1.0	4
1178	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e948-e956.	2.5	14
1179	Attenuated <i>plasmodium</i> sporozoite expressing MAGE-A3 induces antigen-specific CD8+ T cell response against lung cancer in mice. <i>Cancer Biology and Medicine</i> , 2019, 16, 288.	1.4	16
1180	<p>Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7281-7288.	1.0	11
1181	The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 137, 19-22.	0.9	26
1182	Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). <i>Translational Lung Cancer Research</i> , 2019, 8, 461-475.	1.3	38

#	ARTICLE	IF	CITATIONS
1183	Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance. <i>EBioMedicine</i> , 2019, 41, 105-119.	2.7	93
1184	ALK Inhibitors in the Treatment of ALK Positive NSCLC. <i>Frontiers in Oncology</i> , 2018, 8, 557.	1.3	60
1185	Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials. <i>Medicina (Lithuania)</i> , 2019, 55, 29.	0.8	10
1186	Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 1097-1103.	1.1	4
1187	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019, 20, 215-221.	1.1	16
1188	Anesthesia for Open Pulmonary Resection: A Systems Approach. , 2019, , 389-412.		1
1189	Precision Medicine: Disruptive Technology in the Modern Hospital. , 2019, , 121-131.		0
1190	<p></p>The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4109-4118.	0.9	36
1191	Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2163-2174.	1.1	2
1192	Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-1 inhibition. <i>Cancer Science</i> , 2019, 110, 2014-2021.	1.7	14
1193	<p></p>High feasibility of cytological specimens for detection of <em>ROS1</em> fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3305-3311.	1.0	6
1194	<p></p>Poor prognosis of pulmonary sarcomatoid carcinoma with <em>KRAS</em> mutation and <em>ALK</em> fusion</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3321-3325.	1.0	4
1195	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	0.9	85
1196	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
1197	Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43.	0.2	16
1198	The Evolving Modern Management of Brain Metastasis. <i>Clinical Cancer Research</i> , 2019, 25, 6570-6580.	3.2	83
1199	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. <i>Cancer Treatment and Research</i> , 2019, 178, 81-108.	0.2	2
1200	Genomics-Enabled Precision Medicine for Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 137-169.	0.2	9



#	ARTICLE	IF	CITATIONS
1201	A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. <i>British Journal of Cancer</i> , 2019, 121, 131-138.	2.9	16
1202	Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 358-375.	2.6	20
1203	Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas. <i>Cancers</i> , 2019, 11, 866.	1.7	18
1204	The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?. <i>Clinical Oncology</i> , 2019, 31, 824-833.	0.6	66
1205	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	0.9	24
1206	First-Line Systemic Treatments for Stage IV Non-Small Cell Lung Cancer in California: Patterns of Care and Outcomes in a Real-World Setting. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz020.	1.4	12
1207	Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. <i>Clinical Cancer Research</i> , 2019, 25, 5376-5387.	3.2	145
1208	Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. <i>European Journal of Cancer</i> , 2019, 116, 86-97.	1.3	18
1209	Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2019, 11, 1397-1409.	0.6	25
1210	The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly. <i>Cancer Medicine</i> , 2019, 8, 4124-4134.	1.3	13
1211	Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1077-1085.	0.5	9
1212	Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2019, 23, 346-354.	0.6	3
1213	Prognostic value of quantitative measurement of EGFR mutation using peptide nucleic acid clamping in advanced EGFR mutant non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 1561-1566.	0.8	0
1214	New Era for Next-Generation Sequencing in Japan. <i>Cancers</i> , 2019, 11, 742.	1.7	22
1215	Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 1521-1532.	0.8	18
1216	Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2071-2082.	1.2	27
1217	Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma. <i>Internal Medicine</i> , 2019, 58, 2651-2655.	0.3	6
1218	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	0.5	78

#	ARTICLE	IF	CITATIONS
1219	Newer biological agents: CAR T cells, PARP inhibitors, and ALK inhibitors. <i>Journal of Onco-Nephrology</i> , 2019, 3, 92-97.	0.3	0
1220	Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 248-260.	1.8	8
1221	Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e187-e197.	1.8	33
1222	What It Takes to Improve a First-Generation Inhibitor to a Second- or Third-Generation Small Molecule. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 196-205.	1.8	16
1223	A Career in Lung Cancer: Pushing Beyond Chemotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 583-589.	1.8	4
1224	Regulatory Requirements for Companion Diagnostics—Japan. , 2019, , 365-379.		2
1225	Oncogenic Effect of the Novel Fusion Gene VAPA-Rab31 in Lung Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2309.	1.8	8
1226	ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A clinical perspective. <i>Cancer Treatment and Research Communications</i> , 2019, 20, 100149.	0.7	3
1227	Deciphering the universe of genetic context-dependencies using mouse models of cancer. <i>Current Opinion in Genetics and Development</i> , 2019, 54, 97-104.	1.5	3
1228	Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. <i>Cancer</i> , 2019, 125, 2656-2665.	2.0	15
1229	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 266-272.	2.2	19
1230	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	0.5	324
1231	Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of <i>EGFR</i> , <i>ALK</i> , <i>ROS1</i> , <i>KRAS</i> or <i>BRAF</i> . <i>Cancer Medicine</i> , 2019, 8, 2858-2866.	1.3	59
1232	Treatment status and safety of crizotinib in 2028 Japanese patients with ALK-positive NSCLC in clinical settings. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 676-686.	0.6	12
1233	Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e247-e250.	0.2	10
1234	Clinical features and outcomes of <i>ALK</i> rearranged non-small cell lung cancer with primary resistance to crizotinib. <i>Thoracic Cancer</i> , 2019, 10, 1213-1219.	0.8	5
1235	Crizotinib-associated corrosive esophagitis in a bedridden lung cancer patient. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 515-516.	0.8	1
1236	Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 437-446.	5.2	192

#	ARTICLE	IF	CITATIONS
1237	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	15.2	362
1238	The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0215103.	1.1	11
1239	Acute Respiratory Distress Syndrome Phenotypes. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 019-030.	0.8	83
1240	Rifampin may decrease the efficacy of crizotinib in lung cancer treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 580-581.	0.8	2
1241	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	1.0	100
1242	Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema. <i>Tumori</i> , 2019, 105, NP35-NP37.	0.6	2
1243	Detecting disease-defining gene fusions in unclassified round cell sarcomas using anchored multiplex PCR/targeted RNA next-generation sequencing. Molecular and clinicopathological characterization of 16 cases. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 713-722.	1.5	36
1244	Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1255-1265.	0.5	59
1245	Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. <i>Cancers</i> , 2019, 11, 599.	1.7	41
1246	The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations. <i>Molecular and Clinical Oncology</i> , 2019, 10, 610-614.	0.4	4
1247	Detection of NRG1 Gene Fusions in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4966-4972.	3.2	145
1248	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , 2019, 14, 325-333.	1.7	9
1249	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
1250	Gene expression classification of lung adenocarcinoma into molecular subtypes. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2019, 17, 1-1.	1.9	25
1251	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	1.9	101
1252	Leptomeningeal Disease in Solid Cancers. , 2019, , 1-19.		0
1253	Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4881-4887.	3.2	10
1254	Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. <i>Practical Radiation Oncology</i> , 2019, 9, e129-e133.	1.1	1

#	ARTICLE	IF	CITATIONS
1255	Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study. <i>World Neurosurgery</i> , 2019, 125, e487-e496.	0.7	5
1256	Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses. <i>Radiation Oncology</i> , 2019, 14, 44.	1.2	16
1257	Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion. <i>Oncology Letters</i> , 2019, 17, 3071-3076.	0.8	8
1258	Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. <i>Targeted Oncology</i> , 2019, 14, 169-178.	1.7	17
1259	Adjuvant and Neoadjuvant Therapy in Non-Small-Cell Lung Cancer. , 2019, , 35-55.		0
1260	Pleural Effusion Aspirate for Use in 3D Lung Cancer Modeling and Chemotherapy Screening. <i>ACS Biomaterials Science and Engineering</i> , 2019, 5, 1937-1943.	2.6	58
1261	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , 2019, 9, 99.	1.3	10
1262	Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?. <i>Cancers</i> , 2019, 11, 366.	1.7	50
1263	Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. <i>Targeted Oncology</i> , 2019, 14, 159-168.	1.7	33
1264	Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China. <i>Advances in Therapy</i> , 2019, 36, 1114-1125.	1.3	18
1265	Management of Locally Advanced Lung Cancer. , 2019, , 57-86.		1
1266	Approach to Anaplastic Lymphoma Kinase (ALK) Gene Rearranged Non-Small Cell Lung Cancer (NSCLC). , 2019, , 133-142.		0
1267	Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1551-1557.	1.3	30
1268	Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan. <i>International Journal of Clinical Oncology</i> , 2019, 24, 461-467.	1.0	7
1269	Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 872-879.	0.8	9
1270	Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides. <i>Cancers</i> , 2019, 11, 275.	1.7	34
1271	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. <i>Clinical Lung Cancer</i> , 2019, 20, e421-e429.	1.1	27
1272	The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors. <i>Journal of Medical Economics</i> , 2019, 22, 414-420.	1.0	10

#	ARTICLE	IF	CITATIONS
1273	Microsatellite instability in endometrial cancer: New purpose for an old test. <i>Cancer</i> , 2019, 125, 2154-2163.	2.0	23
1274	Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 297-309.	2.6	13
1275	Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, e1070-e1081.	1.9	76
1276	Favorable predictors for survival in advanced ALK $\alpha$ -positive non-small cell lung cancer patients beyond crizotinib resistance. <i>Thoracic Cancer</i> , 2019, 10, 1096-1102.	0.8	1
1277	Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC. <i>Scientific Reports</i> , 2019, 9, 3705.	1.6	30
1278	Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. <i>Cancer Letters</i> , 2019, 451, 11-22.	3.2	28
1279	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	2.7	142
1280	Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 5.	7.1	231
1281	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	0.9	38
1282	The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 129.	1.3	61
1283	Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1195-1196.	1.1	8
1284	Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 942-949.	0.8	5
1285	Working together to deliver stratified medicine research effectively. <i>British Medical Bulletin</i> , 2019, 129, 107-116.	2.7	3
1286	TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various <i>EGFR</i> Mutations Including T790M and Uncommon Mutations G719X. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 920-928.	1.9	11
1287	Efficacy and Safety of $\alpha$ -Tyrosine Kinase Inhibitors in Elderly Patients with Advanced $\alpha$ -Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. <i>Oncology Research and Treatment</i> , 2019, 42, 275-282.	0.8	10
1288	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. <i>Advances in Therapy</i> , 2019, 36, 1497-1508.	1.3	4
1289	Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer in Routine Clinical Practice. <i>Targeted Oncology</i> , 2019, 14, 315-323.	1.7	22
1290	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , 2019, 24, 1270-1284.	1.9	21

#	ARTICLE	IF	CITATIONS
1291	The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2019, 132, 79-86.	0.9	28
1292	Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. <i>Annals of Oncology</i> , 2019, 30, 1121-1126.	0.6	339
1293	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
1294	First-line treatment of advanced non-small cell lung cancer with ALK rearrangement: state of the art and future development. <i>Expert Review of Respiratory Medicine</i> , 2019, , 1-7.	1.0	2
1295	Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 412-420.	0.6	110
1296	Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 574-576.	0.5	3
1297	Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 131, 62-68.	0.9	75
1298	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347
1299	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019, 131, 128-133.	0.9	18
1301	Anaplastic lymphoma kinase expression in small-cell lung cancer. <i>Histopathology</i> , 2019, 75, 20-28.	1.6	7
1302	Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661983190.	1.0	34
1303	Prognostic Value of CD44 and Its Isoforms in Advanced Cancer: A Systematic Meta-Analysis With Trial Sequential Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 39.	1.3	20
1304	Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 830-838.	0.6	88
1305	Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. <i>Investigational New Drugs</i> , 2019, 37, 791-795.	1.2	28
1306	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2019, 21, 21.	1.8	82
1307	Novel insights into the systemic treatment of lung cancer malignant pleural effusion. <i>Clinical Respiratory Journal</i> , 2019, 13, 131-138.	0.6	9
1308	Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. <i>Cancer Research</i> , 2019, 79, 1658-1670.	0.4	79
1309	ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 48-55.	2.0	33

#	ARTICLE	IF	CITATIONS
1310	Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquidâ€based cytology. <i>Diagnostic Cytopathology</i> , 2019, 47, 564-570.	0.5	9
1311	Impact of TP53 immunohistochemistry on the histological grading system for endometrial endometrioid carcinoma. <i>Modern Pathology</i> , 2019, 32, 1023-1031.	2.9	35
1312	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 630-643.	1.6	217
1313	&lt;p&gt;Systematic review of sequencing of ALK inhibitors in &lt;em&gt;ALK&lt;/em&gt;-positive non-small-cell lung cancer&lt;/p&gt;. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 11-20.	1.3	13
1314	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	1.3	10
1315	&lt;p&gt;Brigatinib for &lt;em&gt;ALK&lt;/em&gt;-positive metastatic non-small-cell lung cancer: design, development and place in therapy&lt;/p&gt;. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 569-580.	2.0	17
1316	Molecular analysis of small tissue samples obtained via transbronchial lung biopsy using radial probe endobronchial ultrasound. <i>PLoS ONE</i> , 2019, 14, e0212672.	1.1	9
1317	Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKIâ€Treated Nonâ€Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy. <i>Clinical Lung Cancer</i> , 2019, 20, e229-e232.	1.1	5
1318	Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies. <i>Journal of Thoracic Disease</i> , 2019, 11, S45-S56.	0.6	28
1319	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. , 2019, , 21-38.		1
1320	Polymeric Micelles in Management of Lung Cancer. , 2019, , 193-216.		2
1321	Identification of a new inhibitor of KRASâ€PDEÎ´ interaction targeting KRAS mutant nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2019, 145, 1334-1345.	2.3	29
1322	Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. <i>Acta Cytologica</i> , 2019, 63, 479-488.	0.7	42
1323	Scar tissue to lung cancer; pathways and treatment. <i>Journal of Cancer</i> , 2019, 10, 810-818.	1.2	3
1324	Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. <i>Cancer Biology and Therapy</i> , 2019, 20, 837-842.	1.5	13
1325	Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, 672-682.	0.5	36
1326	Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Nonâ€Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 691-700.	0.5	108
1328	Identification of key biomarkers and potential molecular mechanisms in lung cancer by bioinformatics analysis. <i>Oncology Letters</i> , 2019, 18, 4429-4440.	0.8	14

#	ARTICLE	IF	CITATIONS
1329	How I treat ALK-positive non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000524.	2.0	31
1330	Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?. <i>ESMO Open</i> , 2019, 4, e000483.	2.0	31
1331	From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000548.	2.0	22
1332	Les patients ALK et ROS1: quelle s�quence ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 380-391.	0.0	0
1333	Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape. <i>Medical Science Monitor</i> , 2019, 25, 8764-8776.	0.5	10
1334	Lesser Known Facts of Small Cell Lung Cancer. <i>Journal of Computer Assisted Tomography</i> , 2019, 43, 584-591.	0.5	1
1335	The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. <i>Translational Lung Cancer Research</i> , 2019, 8, 1134-1151.	1.3	3
1336	Comparison of robotic-assisted lobectomy with video-assisted thoracic surgery for stage IIB�III A non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 820-828.	1.3	33
1337	Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 215-220.	1.2	47
1338	Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-17.	1.5	11
1339	Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S383-S386.	1.3	4
1340	Oncog�nese pulmonaire: comprendre les addictions oncog�niques et les r�sistances. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 184-192.	0.0	0
1342	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34
1343	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
1344	Pemetrexed plus cisplatin versus docetaxel plus cisplatin for stage IV lung adenocarcinoma based on propensity score matching. <i>Anti-Cancer Drugs</i> , 2019, 30, 295-301.	0.7	2
1345	Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non�Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-10.	1.0	50
1346	Expanding anaplastic lymphoma kinase therapeutic indication to early stage non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S290-S297.	1.3	6
1347	La r�animation des patients canc�reux � l'heure de l'immunoth�rapie et des th�rapies cibl�es. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 418-425.	0,0	0



#	ARTICLE	IF	CITATIONS
1348	Quel avenir pour les biopsies liquides en oncologie thoracique ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 436-443.	0.0	0
1351	Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines. Anti-Cancer Drugs, 2019, 30, 740-744.	0.7	7
1352	Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 292-297.	0.6	11
1353	Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial. Cancers, 2019, 11, 1835.	1.7	4
1354	QUANTITATIVE DETERMINATION OF CRIZOTINIB IN HUMAN PLASMA WITH HIGHPERFORMANCE LIQUID CHROMATOGRAPHY AND ULTRAVIOLET DETECTION. Asian Journal of Pharmaceutical and Clinical Research, 2019, , 363-367.	0.3	3
1355	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. Respiratory Research, 2019, 20, 263.	1.4	5
1356	Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer. OncoTargets and Therapy, 2019, Volume 12, 10343-10360.	1.0	41
1357	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. Cells, 2019, 8, 1538.	1.8	7
1358	Treatment of oncogene-driven non-small cell lung cancer. Current Opinion in Pulmonary Medicine, 2019, 25, 300-307.	1.2	7
1359	Meta-analysis of overall incidence and risk of ALK inhibitors-induced liver toxicities in advanced non-small-cell lung cancer. Medicine (United States), 2019, 98, e13726.	0.4	7
1360	Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials. Medicine (United States), 2019, 98, e16427.	0.4	2
1361	Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. Journal of Thoracic Disease, 2019, 11, 4258-4270.	0.6	11
1362	Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S265-S279.	1.3	17
1363	Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Scientific Reports, 2019, 9, 18842.	1.6	19
1364	Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer. Medicine (United States), 2019, 98, e18131.	0.4	11
1365	ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib. Medicine (United States), 2019, 98, e14826.	0.4	3
1366	New generation anaplastic lymphoma kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S280-S289.	1.3	14
1367	Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomarker Research, 2019, 7, 27.	2.8	22

#	ARTICLE	IF	CITATIONS
1368	Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 1457.	1.6	20
1369	Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring <i>ALK</i> Y1278S Mutation. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	5
1370	Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients. <i>Journal of Thoracic Disease</i> , 2019, 11, 4992-5003.	0.6	14
1371	Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018. <i>Translational Lung Cancer Research</i> , 2019, 8, 1091-1106.	1.3	27
1372	Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 623-637.	0.5	1
1373	Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. <i>Molecular Cancer Research</i> , 2019, 17, 212-224.	1.5	41
1374	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e39-e51.	1.1	11
1375	Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 20-29.e8.	1.1	42
1376	Adequacy of EBUS-TBNA specimen for mutation analysis of lung cancer. <i>Clinical Respiratory Journal</i> , 2019, 13, 92-97.	0.6	20
1377	Approaches to Capturing Value in Oncology. <i>Recent Results in Cancer Research</i> , 2019, 213, 85-108.	1.8	5
1378	Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2019, 129, 63-71.	0.9	25
1379	Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. <i>Journal of Thoracic Oncology</i> , 2019, 14, 726-731.	0.5	67
1380	Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e133-e136.	1.1	6
1381	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	0.6	214
1382	A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis. <i>Internal Medicine</i> , 2019, 58, 703-705.	0.3	17
1383	Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel <i>KIF5B-ALK</i> Fusion Oncokinase. <i>Anticancer Research</i> , 2019, 39, 413-420.	0.5	18
1384	Liquid Biopsy and Lung Cancer. <i>Acta Cytologica</i> , 2019, 63, 489-496.	0.7	75
1385	Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 47-53.	0.8	29

#	ARTICLE	IF	CITATIONS
1386	The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 8.	1.2	16
1387	Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. <i>Journal of Thoracic Oncology</i> , 2019, 14, 16-24.	0.5	100
1388	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
1389	Gene Fusion in NSCLC. , 2019, , 443-464.		1
1390	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	1.2	110
1391	The clinical features of older patients with lung cancer in comparison with their younger counterparts. <i>Respiratory Investigation</i> , 2019, 57, 40-48.	0.9	4
1392	Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2019, 14, 54-62.	0.5	64
1393	Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 127, 19-24.	0.9	41
1394	Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. <i>Modern Pathology</i> , 2019, 32, 627-638.	2.9	22
1395	Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA. <i>Thoracic Cancer</i> , 2019, 10, 452-458.	0.8	8
1396	Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2691-2698.	3.2	78
1397	Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. <i>Drug Safety</i> , 2019, 42, 199-209.	1.4	8
1398	Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019, 42, 211-233.	1.4	76
1399	A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 "CREATE" trial. <i>European Journal of Cancer</i> , 2019, 109, 192-195.	1.3	15
1400	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. <i>Lung Cancer</i> , 2019, 128, 20-25.	0.9	6
1401	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 697-706.	0.8	3
1402	Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis. <i>Anti-Cancer Drugs</i> , 2019, 30, 201-204.	0.7	2
1403	Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. <i>Current Medical Research and Opinion</i> , 2019, 35, 105-111.	0.9	14

#	ARTICLE	IF	CITATIONS
1404	Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lung adenocarcinoma. <i>Internal Medicine Journal</i> , 2019, 49, 634-643.	0.5	4
1405	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2019, 22, 140-150.	1.0	17
1406	Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives. <i>Current Opinion in Oncology</i> , 2019, 31, 8-12.	1.1	7
1408	Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-L1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 1038-1049.	2.0	66
1409	Recognising Lung Cancer in Primary Care. <i>Advances in Therapy</i> , 2019, 36, 19-30.	1.3	42
1410	Safety issues with the ALK inhibitors in the treatment of NSCLC: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 56-64.	2.0	37
1411	Resistance to molecularly targeted therapy in non-small-cell lung cancer. <i>Respiratory Investigation</i> , 2019, 57, 20-26.	0.9	46
1412	Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients. <i>Current Medical Research and Opinion</i> , 2019, 35, 535-542.	0.9	13
1413	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 173.	3.4	334
1414	Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 645-654.	1.7	6
1415	Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2019, 35, 569-576.	0.9	15
1416	Molecular simulation studies on the binding activity and selectivity of 3-amino-phenyl-5-chloro-pyrimidine-2, 4-diamine derivatives in complexes with kinases c-Met and ALK. <i>Molecular Simulation</i> , 2019, 45, 1-14.	0.9	3
1417	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28.	4.3	51
1418	Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients. <i>Nicotine and Tobacco Research</i> , 2019, 21, 497-504.	1.4	24
1419	Data skyline query protocol based on parallel genetic improvement decision tree. <i>Journal of Supercomputing</i> , 2020, 76, 1116-1127.	2.4	2
1420	An advanced c-MET-amplified NSCLC patient that was treated with crizotinib. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 474-477.	0.5	1
1421	Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib. <i>Internal Medicine</i> , 2020, 59, 253-256.	0.3	3
1422	Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1731-1741.	0.8	60

#	ARTICLE	IF	CITATIONS
1423	A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement. <i>Cancer Biology and Therapy</i> , 2020, 21, 12-16.	1.5	5
1424	How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1011-1018.	0.5	14
1425	Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e113-e117.	0.2	1
1426	Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor tyrosine kinase inhibitors. <i>Cancer</i> , 2020, 126, 219-227.	2.0	20
1427	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. <i>Annals of Palliative Medicine</i> , 2020, 9, 1296-1306.	0.5	5
1428	Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer. <i>Clinical Oncology</i> , 2020, 32, e1-e9.	0.6	6
1429	Therapeutic Targeting of Cancer Cells. , 2020, , 420-430.e2.		0
1430	Impact of Lung Cancer Treatment on Cognitive Functioning. <i>Clinical Lung Cancer</i> , 2020, 21, 114-126.e3.	1.1	8
1431	The impact of overweight on renal toxicity in patients treated with dexamethasone, high-dose cytarabine, and cisplatin. <i>International Journal of Hematology</i> , 2020, 111, 396-400.	0.7	1
1432	Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multicenter study. <i>Cancer Medicine</i> , 2020, 9, 12-18.	1.3	10
1433	Designing clinical studies for biomarker discovery: The Design criteria. , 2020, , 441-466.		0
1434	Factors correlating with shorter survival after treatment: aiding oncologists to choose who (not) to receive palliative systemic therapy. <i>Annals of Palliative Medicine</i> , 2020, 9, 4430-4445.	0.5	0
1435	Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 274-281.	1.0	7
1436	Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 3-8.	0.1	1
1437	Synthetic lethality as an engine for cancer drug target discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 23-38.	21.5	295
1438	Utility-Based Interim Decision Rule Planning in Adaptive Population Selection Designs With Survival Endpoints. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 360-368.	0.6	1
1439	Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. <i>Lung Cancer</i> , 2020, 139, 185-194.	0.9	11
1440	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117

#	ARTICLE	IF	CITATIONS
1441	Brain malignancies: Glioblastoma and brain metastases. <i>Seminars in Cancer Biology</i> , 2020, 60, 262-273.	4.3	208
1442	Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265.	0.5	53
1443	Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma. <i>In Vivo</i> , 2020, 34, 247-253.	0.6	6
1444	Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 367-383.	1.0	21
1445	Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 188, 110795.	2.5	30
1446	Tumor-educated platelet as liquid biopsy in lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102863.	2.0	27
1447	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	39
1448	Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study. <i>Thrombosis Research</i> , 2020, 186, 36-41.	0.8	32
1449	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
1450	Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 408-414.	0.8	12
1451	Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer. <i>Frontiers in Chemistry</i> , 2019, 7, 920.	1.8	9
1452	Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 142, 105153.	1.9	12
1453	Precision Medicine in Lung Cancer Treatment. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 15-21.	0.6	23
1454	The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 63-69.	0.7	12
1455	Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-small Cell Lung Cancer Patients Treated With Crizotinib. <i>Journal of Thoracic Imaging</i> , 2020, 35, 101-107.	0.8	7
1456	Oncogene addiction and tumor mutational burden in non-small cell lung cancer: Clinical significance and limitations. <i>Thoracic Cancer</i> , 2020, 11, 205-215.	0.8	22
1457	Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer. <i>Clinical Drug Investigation</i> , 2020, 40, 183-189.	1.1	21
1458	Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches. <i>Radiotherapy and Oncology</i> , 2020, 144, 165-179.	0.3	42

#	ARTICLE	IF	CITATIONS
1459	Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. Cellular Oncology (Dordrecht), 2020, 43, 31-49.	2.1	35
1460	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. Journal of Thoracic Oncology, 2020, 15, 404-415.	0.5	102
1461	Low frequency of mutation of epidermal growth factor receptor ( EGFR ) and arrangement of anaplastic lymphoma kinase ( ALK ) in primary pulmonary lymphoepithelioma-like carcinoma. Thoracic Cancer, 2020, 11, 346-352.	0.8	13
1463	Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 609-617.	0.5	27
1464	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). Journal of Clinical Oncology, 2020, 38, 793-803.	0.8	28
1465	Characteristics of surgically resected non-small cell lung cancer patients with post-recurrence cure. Thoracic Cancer, 2020, 11, 3280-3288.	0.8	15
1466	The Clinical Characteristics and Prognosis of Different Age Patients with Lung Cancer. Cancer Management and Research, 2020, Volume 12, 8445-8450.	0.9	0
1467	A cascade dual-targeted nanocarrier for enhanced alectinib delivery to ALK-positive lung cancer. Biomaterials Science, 2020, 8, 6404-6413.	2.6	7
1468	Non-small cell lung cancer targetable mutations: present and future. Precision Cancer Medicine, 0, 3, 5-5.	1.8	3
1469	Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review. Cancers, 2020, 12, 2658.	1.7	10
1471	Discovery of 4-methyl-N-(4-((4-methylpiperazin-1-yl)ethoxy)-2-methylphenyl)-3-(trifluoromethyl)phenyl-3-oxo-1,2,3,4-tetrahydroquinoline-2-carboxamide as a potent inhibitor of RET and its gatekeeper mutant. European Journal of Medicinal Chemistry, 2020, 207, 112755.	2.6	8
1472	Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences. Journal of Thoracic Oncology, 2020, 15, 1425-1433.	0.5	4
1473	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. Lung Cancer, 2020, 149, 154-161.	0.9	21
1474	Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Cancer Science, 2020, 111, 3726-3738.	1.7	12
1475	Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib. Anti-Cancer Drugs, 2020, 31, 1106-1110.	0.7	13
1476	The Problem of Cancer Drugs Costs. Cancer Journal (Sudbury, Mass ), 2020, 26, 287-291.	1.0	2
1477	Emerging pathways for precision medicine in management of cholangiocarcinoma. Surgical Oncology, 2020, 35, 47-55.	0.8	5
1479	Les patients ALK et ROS1 : quelle séquence ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S212-2S222.	0.0	0

#	ARTICLE	IF	CITATIONS
1481	Quel avenir pour les biopsies liquides en oncologie thoracique ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S299-2S306.	0.0	0
1482	Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report. Annals of Translational Medicine, 2020, 8, 770-770.	0.7	6
1483	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. JTO Clinical and Research Reports, 2020, 1, 100013.	0.6	4
1484	18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer. Clinical Nuclear Medicine, 2020, 45, 209-210.	0.7	1
1485	Emerging role of phytochemicals in targeting predictive, prognostic, and diagnostic biomarkers of lung cancer. Food and Chemical Toxicology, 2020, 144, 111592.	1.8	19
1487	Tyrosine Kinase Receptors in Oncology. International Journal of Molecular Sciences, 2020, 21, 8529.	1.8	46
1488	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. New England Journal of Medicine, 2020, 383, 2018-2029.	13.9	592
1489	A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC. JTO Clinical and Research Reports, 2020, 1, 100045.	0.6	8
1490	How should molecular findings be integrated in the classification for lung cancer?. Translational Lung Cancer Research, 2020, 9, 2245-2254.	1.3	5
1491	Multi-line treatment with tyrosine kinase inhibitors enabled in 4-year survival for patient with stage IV lung adenocarcinoma: a case report. Annals of Palliative Medicine, 2021, 10, 6990-6996.	0.5	2
1492	Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review. Translational Lung Cancer Research, 2020, 9, 2137-2144.	1.3	8
1493	Surgical Management of Stage IIIA Non-small Cell Lung Cancer. Current Pulmonology Reports, 2020, 9, 151-163.	0.5	0
1494	Overexpression of P4HA1 Is Correlated with Poor Survival and Immune Infiltrates in Lung Adenocarcinoma. BioMed Research International, 2020, 2020, 1-15.	0.9	5
1495	Remarkable Role of Chemotherapy in Selected ALK-Positive Non-Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports. JCO Precision Oncology, 2020, 4, 1425-1428.	1.5	1
1496	Novel ALK mutation with durable response to brigatinib—a case report. Translational Lung Cancer Research, 2020, 9, 2145-2148.	1.3	2
1497	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer, 2020, 150, 240-246.	0.9	10
1498	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. Nature Communications, 2020, 11, 6119.	5.8	53
1499	Association between continuous decrease of plasma VEGF-A levels and the efficacy of chemotherapy in combination with anti-programmed cell death 1 antibody in non-small cell lung cancer patients. Cancer Treatment and Research Communications, 2020, 25, 100249.	0.7	1



#	ARTICLE	IF	CITATIONS
1500	ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients. <i>Scientific Reports</i> , 2020, 10, 21063.	1.6	21
1501	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
1502	Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 50.	0.6	7
1503	Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung carcinoma. <i>Translational Lung Cancer Research</i> , 2020, 9, 257-268.	1.3	16
1504	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor- Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	0.8	224
1505	Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. <i>Lung Cancer</i> , 2020, 147, 130-136.	0.9	8
1506	CT features associated with EGFR mutations and ALK positivity in patients with multiple primary lung adenocarcinomas. <i>Cancer Imaging</i> , 2020, 20, 51.	1.2	18
1507	KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting. <i>Journal of Thoracic Disease</i> , 2020, 12, 3836-3843.	0.6	47
1508	Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer. <i>Drugs - Real World Outcomes</i> , 2020, 7, 261-269.	0.7	13
1509	Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. <i>Thoracic Cancer</i> , 2020, 11, 2580-2589.	0.8	8
1510	Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer. , 2020, 8, e000970.		16
1511	HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. <i>Frontiers in Oncology</i> , 2020, 10, 1162.	1.3	8
1512	<p>Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6615-6628.	0.9	14
1513	An Assessment of the Treatment Effect in Treatment of Physician Choice Trials. <i>Statistics in Biopharmaceutical Research</i> , 2022, 14, 103-113.	0.6	0
1514	PI16 attenuates response to sorafenib and represents a predictive biomarker in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2020, 9, 6972-6983.	1.3	10
1515	The quest for efficient trial designs in precision oncology. <i>Lancet Oncology</i> , The, 2020, 21, 1539-1541.	5.1	3
1516	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2020, 11, 3585-3595.	0.8	32
1517	Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). <i>Journal of Hematology and Oncology</i> , 2020, 13, 143.	6.9	226

#	ARTICLE	IF	CITATIONS
1518	Challenges associated with systemic therapy for older patients with inoperable non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2185-2194.	0.9	1
1519	Capmatinib in <i>MET</i> Exon 14 Mutated or <i>MET</i> -Amplified Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	13.9	542
1520	Management of brain metastases according to molecular subtypes. <i>Nature Reviews Neurology</i> , 2020, 16, 557-574.	4.9	104
1521	Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. <i>Journal of Personalized Medicine</i> , 2020, 10, 107.	1.1	4
1522	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. <i>Molecules</i> , 2020, 25, 3987.	1.7	14
1523	Impact of ALK variants on brain metastasis and treatment response in advanced NSCLC patients with oncogenic ALK fusion. <i>Translational Lung Cancer Research</i> , 2020, 9, 1452-1463.	1.3	7
1524	Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. <i>BMC Cancer</i> , 2020, 20, 875.	1.1	32
1525	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131.	3.2	9
1526	Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer. <i>Carcinogenesis</i> , 2020, 41, 1507-1517.	1.3	11
1527	Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature. <i>BMC Pulmonary Medicine</i> , 2020, 20, 209.	0.8	4
1528	Novel <i>ALK</i> Fusion, <i>PPFIBP1-ALK</i> , in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib. <i>JCO Precision Oncology</i> , 2020, 4, 865-870.	1.5	15
1530	Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival. <i>Frontiers in Immunology</i> , 2020, 11, 1933.	2.2	6
1531	Coexisting of <i>COX7A2L</i> ALK, <i>LINC01210</i> ALK, <i>ATP13A4</i> ALK and Acquired <i>SLCO2A1</i> ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 8313-8316.	1.0	8
1532	The More, The Better?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3581-3583.	0.8	0
1535	Prevalence and Clinical Impact of Concomitant Mutations in Anaplastic Lymphoma Kinase Rearrangement Advanced Non-small-Cell Lung Cancer (Guangdong Association of Thoracic Oncology) <a href="#">Tj ETQq0 0 Org BT / Overlock 10 T</a>		
1536	Development of chemotherapeutics for unresectable advanced esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 1083-1092.	1.1	9
1537	A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis". <i>Lung Cancer</i> , 2020, 150, 259-260.	0.9	0
1538	Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study. <i>International Journal of Analytical Chemistry</i> , 2020, 2020, 1-10.	0.4	4

#	ARTICLE	IF	CITATIONS
1539	Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2096689.	0.2	3
1540	Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d. <i>Cancers</i> , 2020, 12, 3805.	1.7	8
1541	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020, 12, 3804.	1.7	26
1542	The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 474.	1.7	51
1543	Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9376.	1.8	24
1544	Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 596937.	1.3	21
1545	Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9705.	1.8	12
1546	Prolonged survival without progression under crizotinib treatment. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100259.	0.7	1
1548	Commentary: Importance of surgical treatment in the era of precision medicine. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 455.	0.4	0
1549	What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 485-495.	1.0	5
1550	Combined immune checkpoint inhibitor and chemotherapy is effective in a patient with ALK rearranged non-small cell lung cancer: a case report. <i>Translational Cancer Research</i> , 2020, 9, 2045-2048.	0.4	2
1551	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 517-524.	1.0	18
1552	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	1.3	1
1553	Prognostic impact and distinctive characteristics of surgically resected anaplastic lymphoma kinase-rearranged lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 441-451.e1.	0.4	10
1554	New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives. <i>Journal of Clinical Medicine</i> , 2020, 9, 3543.	1.0	28
1555	A user's guide to lorlatinib. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102969.	2.0	26
1556	Gene Alterations in Paired Supernatants and Precipitates from Malignant Pleural Effusions of Non-Squamous Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2020, 13, 100784.	1.7	13
1557	Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10726-10741.	2.9	30

#	ARTICLE	IF	CITATIONS
1558	Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 743-754.	0.7	10
1559	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
1560	Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 480.	1.3	28
1561	Oviz-Bio: a web-based platform for interactive cancer genomics data visualization. <i>Nucleic Acids Research</i> , 2020, 48, W415-W426.	6.5	17
1562	Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 145, 167-172.	0.9	1
1563	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020, 146, 78-85.	0.9	24
1564	Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib. <i>Lung Cancer</i> , 2020, 146, 370-372.	0.9	7
1565	Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC. <i>Lung Cancer</i> , 2020, 146, 382-384.	0.9	2
1566	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
1567	Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners. <i>Advances in Therapy</i> , 2020, 37, 3019-3030.	1.3	27
1568	Systemic treatment of brain metastases in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 187-198.	1.3	61
1569	Current Landscape of Personalized Therapy. <i>Thoracic Surgery Clinics</i> , 2020, 30, 121-125.	0.4	2
1570	Genomics-guided pre-clinical development of cancer therapies. <i>Nature Cancer</i> , 2020, 1, 482-492.	5.7	23
1571	Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. <i>Advances in Therapy</i> , 2020, 37, 3311-3323.	1.3	13
1572	Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 137-146.	0.4	8
1573	Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study. <i>BMC Cancer</i> , 2020, 20, 479.	1.1	4
1574	Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2020, 146, 209-216.	0.9	2
1575	Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1547-1554.	0.9	13

#	ARTICLE	IF	CITATIONS
1576	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020, 146, 350-354.	0.9	14
1577	Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. <i>Redox Biology</i> , 2020, 36, 101510.	3.9	45
1578	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
1579	Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for <i>ALK+</i> Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 867-877.	1.9	21
1580	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434.	0.8	11
1581	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	0.8	3
1582	Lung cancer in India: The rewards of REWERDS (REal World Evidence from Retrospective Data) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 500	1.0	5
1583	Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 224-229.	0.9	9
1584	Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2020, 9, 1782-1796.	0.5	5
1585	Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. <i>European Journal of Radiology Open</i> , 2020, 7, 100210.	0.7	4
1586	The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7
1587	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	68
1588	<i>ALK</i> -Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020, 25, 641-649.	1.9	8
1589	Chr2 30297612-ALK, A Novel Intergenic Fusion With Exon18 of ALK, Responds to Crizotinib. <i>Clinical Lung Cancer</i> , 2020, 21, e564-e566.	1.1	7
1590	Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint. <i>Journal of Thoracic Oncology</i> , 2020, 15, 485-488.	0.5	4
1591	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. <i>Scientific Reports</i> , 2020, 10, 4803.	1.6	48
1592	Clinical utility of liquid biopsy for the diagnosis and monitoring of <i>EML4-ALK</i> NSCLC patients. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
1593	Predictive biomarkers for molecular pathology in lung cancer. <i>Biomarkers in Medicine</i> , 2020, 14, 253-257.	0.6	7

#	ARTICLE	IF	CITATIONS
1594	Lorlatinib for the treatment of <i>ALK</i> -positive metastatic non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 233-240.	1.1	12
1595	Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 931-940.	0.9	7
1596	Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). Expert Opinion on Therapeutic Patents, 2020, 30, 351-373.	2.4	6
1597	Treatment options after first-line immunotherapy in metastatic NSCLC. Expert Review of Anticancer Therapy, 2020, 20, 221-228.	1.1	8
1598	Subtyping and EGFR mutation testing from blocks of cytological materials, based on liquid-based cytology for lung cancer at bronchoscopic examinations. Diagnostic Cytopathology, 2020, 48, 516-523.	0.5	11
1599	Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. Lung Cancer, 2020, 143, 86-92.	0.9	14
1600	Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China. Journal of Comparative Effectiveness Research, 2020, 9, 93-102.	0.6	7
1601	Conquering lung cancer: current status and prospects for the future. Pulmonology, 2020, 26, 283-290.	1.0	51
1602	Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Translational Lung Cancer Research, 2020, 9, 111-138.	1.3	27
1603	&lt;p&gt;Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib&lt;/p&gt;. International Medical Case Reports Journal, 2020, Volume 13, 89-93.	0.3	1
1604	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 333-341.	1.1	26
1605	Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827. Thoracic Cancer, 2020, 11, 1129-1138.	0.8	7
1606	MicroRNAs and Long Non-coding RNAs in c-Met-Regulated Cancers. Frontiers in Cell and Developmental Biology, 2020, 8, 145.	1.8	19
1607	Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study. Anticancer Research, 2020, 40, 957-964.	0.5	7
1608	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
1609	Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. Journal of Thoracic Oncology, 2020, 15, 1027-1036.	0.5	55
1610	CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study. Frontiers in Oncology, 2020, 10, 57.	1.3	32
1611	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035.	2.0	5

#	ARTICLE	IF	CITATIONS
1612	&lt;p&gt;Analysis of Patient Preferences in Lung Cancer â€“ Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects&lt;/p&gt;. Patient Preference and Adherence, 2020, Volume 14, 927-937.	0.8	39
1613	Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung Cancer. Applied Sciences (Switzerland), 2020, 10, 3704.	1.3	1
1614	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Settingâ€™Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884.	1.0	5
1616	Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients. In Vivo, 2020, 34, 2001-2007.	0.6	5
1617	Molecular therapeutic targets in non-small cell lung cancer. Expert Review of Anticancer Therapy, 2020, 20, 647-661.	1.1	46
1618	Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis. In Vivo, 2020, 34, 2095-2100.	0.6	7
1619	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors. Clinical Cancer Research, 2020, 26, 4777-4784.	3.2	31
1620	Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA. Journal of Thoracic Oncology, 2020, 15, 482-484.	0.5	0
1621	Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 369-376.	0.8	3
1622	Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report. BMC Cancer, 2020, 20, 156.	1.1	6
1623	SOX13 promotes colorectal cancer metastasis by transactivating SNAI2 and c-MET. Oncogene, 2020, 39, 3522-3540.	2.6	32
1624	Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with <i>ALK</i> Translocation. Oncologist, 2020, 25, 562-e1012.	1.9	26
1625	A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75Âˆyears or more with advanced non-small cell lung cancer -TCOG 1101-. International Journal of Clinical Oncology, 2020, 25, 867-875.	1.0	1
1626	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Targeted Oncology, 2020, 15, 55-65.	1.7	86
1627	ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. PLoS ONE, 2020, 15, e0229179.	1.1	57
1628	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. Future Oncology, 2020, 16, 4289-4301.	1.1	12
1629	Identification of Novel CD74-NRG2Î± Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers. Journal of Thoracic Oncology, 2020, 15, 948-961.	0.5	30
1630	Drug resistance mechanisms in Japanese anaplastic lymphoma kinaseâ€™positive nonâ€™small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Science, 2020, 111, 932-939.	1.7	39

#	ARTICLE	IF	CITATIONS
1631	Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition. <i>Clinical Proteomics</i> , 2020, 17, 5.	1.1	3
1632	Successful lung cancer EGFR sequencing from DNA extracted from TTF-1 immunohistochemistry slides: a new means to extend insufficient tissue. <i>Human Pathology</i> , 2020, 97, 52-59.	1.1	3
1633	Enabling Precision Oncology Through Precision Diagnostics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 97-121.	9.6	50
1634	Los parámetros volumétricos de la PET pueden predecir la supervivencia global en el adenocarcinoma pulmonar avanzado. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 3-8.	0.0	4
1635	Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 581-587.	0.8	26
1636	Administration of docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte colony-stimulating factor for pretreated non-small cell lung cancer: a phase II study. <i>Supportive Care in Cancer</i> , 2020, 28, 4825-4831.	1.0	8
1637	Precision Management of Advanced Non-Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 117-136.	5.0	101
1638	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	0.9	27
1640	Does progress achieved in the treatment of patients with metastatic non-small cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland. <i>European Journal of Cancer Care</i> , 2020, 29, e13206.	0.7	3
1641	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020, 99, e18726.	0.4	23
1642	Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial. <i>European Radiology</i> , 2020, 30, 2692-2702.	2.3	31
1643	Pharmacological cancer treatment and venous thromboembolism risk. <i>European Heart Journal Supplements</i> , 2020, 22, C2-C14.	0.0	11
1644	Economic burden in patients with ALK-positive non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. <i>Journal of Medical Economics</i> , 2020, 23, 894-901.	1.0	8
1645	Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1268.	1.0	42
1646	Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 257-270.	1.9	0
1647	Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 134-140.	1.3	4
1648	TRK Inhibitors in Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 39.	1.3	11
1649	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123



#	ARTICLE	IF	CITATIONS
1650	Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. <i>Trials</i> , 2020, 21, 298.	0.7	6
1651	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. <i>Clinical Cancer Drugs</i> , 2020, 7, 3-15.	0.3	2
1652	Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. <i>BMC Cancer</i> , 2020, 20, 328.	1.1	85
1653	Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature. <i>Case Reports in Hepatology</i> , 2020, 2020, 1-5.	0.4	6
1654	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
1655	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting <i>ALK</i> and <i>ROS1</i> Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	1.5	36
1656	Small-molecule PROTACs: novel agents for cancer therapy. <i>Future Medicinal Chemistry</i> , 2020, 12, 915-938.	1.1	19
1657	Lung Cancer in Israel. <i>Journal of Thoracic Oncology</i> , 2020, 15, 493-498.	0.5	2
1658	Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, e481-e486.	1.1	5
1659	Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 37-44.	0.6	17
1660	The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 256-266.	0.7	15
1661	Targetable <i>BRAF</i> and <i>RAF1</i> Alterations in Advanced Pediatric Cancers. <i>Oncologist</i> , 2021, 26, e153-e163.	1.9	14
1662	Detailed structural study of cyclic anticancer drug Lorlatinib: spectroscopic and stereostructure investigation (IR, ECD and NMR) using density functional theory approach. <i>Journal of Molecular Structure</i> , 2021, 1225, 129295.	1.8	8
1663	Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2021, 81, 87-100.	4.9	13
1664	Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL). <i>Leukemia and Lymphoma</i> , 2021, 62, 571-580.	0.6	3
1665	Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound-guided transbronchial needle aspiration samples for next-generation sequencing analysis. <i>Thoracic Cancer</i> , 2021, 12, 251-258.	0.8	13
1666	Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model. <i>Thoracic Cancer</i> , 2021, 12, 13-20.	0.8	12
1667	The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 7-14.	1.4	7

#	ARTICLE	IF	CITATIONS
1668	A fusion of CD63 and BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis. <i>British Journal of Cancer</i> , 2021, 124, 290-298.	2.9	5
1669	Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 49-57.	1.1	39
1670	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
1671	Opportunities and Challenges in Drug Development for Pediatric Cancers. <i>Cancer Discovery</i> , 2021, 11, 545-559.	7.7	25
1672	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. <i>Biochemical and Biophysical Research Communications</i> , 2021, 534, 1-7.	1.0	2
1673	Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 822-829.	1.9	37
1674	Relevance of sun safety in patients commencing crizotinib for non-small cell lung cancer. <i>Australasian Journal of Dermatology</i> , 2021, 62, e332-e333.	0.4	0
1675	Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. <i>Thoracic Cancer</i> , 2021, 12, 272-276.	0.8	3
1676	Molecular mechanisms underlining the role of metformin as a therapeutic agent in lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1-18.	2.1	18
1677	NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy. <i>Clinical Lung Cancer</i> , 2021, 22, 1-5.	1.1	43
1678	Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells. <i>Translational Oncology</i> , 2021, 14, 100887.	1.7	10
1679	68-months progression-free survival with crizotinib treatment in a patient with metastatic ALK positive lung adenocarcinoma and sarcoidosis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 984-989.	0.5	0
1681	Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials. <i>Clinical Drug Investigation</i> , 2021, 41, 161-167.	1.1	8
1682	Tumors: Non-small Cell Lung Cancer. , 2021, , 1-10.		0
1683	Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series. <i>Translational Lung Cancer Research</i> , 2021, 10, 487-495.	1.3	19
1684	Successful treatment with crizotinib after alectinib-induced interstitial lung disease. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110429.	0.2	4
1685	The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?. <i>Journal of Intensive Care</i> , 2021, 9, 14.	1.3	13
1686	Synthesis of phenyl (6-(2-fluoro-4-nitrophenoxy)pyrimidin-4-yl)carbamate. <i>AIP Conference Proceedings</i> , 2021, , .	0.3	0

#	ARTICLE	IF	CITATIONS
1687	Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?. <i>Current Oncology Reports</i> , 2021, 23, 10.	1.8	9
1688	Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 607-621.	1.3	9
1689	Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients: A single-institution retrospective analysis. <i>Indian Journal of Cancer</i> , 2022, 59, 251.	0.2	1
1690	Lorlatinib in ALK-Rearranged Lung Cancer. <i>Cancer Cell</i> , 2021, 39, 25-27.	7.7	7
1691	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 139.	1.7	17
1692	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	0.9	31
1693	Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 758-769.	0.9	4
1694	Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 292-303.	1.3	4
1695	Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098055.	1.4	33
1696	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. <i>JCI Insight</i> , 2021, 6, .	2.3	20
1697	Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100291.	0.7	1
1698	Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study. <i>Clinics</i> , 2021, 76, e2251.	0.6	2
1699	Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 603671.	1.3	8
1700	Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100319.	0.7	5
1701	Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis. <i>Molecular Cancer</i> , 2021, 20, 22.	7.9	103
1702	Small-Cell Lung Cancer: Is the Black Box Finally Opening Up?. <i>Cancers</i> , 2021, 13, 236.	1.7	0
1703	Analysis of Clinical Features of ALK Rearrangement Lung Cancer. <i>Advances in Clinical Medicine</i> , 2021, 11, 1-8.	0.0	0
1704	Carcinoma de pulmão no microcítico. <i>Medicine</i> , 2021, 13, 1377-1387.	0.0	2

#	ARTICLE	IF	CITATIONS
1705	The role of MET in chemotherapy resistance. <i>Oncogene</i> , 2021, 40, 1927-1941.	2.6	54
1706	Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 148-160.	1.3	11
1707	Nongenetic Evolution Drives Lung Adenocarcinoma Spatial Heterogeneity and Progression. <i>Cancer Discovery</i> , 2021, 11, 1490-1507.	7.7	67
1708	Precision treatment for metastatic non-small cell lung cancer: A conceptual overview. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 117-127.	0.6	3
1709	Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. <i>ESMO Open</i> , 2021, 6, 100045.	2.0	18
1710	Discovery of a PROTAC targeting ALK with in vivo activity. <i>European Journal of Medicinal Chemistry</i> , 2021, 212, 113150.	2.6	32
1711	BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma. <i>Medicine (United States)</i> , 2021, 100, e24917.	0.4	9
1712	Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing. <i>Diagnostics</i> , 2021, 11, 391.	1.3	20
1713	Real-World Data on Liquid Biopsy Use in Non-Small Cell Lung Cancer in the Community Setting. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 1-5.	0.6	0
1714	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. <i>Clinical Cancer Research</i> , 2021, 27, 2424-2429.	3.2	35
1715	Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach. <i>Oncotarget</i> , 2021, 12, 316-332.	0.8	14
1716	Acute Tubular Injury and Renal Arterial Myocyte Vacuolization Following Crizotinib Administration. <i>Kidney International Reports</i> , 2021, 6, 526-528.	0.4	8
1717	The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e24917.	0.4	8
1718	The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2637-2643.	1.2	2
1719	Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 699.	1.7	15
1720	Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 355-372.	5.7	68
1721	Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. <i>Nature Communications</i> , 2021, 12, 1261.	5.8	52
1722	ALK-rearranged squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2021, 12, 1106-1114.	0.8	12

#	ARTICLE	IF	CITATIONS
1723	High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study. <i>Journal of Translational Medicine</i> , 2021, 19, 92.	1.8	5
1724	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Cancers</i> , 2021, 13, 804.	1.7	76
1725	Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1â€“5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e043628.	0.8	6
1726	OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient. <i>Lung Cancer</i> , 2021, 153, 171-173.	0.9	2
1727	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. <i>Lung Cancer</i> , 2021, 153, 108-116.	0.9	28
1728	A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. <i>Translational Lung Cancer Research</i> , 2021, 10, 1536-1556.	1.3	28
1729	Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma. <i>Scientific Reports</i> , 2021, 11, 5679.	1.6	9
1730	Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2131-2138.	1.0	7
1731	Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. <i>Cancer Medicine</i> , 2021, 10, 2286-2292.	1.3	5
1732	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 145, 183-193.	1.3	15
1734	Cholangiocarcinoma: shedding light on the most promising drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 419-427.	1.9	5
1735	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3120-3133.	5.7	16
1736	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	3.4	14
1737	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2022, 41, 168-179.	0.9	9
1738	Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib. <i>Translational Lung Cancer Research</i> , 2021, 10, 1525-1535.	1.3	11
1739	Case Report: Neoadjuvant and Adjuvant Crizotinib Targeted Therapy in Stage IIIA-N2 ALK-Positive Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 655856.	1.3	8
1740	Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes. <i>Precision Cancer Medicine</i> , 0, 4, 8-8.	1.8	1
1742	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions. <i>Clinical Cancer Research</i> , 2021, 27, 2920-2927.	3.2	42

#	ARTICLE	IF	CITATIONS
1743	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 461-464.	1.1	3
1744	Exploration in the mechanism of fucosterol for the treatment of non-small cell lung cancer based on network pharmacology and molecular docking. <i>Scientific Reports</i> , 2021, 11, 4901.	1.6	13
1745	A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed. <i>BMC Cancer</i> , 2021, 21, 309.	1.1	4
1746	VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers. <i>Cancer Science</i> , 2021, 112, 1853-1864.	1.7	29
1748	Routine Molecular Screening of Patients with Advanced Non-Small Cell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM™ EGFR V2 and NGS Technologies. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 239-250.	1.6	6
1749	EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib. <i>BMJ Case Reports</i> , 2021, 14, e240295.	0.2	2
1750	Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 532-536.	0.5	23
1751	Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer. <i>JCO Global Oncology</i> , 2021, 7, 639-645.	0.8	10
1752	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. <i>Current Problems in Cancer</i> , 2021, 45, 100734.	1.0	9
1753	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , 2021, 11, 650293.	1.3	26
1754	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103299.	2.0	5
1755	Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes. <i>Cancer Cell International</i> , 2021, 21, 219.	1.8	30
1756	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
1757	Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group. <i>Journal of Geriatric Oncology</i> , 2021, 12, 410-415.	0.5	3
1758	Routine Molecular Pathology Diagnostics in Precision Oncology. <i>Deutsches Arzteblatt International</i> , 2021, 118, .	0.6	2
1759	Crizotinib for c-MET amplified advanced NSCLC: a single-center experience. <i>Tumori</i> , 2022, 108, 258-262.	0.6	2
1760	Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , 2021, 99, 435-447.	1.0	6
1761	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19

#	ARTICLE	IF	CITATIONS
1762	Systemic Therapy for Mutation-Driven NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 140-148.	1.0	4
1763	Outcomes of Palliative Radiotherapy in Metastatic Epidural Spinal Cord Compression in Lung Cancer—A Prospective Observational Study from Tata Memorial Hospital. <i>South Asian Journal of Cancer</i> , 2021, 10, 120-126.	0.2	0
1764	Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. <i>Npj Precision Oncology</i> , 2021, 5, 33.	2.3	5
1765	Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively. <i>BMC Cancer</i> , 2021, 21, 445.	1.1	2
1766	High concordance of actionable genomic alterations identified between circulating tumor DNA–based and tissue–based next–generation sequencing testing in advanced non–small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	2.0	37
1767	Factors affecting survival after palliative radiotherapy in patients with lung cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2021, 26, 674-682.	0.3	0
1768	Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies. <i>Cancer Reports</i> , 2021, 4, e1377.	0.6	4
1769	Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100157.	0.6	7
1770	Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib. <i>Clinical Lung Cancer</i> , 2021, 22, e851-e855.	1.1	6
1771	Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.	1.3	10
1772	Utility of Endoscopic Ultrasound with Bronchoscope-guided Fine-needle Aspiration for Detecting Driver Oncogenes in Non-small-cell Lung Cancer during Emergency Situations: Case Series. <i>Internal Medicine</i> , 2021, 60, 1061-1065.	0.3	4
1773	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	1.0	2
1774	Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2237-2251.	1.3	8
1775	VATS right upper lobectomy after alectinib administration for ALK-positive lung adenocarcinoma. <i>The Journal of the Japanese Association for Chest Surgery</i> , 2021, 35, 297-302.	0.0	0
1776	Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview. <i>Cancers</i> , 2021, 13, 2394.	1.7	6
1777	Current advances in the treatment of lung cancer with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 333-341.	0.1	0
1778	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK+ non–small cell lung cancer (ALTA-1L). <i>Lung Cancer</i> , 2021, 155, 68-77.	0.9	12
1779	Oncogenic gene transcripts detection by FISH on liquid-based cytology slides of 338 advanced lung cancer patients. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 270-277.	0.2	2

#	ARTICLE	IF	CITATIONS
1780	Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data. <i>BioMed Research International</i> , 2021, 2021, 1-8.	0.9	1
1781	Characteristics of central nervous system progression in non-small cell lung cancer treated with crizotinib or alectinib. <i>Cancer Reports</i> , 2021, , e1414.	0.6	4
1782	Adherence to National Comprehensive Cancer Network ALK Testing Guidelines for Patients with Advanced Non-small Cell Lung Cancer in U.S. Community Medical Centers. <i>Oncologist</i> , 2021, 26, e1050-e1057.	1.9	10
1783	A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks. <i>Genome Biology</i> , 2021, 22, 156.	3.8	17
1784	Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report. <i>JCO Precision Oncology</i> , 2021, 5, 771-778.	1.5	8
1785	Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap. <i>Scientific Reports</i> , 2021, 11, 9789.	1.6	3
1786	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , 2021, 5, 41.	2.3	22
1787	An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. <i>Bosnian Journal of Basic Medical Sciences</i> , 2021, , .	0.6	4
1788	Recognition and Management of Toxicities from Immunotherapy and Targeted Therapy in Elderly Patients with Lung Cancer. <i>Advances in Oncology</i> , 2021, 1, 73-84.	0.1	0
1789	A Homotypic Membrane-Camouflaged Biomimetic Nanoplatform with Gold Nanocrystals for Synergistic Photothermal/Starvation/Immunotherapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 23469-23480.	4.0	28
1790	Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 2236.	1.0	4
1791	Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 809-817.	1.1	2
1792	Genetic Analysis and Operative Outcomes in Patients with Oncogene-Driven Advanced NSCLC Treated with Cytoreductive Surgery as a Component of Local Consolidative Therapy. <i>Cancers</i> , 2021, 13, 2549.	1.7	3
1793	Targeted Therapies in Older Adults With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 2128-2137.	0.8	7
1794	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 211-221.	1.3	9
1795	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569.	21.5	497
1796	Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 201.	7.1	607
1797	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2021, 16, 827-839.	0.5	24



#	ARTICLE	IF	CITATIONS
1798	Challenges in the Treatment of Oligometastatic Non-small Cell Lung Cancer. , 0, , .		0
1799	Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646526.	1.3	6
1800	Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 487-494.	1.6	9
1801	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1091-1103.	2.5	6
1802	Current clinical trials and patent update on lung cancer: a retrospective review. <i>Lung Cancer Management</i> , 2021, 10, LMT45.	1.5	0
1803	Biomarker Testing for People With Advanced Lung Cancer in England. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100176.	0.6	8
1804	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2021, 22, 71.	1.3	3
1805	Immunotherapy in oncogene addicted non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2736-2751.	1.3	7
1806	Monitoring therapeutic response and resistance with liquid biopsy. <i>Precision Cancer Medicine</i> , 0, 4, 15-15.	1.8	0
1807	Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography. <i>PLoS ONE</i> , 2021, 16, e0252950.	1.1	8
1808	Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. <i>Nature Communications</i> , 2021, 12, 3414.	5.8	65
1809	Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitorâ€œnaive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 87-96.	0.7	18
1810	TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1499-1507.	1.9	50
1811	Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. <i>IScience</i> , 2021, 24, 102522.	1.9	4
1812	HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. <i>Oncogene</i> , 2021, 40, 4625-4651.	2.6	81
1813	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve <i>ALK-, ROS1-</i>, or <i>EGFR</i>-altered Nonâ€œsmall Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1653-1662.	1.9	7
1814	Uterine Leiomyosarcoma with FNI-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib. <i>Case Reports in Oncology</i> , 2021, 14, 812-819.	0.3	5
1815	The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 163-170.	0.0	0

#	ARTICLE	IF	CITATIONS
1816	Targeted therapy for advanced non-small cell lung cancer with ALK translocation: brigatinib expands our capabilities and ensures success in fight against disease progression. <i>Medical Alphabet</i> , 2021, , 53-60.	0.0	0
1817	Basement membrane collagen IV deficiency promotes abdominal aortic aneurysm formation. <i>Scientific Reports</i> , 2021, 11, 12903.	1.6	18
1818	Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6288.	1.8	51
1819	The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden. <i>Pharmacoeconomics</i> , 2021, 39, 941-952.	1.7	8
1820	Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysisâ€targeting chimeras. <i>MedComm</i> , 2021, 2, 341-350.	3.1	36
1821	Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Oncology and Therapy</i> , 2021, 9, 505-524.	1.0	6
1822	Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes. <i>Precision Cancer Medicine</i> , 0, 4, 20-20.	1.8	0
1823	Mutation status and postresection survival of patients with nonâ€small cell lung cancer brain metastasis: implications of biomarker-driven therapy. <i>Journal of Neurosurgery</i> , 2022, 136, 56-66.	0.9	3
1824	Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 72.	1.3	9
1825	Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion. <i>Annals of Translational Medicine</i> , 2021, 9, 1014-1014.	0.7	4
1826	Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 2551-2561.	1.3	12
1827	Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper. <i>Drug Safety</i> , 2021, 44, 825-834.	1.4	5
1828	Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis. <i>Cancers</i> , 2021, 13, 3704.	1.7	18
1830	Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1395-1404.	0.8	4
1831	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200294.	3.0	7
1832	Advances in targeted therapy in nonâ€small cell lung cancer with actionable mutations and leptomeningeal metastasis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, , .	0.7	4
1833	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e148-e153.	1.1	16
1834	Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive nonâ€small cell lung cancer patients. <i>Anti-Cancer Drugs</i> , 2021, 32, 1099-1104.	0.7	8

#	ARTICLE	IF	CITATIONS
1835	Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. <i>Journal of the National Cancer Center</i> , 2021, 1, 123-131.	3.0	5
1836	Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. <i>Biomedicines</i> , 2021, 9, 906.	1.4	30
1837	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	0.9	7
1838	Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer. <i>Gastroenterology</i> , 2021, 161, 196-210.	0.6	23
1839	Paradigm shift in the management of metastatic nonsmall cell lung cancer. <i>International Journal of Clinical Practice</i> , 2021, 75, e14533.	0.8	0
1840	Brigatinib as a treatment of ALK-positive non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 299-305.	0.4	0
1841	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
1842	An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1815-1824.	0.9	1
1843	Comparison of solid tissue sequencing and liquid biopsy accuracy in identification of clinically relevant gene mutations and rearrangements in lung adenocarcinomas. <i>Modern Pathology</i> , 2021, 34, 2168-2174.	2.9	21
1844	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021, 23, 119.	1.8	4
1845	Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients. <i>Human Pathology</i> , 2021, 114, 90-98.	1.1	5
1846	The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. <i>Cancer Cell International</i> , 2021, 21, 454.	1.8	19
1847	Malayoside, a cardenolide glycoside extracted from <i>Antiaris toxicaria</i> Lesch, induces apoptosis in human non-small lung cancer cells via MAPK-Nur77 signaling pathway. <i>Biochemical Pharmacology</i> , 2021, 190, 114622.	2.0	9
1848	A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 512-518.	0.6	1
1849	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	4
1850	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 116-129.	0.5	50
1851	Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. <i>Lung Cancer</i> , 2021, 158, 126-136.	0.9	53
1852	Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021, 22, 833-847.	0.6	4

#	ARTICLE	IF	CITATIONS
1853	Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis. <i>Cancer Cell International</i> , 2021, 21, 426.	1.8	7
1854	Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis. <i>JCO Oncology Practice</i> , 2021, 17, e1085-e1093.	1.4	8
1855	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2029-2039.	0.5	34
1856	Reference standards for gene fusion molecular assays on cytological samples: an international validation study. <i>Journal of Clinical Pathology</i> , 2023, 76, 47-52.	1.0	9
1857	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 987-996.	0.4	1
1858	Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. <i>ESMO Open</i> , 2021, 6, 100187.	2.0	2
1859	A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient. <i>Medicine (United States)</i> , 2021, 100, e26801.	0.4	0
1860	Polyclonal on- and off-target resistance mutations in an <i>EML4-ALK</i> positive non-small cell lung cancer patient under ALK inhibition. <i>Oncotarget</i> , 2021, 12, 1946-1952.	0.8	3
1861	Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non-Small-Cell Lung Cancer from Chile, Brazil, and Peru. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1127-1137.	1.2	1
1862	Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 278.	0.8	3
1863	First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4376.	1.0	8
1864	A novel <i>GHR-ALK</i> fusion gene in a patient with metastatic lung adenocarcinoma and its response to crizotinib: a case report. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110446.	0.4	2
1865	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. <i>Chest</i> , 2021, 160, 1095-1107.	0.4	23
1866	Treatment of brain metastases in ALK-positive non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103400.	2.0	10
1867	Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106841.	0.6	0
1868	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1617.	3.4	105
1869	Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition. <i>Cell Death Discovery</i> , 2021, 7, 264.	2.0	7
1870	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. <i>Cancers</i> , 2021, 13, 4705.	1.7	86

#	ARTICLE	IF	CITATIONS
1871	Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 691253.	1.2	0
1872	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
1873	Immunotherapy for lung cancer: Focusing on chimeric antigen receptor (CAR)-T cell therapy. <i>Current Problems in Cancer</i> , 2022, 46, 100791.	1.0	6
1874	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. <i>Case Reports in Oncology</i> , 2022, 14, 1323-1327.	0.3	4
1875	Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood-Brain Barrier. <i>Pharmaceutics</i> , 2021, 13, 1446.	2.0	11
1876	Engineering chromosome rearrangements in cancer. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	1.2	2
1877	ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 724815.	1.3	11
1878	Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report. <i>Clinical Lung Cancer</i> , 2021, 22, e699-e702.	1.1	2
1879	Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4915-4920.	1.0	3
1880	Long-Term Progression-Free Survival in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Patient Treated With Crizotinib. <i>Journal of Medical Cases</i> , 2021, 12, 366-368.	0.4	1
1881	Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World. <i>Clinical Lung Cancer</i> , 2021, 22, e723-e733.	1.1	7
1882	Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer: A Likely Limited Role on a Deep Bench. <i>JAMA Oncology</i> , 2021, 7, 1615.	3.4	4
1883	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	2.9	10
1884	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103460.	2.0	3
1885	Is cancer biology different in older patients?. <i>The Lancet Healthy Longevity</i> , 2021, 2, e663-e677.	2.0	53
1886	Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. <i>European Journal of Cancer</i> , 2021, 156, 1-11.	1.3	24
1887	The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 713530.	1.3	54
1888	ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis. <i>Lung Cancer</i> , 2021, 161, 9-17.	0.9	16

#	ARTICLE	IF	CITATIONS
1889	Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?. Lung Cancer, 2021, 161, 98-107.	0.9	1
1890	Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?. Translational Oncology, 2021, 14, 101191.	1.7	24
1891	Systemic treatments other than TKI: Reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC. , 2021, , 55-69.		1
1892	State of the art and future perspectives. , 2021, , 177-190.		0
1893	Pulmonary Inflammation and KRAS Mutation in Lung Cancer. Advances in Experimental Medicine and Biology, 2021, 1303, 71-87.	0.8	4
1894	Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 725-737.	1.2	9
1895	Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences, 2021, 22, 593.	1.8	35
1896	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. Current Cancer Research, 2021, , 27-54.	0.2	0
1897	Using Disposable Membrane Cell Collector to Enrich Lung Adenocarcinoma Cells in Bloody Pleural Effusion for Anaplastic Lymphoma Kinase Fusion Gene Detection. Acta Cytologica, 2021, 65, 235-241.	0.7	0
1899	Narrative review: mesenchymal-epithelial transition inhibitors"meeting their target. Translational Lung Cancer Research, 2021, 10, 462-474.	1.3	6
1900	ALK rearranged lung cancer: TKI treatment and outcome. , 2021, , 31-53.		0
1901	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	1.5	2
1902	Crizotinib for recurring non-small cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial. Thoracic Cancer, 2021, 12, 643-649.	0.8	5
1903	Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer. Japanese Journal of Clinical Oncology, 2021, 51, 333-344.	0.6	6
1904	Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals, 2021, 14, 80.	1.7	38
1906	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. Journal of Pathology, 2017, 243, 307-319.	2.1	63
1907	Serious Mental Illness. , 2020, , 91-97.		2
1908	Resistance to ALK Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 147-163.	0.1	1

#	ARTICLE	IF	CITATIONS
1909	Alectinib. Recent Results in Cancer Research, 2018, 211, 247-256.	1.8	12
1910	Genomic Applications in Pulmonary Malignancies. , 2019, , 363-392.		1
1911	Onkologika. , 2017, , 597-639.		1
1913	Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer, 2020, 144, 57-63.	0.9	17
1914	ECOG performance status $\geq 2$ as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis of real world data. Lung Cancer, 2020, 145, 95-104.	0.9	96
1915	Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. Cell Death and Disease, 2020, 11, 111.	2.7	18
1916	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews Clinical Oncology, 2019, 16, 341-355.	12.5	347
1917	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2018, 18, 35-45.	1.5	42
1921	Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: meta-analysis. Thoracic Cancer, 2017, 8, 471-476.	0.8	3
1922	Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice. Thoracic Cancer, 2021, 12, 504-511.	0.8	18
1923	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. Cancer Science, 2020, 111, 2482-2487.	1.7	14
1924	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open, 2017, 2, e000219.	2.0	87
1925	Personalized therapy for lung cancer: Striking a moving target. JCI Insight, 2018, 3, .	2.3	114
1926	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989575.	1.4	39
1927	Emerging therapeutic agents for advanced non-small cell lung cancer. Journal of Hematology and Oncology, 2020, 13, 58.	6.9	161
1928	Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report. American Journal of Case Reports, 2017, 18, 799-804.	0.3	22
1929	Correlation Between Circulating Tumor DNA Levels and Response to Tyrosine Kinase Inhibitors (TKI) Treatment in Non-Small Cell Lung Cancer. Medical Science Monitor, 2017, 23, 3627-3634.	0.5	13
1930	Tumor-Derived Exosomal eIF4E as a Biomarker for Survival Prediction in Patients with Non-Small Cell Lung Cancer. Medical Science Monitor, 2020, 26, e923210.	0.5	9

#	ARTICLE	IF	CITATIONS
1931	Crizotinib-induced acute fatal liver failure in an Asian <i>ALK</i> -positive lung adenocarcinoma patient with liver metastasis: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 1080-1086.	0.3	3
1932	Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis. <i>PLoS ONE</i> , 2016, 11, e0158125.	1.1	18
1933	Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. <i>PLoS ONE</i> , 2017, 12, e0184922.	1.1	54
1934	The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis. <i>PLoS ONE</i> , 2018, 13, e0192161.	1.1	26
1935	ALK Inhibitors in NSCLC- Crizotinib and Beyond. <i>Journal of Cancer Prevention &amp; Current Research</i> , 2017, 8, .	0.1	1
1936	Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada. <i>Oncologist</i> , 2020, 25, e130-e137.	1.9	19
1937	Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer. <i>Oncology &amp; Hematology Review</i> , 2018, 14, 38.	0.2	3
1938	Constructing a global transcriptional regulatory landscape for early non-small cell lung cancer to identify hub genes and key pathways. <i>Aging</i> , 2020, 12, 17948-17957.	1.4	5
1939	Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing. <i>Oncotarget</i> , 2016, 7, 65208-65217.	0.8	49
1940	GBM-associated mutations and altered protein expression are more common in young patients. <i>Oncotarget</i> , 2016, 7, 69466-69478.	0.8	27
1941	Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 70128-70142.	0.8	6
1942	Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions. <i>Oncotarget</i> , 2017, 8, 5540-5565.	0.8	14
1943	Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis. <i>Oncotarget</i> , 2016, 7, 81090-81098.	0.8	9
1944	Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 2771-2780.	0.8	68
1945	Detection of <i>ALK</i> rearrangements in lung cancer patients using a homebrew PCR assay. <i>Oncotarget</i> , 2017, 8, 7722-7728.	0.8	2
1946	The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC. <i>Oncotarget</i> , 2017, 8, 23517-23528.	0.8	26
1947	Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 41631-41640.	0.8	10
1948	C3orf21 ablation promotes the proliferation of lung adenocarcinoma, and its mutation at the rs2131877 locus may serve as a susceptibility marker. <i>Oncotarget</i> , 2017, 8, 33422-33431.	0.8	5



#	ARTICLE	IF	CITATIONS
1949	Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement. <i>Oncotarget</i> , 2017, 8, 58771-58780.	0.8	14
1950	The detection and significance of <i>EGFR</i> and <i>BRAF</i> in cell-free DNA of peripheral blood in NSCLC. <i>Oncotarget</i> , 2017, 8, 49773-49782.	0.8	29
1951	Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. <i>Oncotarget</i> , 2017, 8, 57379-57385.	0.8	9
1952	Intersecting transcriptomic profiling technologies and long non-coding RNA function in lung adenocarcinoma: discovery, mechanisms, and therapeutic applications. <i>Oncotarget</i> , 2017, 8, 81538-81557.	0.8	21
1953	Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with <i>ALK</i> -positive NSCLC. <i>Oncotarget</i> , 2017, 8, 75372-75380.	0.8	9
1954	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. <i>Oncotarget</i> , 2017, 8, 77897-77914.	0.8	19
1955	Comparison of ALK status between primary and corresponding lymph node metastatic tumors in lung cancer patients. <i>Oncotarget</i> , 2017, 8, 108840-108847.	0.8	5
1956	Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 113807-113816.	0.8	8
1957	Targeted drugs for systemic therapy of lung cancer with brain metastases. <i>Oncotarget</i> , 2018, 9, 5459-5472.	0.8	47
1958	Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 9480-9488.	0.8	23
1959	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2018, 9, 11846-11857.	0.8	2
1960	Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. <i>Oncotarget</i> , 2018, 9, 15340-15349.	0.8	4
1961	Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein. <i>Oncotarget</i> , 2018, 9, 20213-20218.	0.8	4
1962	Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 22137-22146.	0.8	29
1963	Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 27789-27796.	0.8	9
1964	Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. <i>Oncotarget</i> , 2018, 9, 35181-35194.	0.8	30
1965	Targeted therapies for advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 37589-37607.	0.8	52
1966	Ca <sup>2+</sup> /calmodulin-dependent protein kinase II <sup>3</sup> enhances stem-like traits and tumorigenicity of lung cancer cells. <i>Oncotarget</i> , 2015, 6, 16069-16083.	0.8	38

#	ARTICLE	IF	CITATIONS
1967	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	0.8	32
1968	SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. <i>Oncotarget</i> , 2016, 7, 638-655.	0.8	28
1969	Mapping of deletion breakpoints at the <i>CDKN2A</i> locus in melanoma: detection of <i>MTAP-ANRIL</i> fusion transcripts. <i>Oncotarget</i> , 2016, 7, 16490-16504.	0.8	22
1970	Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer. <i>Oncotarget</i> , 2016, 7, 24860-24870.	0.8	25
1971	Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, <i>Drosophila</i> and mice. <i>Oncotarget</i> , 2016, 7, 29011-29022.	0.8	51
1972	The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. <i>Oncotarget</i> , 2016, 7, 46750-46767.	0.8	97
1973	Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. <i>Oncotarget</i> , 2016, 7, 34442-34452.	0.8	41
1974	Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. <i>Oncotarget</i> , 2016, 7, 46628-46635.	0.8	36
1975	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase ( <i>ALK</i> ) alterations in patients with non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 37160-37176.	0.8	8
1976	Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies. <i>Acta Medica Okayama</i> , 2020, 74, 371-379.	0.1	2
1977	Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1307-1307.	0.7	14
1978	The KEY to the end of chemotherapy in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2017, 5, 166-166.	0.7	4
1979	Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance. <i>Annals of Translational Medicine</i> , 2017, 5, 377-377.	0.7	15
1980	Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. <i>Annals of Translational Medicine</i> , 2017, 5, 371-371.	0.7	2
1981	Alectinib can replace crizotinib as standard first-line therapy for ALK-positive lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 433-433.	0.7	3
1982	The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138.	0.7	29
1983	Treating ALK-positive non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 141-141.	0.7	23
1984	Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 106-106.	0.7	11

#	ARTICLE	IF	CITATIONS
1985	Systemic therapy of elderly patients with advanced non-small cell lung cancer—individualized treatment is key. <i>Annals of Translational Medicine</i> , 2019, 7, S48-S48.	0.7	3
1986	EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. <i>Translational Cancer Research</i> , 2018, 8, S76-S78.	0.4	19
1987	Rare GCC2-ALK fusion G13:A20 detected by next generation sequencing in non-small cell lung cancer patients and treatment response. <i>Translational Cancer Research</i> , 2019, 8, 2187-2191.	0.4	4
1988	A case report of exceptional clinical response to chemoradiotherapy and tyrosine kinase inhibitors in a patient with EML4-ALK fusion variant 1 non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2500-2507.	1.3	3
1989	How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 2521-2534.	1.3	15
1990	Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2656-2673.	1.3	16
1991	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review. <i>Translational Lung Cancer Research</i> , 2020, 9, 2674-2685.	1.3	2
1992	Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies. <i>Translational Lung Cancer Research</i> , 2020, 9, 2581-2598.	1.3	11
1993	ALK gene expression status in pleural effusion predicts tumor responsiveness to crizotinib in Chinese patients with lung adenocarcinoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 606-616.	0.7	7
1994	Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2019, 31, 349-356.	0.7	5
1995	Crizotinib-induced Rectal Perforation with Abscess. <i>Internal Medicine</i> , 2017, 56, 3211-3213.	0.3	5
1996	Crizotinib Versus Chemotherapy on ALK-positive NSCLC: A Systematic Review of Efficacy and Safety. <i>Current Cancer Drug Targets</i> , 2018, 19, 41-49.	0.8	6
1997	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
1998	A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 1129-1144.	1.0	16
1999	RT-PCR for Detecting ALK Translocations in Cytology Samples from Lung Cancer Patients. <i>Anticancer Research</i> , 2017, 37, 3295-3299.	0.5	8
2000	Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review. <i>Anticancer Research</i> , 2019, 39, 897-902.	0.5	10
2001	Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. <i>In Vivo</i> , 2017, 31, 475-479.	0.6	7
2002	A Case of EML4-ALK-positive Lung Adenocarcinoma That Was Successfully Treated with Alectinib After the Discontinuation of Crizotinib due to Drug-induced Edema and Stasis Dermatitis. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 212-217.	0.0	3

#	ARTICLE	IF	CITATIONS
2003	Improvement of Crizotinib-resistant Leptomeningeal Carcinomatosis by Switching to Alectinib in a Case of Non-small Cell Lung Cancer Anaplastic Lymphoma Kinase (ALK) Translocation. Japanese Journal of Lung Cancer, 2015, 55, 223-227.	0.0	3
2004	A Case of ALK-rearranged Squamous Cell Lung Cancer Accompanied by Severe Liver Dysfunction Caused by Crizotinib but Not Alectinib. Japanese Journal of Lung Cancer, 2015, 55, 53-58.	0.0	4
2005	The Dramatic and Long-lasting Effect of Alectinib Against Crizotinib-resistant Leptomeningeal Carcinomatosis in a Patient with ALK-positive Lung Cancer. Japanese Journal of Lung Cancer, 2016, 56, 263-267.	0.0	1
2006	A Case of Post-operative Recurrence ALK-positive Lung Cancer Accompanied by Liver Dysfunction and Drug Eruption Caused by Crizotinib But Not Alectinib. Japanese Journal of Lung Cancer, 2016, 56, 337-341.	0.0	1
2007	Treatment of ALK-positive Lung Cancer with Crizotinib-derived Complexed Renal Cysts Using Alectinib and Ceritinib: a Case Study. Japanese Journal of Lung Cancer, 2019, 59, 260-264.	0.0	1
2008	Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting. Journal of Clinical Pathways: the Foundation of Value-based Care, 2018, 4, 49-54.	0.2	15
2009	Exhaled Breath Condensate: A Non-Invasive Source for Tracking of Genetic and Epigenetic Alterations in Lung Diseases. Pharmaceutical Sciences, 2020, 27, 149-161.	0.1	6
2012	Histone deacetylase inhibitor OBPA801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis. International Journal of Oncology, 2020, 56, 848-856.	1.4	1
2013	Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (Review). Oncology Reports, 2021, 45, 13-28.	1.2	15
2014	KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. Korean Journal of Internal Medicine, 2017, 32, 514-522.	0.7	21
2015	Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 1116-1124.	0.7	6
2016	Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Korean Journal of Internal Medicine, 2019, 34, 50-59.	0.7	14
2017	Targeted Therapy for Non-Small Cell Lung Cancer. Korean Journal of Medicine, 2020, 95, 78-88.	0.1	3
2018	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. Journal of Thoracic Disease, 2015, 7, 1181-8.	0.6	17
2019	Interpretation of lung cancer study outcomes. Journal of Thoracic Disease, 2015, 7, E541-7.	0.6	3
2020	Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. Translational Lung Cancer Research, 2015, 4, 639-41.	1.3	16
2021	PROFILE 1014: lessons for the new era of lung cancer clinical research. Translational Lung Cancer Research, 2015, 4, 642-8.	1.3	9
2022	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. Translational Lung Cancer Research, 2015, 4, 392-403.	1.3	24

#	ARTICLE	IF	CITATIONS
2023	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 584-97.	1.3	52
2024	Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies. <i>Translational Lung Cancer Research</i> , 2015, 4, 545-52.	1.3	70
2025	Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. <i>Chinese Clinical Oncology</i> , 2015, 4, 20.	0.4	14
2026	Current Status of Immunotherapy for Lung Cancer and Future Perspectives. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 14.	0.7	19
2027	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16
2028	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. <i>Indian Journal of Cancer</i> , 2017, 54, 89.	0.2	5
2029	New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer. <i>Indian Journal of Cancer</i> , 2017, 54, 203.	0.2	6
2030	Management of leptomeningeal metastases in non-small cell lung cancer. <i>Indian Journal of Cancer</i> , 2019, 56, 1.	0.2	14
2031	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line – Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17.	0.2	8
2032	First-line management of metastatic non-small cell lung cancer: An Indian perspective. <i>South Asian Journal of Cancer</i> , 2019, 08, 073-079.	0.2	4
2033	Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey. <i>South Asian Journal of Cancer</i> , 2018, 07, 203-206.	0.2	7
2034	Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association. <i>South Asian Journal of Cancer</i> , 2019, 08, 250-254.	0.2	4
2035	c-Met as a Target for Personalized Therapy. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 13-31.	1.7	102
2036	Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 691-700.	1.3	50
2037	Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment. <i>Cancer Research and Treatment</i> , 2018, 50, 1164-1174.	1.3	5
2038	Development of Aseptic Renal Abscess in a Patient with Non-Small-Cell Lung Cancer with ALK Translocation during Crizotinib Treatment. <i>Advances in Lung Cancer (Irvine)</i> , 2015, 04, 53-57.	0.2	1
2039	Defining lung cancer stem cells exosomal payload of miRNAs in clinical perspective. <i>World Journal of Stem Cells</i> , 2020, 12, 406-421.	1.3	16
2040	Renal complication of crizotinib: Crizotinib-associated complex renal cyst. <i>The Asean Journal of Radiology</i> , 2020, , 44-56.	0.1	1

#	ARTICLE	IF	CITATIONS
2041	Complete response in anaplastic lymphoma kinase-rearranged oncocyctic thyroid cancer: A case report and review of literature. <i>World Journal of Clinical Oncology</i> , 2020, 11, 495-503.	0.9	17
2042	Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. <i>World Journal of Clinical Oncology</i> , 2015, 6, 104.	0.9	12
2043	UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells. <i>BMB Reports</i> , 2018, 51, 642-647.	1.1	25
2044	Inflammatory myofibroblastic tumour arising incidentally as a polypoid lesion in the gallbladder. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2015, 51, .	0.3	3
2045	Alectinib and Brigatinib: â€˜New Second-Generation â€™ALK Inhibitors for the Treatment of Nonâ€™Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, .	0.2	6
2046	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
2047	Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicatorsâ„¢ (CII). <i>Drugs in Context</i> , 2017, 6, 1-12.	1.0	3
2048	First-line alectinib for ALK-positive lung cancer: is there room for further improvement?. <i>Drugs in Context</i> , 2018, 7, 1-6.	1.0	3
2049	Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report. <i>Cureus</i> , 2017, 9, e1068.	0.2	3
2050	Front-Line Treatment for Advanced Non-Small-Cell Lung Cancer and ALK Fusion: A Network Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2052	Les patients ALK et ROS1 : quelle sÃ©quence ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S174-2S184.	0.0	0
2054	Brigatinib treated <scp>ALK</scp> positive lung squamous cell carcinoma after failed chemotherapy: A case report. <i>Thoracic Cancer</i> , 2021, 12, 3273-3276.	0.8	3
2055	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Nonâ€™Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 72-81.	1.1	17
2056	Highly sensitive detection of driver mutations from cytological samples and cfDNA in lung cancer. <i>Cancer Medicine</i> , 2021, 10, 8595-8603.	1.3	3
2057	Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. <i>Scientific Reports</i> , 2021, 11, 20939.	1.6	4
2058	Phaseâ€™separated foci of EML4â€™ALK facilitate signalling and depend upon an active kinase conformation. <i>EMBO Reports</i> , 2021, 22, e53693.	2.0	31
2059	Realâ€™world data on NGS using the Oncomine DxTT for detecting genetic alterations in nonâ€™smallâ€™cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	1.7	31
2060	Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy. <i>Frontiers in Oncology</i> , 2021, 11, 684865.	1.3	4

#	ARTICLE	IF	CITATIONS
2061	Unique Genomic Alterations of Cerebrospinal Fluid Cell-Free DNA Are Critical for Targeted Therapy of Non-Small Cell Lung Cancer With Leptomeningeal Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 701171.	1.3	6
2062	A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. <i>Pharmacological Research</i> , 2021, 174, 105931.	3.1	7
2063	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. <i>Thoracic Surgery Clinics</i> , 2021, 31, 399-406.	0.4	1
2064	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
2065	Past and Current Developments in ALK-TKI Resistant NSCLC. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 936-940.	0.0	0
2066	Current Status and Future Perspective on Cytotoxic Agents for Squamous Cell Carcinoma of the Lung. <i>Japanese Journal of Lung Cancer</i> , 2015, 55, 973-981.	0.0	0
2069	Targeted Therapies for Non-Small Cell Lung Cancer. <i>Current Clinical Pathology</i> , 2015, , 89-101.	0.0	1
2071	Oncogenic drivers and immunotherapy: staying one step ahead of lung cancer. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 260-267.	0.1	0
2072	ALK Rearrangement in Anaplastic Thyroid Carcinoma: A Discovery Towards a Personalized Approach?. <i>Journal of Nuclear Medicine &amp; Radiation Therapy</i> , 2016, 07, .	0.2	0
2073	14. Molecular Target Therapy for Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 128b-129a.	0.0	0
2074	<i>Neue Arzneimittel</i> 2015. , 2016, , 49-134.		2
2075	14. Molecular Target Therapy for Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 1840-1848.	0.0	0
2076	VII. Developments of Chemotherapy and Improvements of Prognosis in Lung Cancer. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2016, 105, 997-1003.	0.0	0
2077	Successful Desensitization Therapy with Crizotinib for Disease-recurrence of Resected Lung Adenocarcinoma. <i>Japanese Journal of Lung Cancer</i> , 2016, 56, 215-218.	0.0	0
2079	Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-188.	0.1	0
2080	TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 185-185.	0.7	0
2082	Cerebrospinal Fluid Concentration of Crizotinib and Its Activity Against Brain Metastasis in an Elderly Patient. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 832-837.	0.0	0
2083	<i>Cancer Drug Delivery</i> . , 2017, , 185-228.		0

#	ARTICLE	IF	CITATIONS
2084	Methods in Molecular Diagnosis. , 2017, , 63-77.		0
2085	ALK Mutant. , 2017, , 191-197.		0
2086	Gene Signature. , 2017, , 279-292.		1
2087	Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region. Annals of Thoracic Medicine, 2017, 12, 219.	0.7	0
2088	Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Translational Cancer Research, 2017, 6, S151-S157.	0.4	2
2089	Treatment After Crizotinib Resistance in ALK+ Non-Small-Cell Lung Cancer. UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, 2017, 27, 60-68.	0.1	0
2090	Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer. Annals of Translational Medicine, 2017, 5, 165-165.	0.7	0
2091	Nicht-kleinzelliges Lungenkarzinom. Pharma-Kritik (discontinued), 2017, 39, .	0.0	0
2092	Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233.		0
2093	Translocations as Predictive Biomarkers in Lung Cancer. Molecular Pathology Library, 2018, , 159-171.	0.1	0
2094	Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure. Anticancer Research, 2017, 37, 6477-6480.	0.5	7
2095	Crizotinib: From Chemical Entity to Anticancer Agent. Journal of Pharmacy and Pharmacology, 2017, 5, .	0.1	0
2096	Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-“Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	1
2098	Respiratory Organ Aging and Cancer. , 2018, , 1-30.		0
2099	Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer. Translational Cancer Research, 2018, 8, S48-S54.	0.4	1
2101	Pediatric Anaplastic Large Cell Lymphoma-“A Review. Oncology & Hematology Review, 2018, 14, 21.	0.2	1
2102	Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform. Translational Cancer Research, 2018, 8, S3-S15.	0.4	3
2103	Onkologika. , 2018, , 645-691.		1



#	ARTICLE	IF	CITATIONS
2104	ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer?. Respiratory Disease Series, 2018, , 295-315.	0.1	0
2105	Relative Chemo-, Hormonal, and Immunosensitivity. , 2018, , 29-40.		0
2106	Tratamiento de c�ncer de pulm�n metast�sico (estadio IV) de c�lula no peque�a : consenso de expertos, Asociaci�n Colombiana de Hematolog�a y Oncolog�a (ACHO).. Revista Colombiana De Hematolog�a Y Oncolog�a, 2018, 5, 61-71.	0.0	1
2107	The Treatment Strategy for ALK-positive Non-small-cell Lung Carcinoma. Japanese Journal of Lung Cancer, 2018, 58, 258-261.	0.0	0
2108	Congr�s de lâ™association am�ricaine de recherche contre le cancer � AACR 2018. Oncologie, 2018, 20, 49-70.	0.2	0
2109	Non-small-cell lung cancer (NSCLC) harboring driver mutation (EGFR mutation or ALK translocations) with clinical characteristics and management in a real-life setting: a retrospective observational multicenter case series study. Ortado�y T�p Dergisi, 2018, 10, 361-367.	0.1	0
2110	K�rli H�creli D� Akci�yer Kanseri Hastalar�nda Onkogen Mutasyonlar�n Ara�tmas�, S�leyman Demirel �niversitesi T�p Fak�ltesi Dergisi, 0, , .	0.0	0
2111	Treatment of patients with non-small cell lung cancer with ALK rearrangement. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT/Overlo	0.0	0
2112	Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +). Meditsinskiy Sovet, 2018, , 68-72.	0.1	0
2113	Inflammatory and Connective Tissue Disorders of the Aorta. , 2019, , 231-258.		1
2114	Non small cell lung cancer with targetable driver alterations: Imaging perspective. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	0
2115	Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma. Indian Journal of Pathology and Microbiology, 2019, 62, 566.	0.1	0
2116	Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 481-488.	0.7	5
2118	Onkologika. , 2019, , 817-875.		0
2119	Nursing Considerations with ALK and ROS1 Inhibitors in NSCLC. , 2019, , 27-37.		0
2120	Stereotactic Body Radiation Therapy (SBRT) for Lung Metastases. , 2019, , 247-264.		0
2122	New opportunities in the treatment of patients with ALK-positive non-small cell lung cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 226.	0.0	1
2123	Anaplastic Lymphoma Kinase. Current Cancer Research, 2019, , 31-54.	0.2	0

#	ARTICLE	IF	CITATIONS
2124	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
2125	Les avancées dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le réanimateur. Medecine Intensive Reanimation, 2019, 28, 290-299.	0.1	0
2126	Experiencia en el manejo de pacientes con Cáncer de Pulmón Avanzado ALK+ en el Instituto Oncológico Nacional de Panamá. Revista Medica De Panama, 2019, 38, .	0.0	0
2127	What are the Uncommon Anaplastic Lymphoma Kinase (ALK) Fusions in Non-Small Cell Lung Cancer?. Integrative Journal of Medical Sciences, 0, 6, .	0.0	0
2128	Talc Pleurodesis in Pleural Disease. , 2019, , .		0
2130	Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. Revista Colombiana De Hematología Y Oncología, 2019, 6, 10-22.	0.0	0
2131	Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria. , 2019, , .		0
2132	Analysis of real-word mutations of lung cancer driver genes in five regions of China. Translational Cancer Research, 2019, 8, 2581-2592.	0.4	4
2133	Determining Missing Key Elements in Oncology Information System to Improve Patient Experience and Clinical Care. Healthcare Delivery in the Information Age, 2020, , 567-586.	0.3	0
2134	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
2135	Clinical case of prolonged use of alectinib in the treatment of ALK-positive NSCLC. Meditsinskiy Sovet, 2019, , 120-124.	0.1	0
2137	Systemic Therapy of Brain Metastases: Lung Cancer. , 2020, , 207-217.		0
2140	Cardiovascular effects of innovative therapies in lung cancer. , 2020, , 154-166.		0
2141	Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy. Journal of Pediatric Hematology/Oncology, 2021, 43, e521-e524.	0.3	0
2144	Prognostic effects of the expression of inhibitor of DNA-binding family members on patients with lung adenocarcinoma. Oncology Letters, 2020, 20, 1-1.	0.8	3
2145	Long-Term Recurrence of Completely Resected NSCLC. JTO Clinical and Research Reports, 2020, 1, 100076.	0.6	1
2146	Kystes rénaux complexes sous crizotinib. Journal D'imagerie Diagnostique Et Interventionnelle, 2021, , .	0.0	0
2147	A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report. Frontiers in Oncology, 2021, 11, 727662.	1.3	3

#	ARTICLE	IF	CITATIONS
2148	Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. <i>BMC Cancer</i> , 2021, 21, 1162.	1.1	2
2149	Clinicopathological features and resistance mechanisms in ROS1-rearranged lung cancer: A multicenter study. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 177-186.	1.5	7
2150	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. <i>Topics in Medicinal Chemistry</i> , 2020, , 125-153.	0.4	0
2151	Crizotinib Wins the Battle against Advanced ALK-Positive NSCLC: A Meta Analysis for Phase 3 and 4 Clinical Trails. <i>Advances in Clinical Medicine</i> , 2020, 10, 724-732.	0.0	0
2152	Testing for Driver Oncogenes is Essential for the Optimal Treatment of Advanced Non-small-cell Lung Cancer. <i>Juntendo Medical Journal</i> , 2020, 66, 403-409.	0.1	0
2153	Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. <i>Biomarkers in Medicine</i> , 2020, 14, 1651-1662.	0.6	0
2154	Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 2494-2499.	1.3	7
2156	Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. <i>Drugs in Research and Development</i> , 2021, 21, 65-78.	1.1	1
2157	Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment. <i>Current Oncology</i> , 2020, 27, 552-559.	0.9	4
2158	Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case. <i>Meditsinskiy Sovet</i> , 2020, , 181-186.	0.1	0
2159	Application Research of Precision Medical Model Based on Big Data in Primary Health Care in China. <i>African and Asian Studies</i> , 2020, 19, 323-335.	0.2	2
2160	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2599-2617.	1.3	10
2161	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
2162	Biomarker Driven Cancer Therapeutics: Existing Tools and Remaining Gaps. <i>Open Access Library Journal (oalib)</i> , 2020, 07, 1-10.	0.1	0
2163	Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2019, 6, 10-22.	0.0	0
2164	Leptomeningeal Disease in Solid Cancers. , 2020, , 409-427.		0
2165	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
2166	Genetics of Lung Cancer. <i>Respiratory Medicine</i> , 2020, , 87-103.	0.1	0

#	ARTICLE	IF	CITATIONS
2167	Therapy Response Imaging in Thoracic Malignancy. <i>Medical Radiology</i> , 2020, , 79-97.	0.0	0
2168	The Relationship Between Primary Tumor Localization and Driver Mutation in Lung Cancer. <i>Eurasian Journal of Medicine and Oncology</i> , 0, , .	1.0	0
2169	Anaplastic lymphoma kinase-positive metastatic non-small-cell lung cancer: Emerging resistance and treatment options. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 403.	0.1	2
2173	Renal complication of crizotinib: Crizotinib-associated complex renal cyst. <i>The Asean Journal of Radiology</i> , 2020, 21, 44-56.	0.1	0
2174	Utilidad cl�nica de la biopsia l�quida para el diagn�stico y seguimiento de los pacientes con CPNM y <i>EML4-ALK</i> . <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2020, 1, .	0.1	0
2175	Implementation of a molecular tumour board in LATAM: the impact on treatment decisions for patients evaluated at Instituto Alexander Fleming, Argentina. <i>Ecancelmedscience</i> , 2021, 15, 1312.	0.6	3
2176	Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 754768.	1.3	13
2177	Sequencing Therapy for Patients With Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 945-948.	2.3	0
2178	Experience of using Crizotinib in patients with ALKpositive non-small cell lung cancer. <i>Meditinskiy Sovet</i> , 2020, , 176-181.	0.1	0
2179	Cancer Drug Delivery. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 0, , 52-95.	0.3	0
2180	Perspective of a pulmonologist: what might we expect and what do we need to know?. , 0, , 261-273.		0
2181	Multiple Choice Questions with explanations. , 0, , 1-544.		0
2182	Question 180. , 0, , 373-374.		0
2183	Tyrosine kinase inhibitors in the treatment of advanced lung cancer from example of preferential medicine provision in Moscow city. <i>Pulmonologiya</i> , 2020, 30, 463-472.	0.2	1
2184	Landmark Studies of Targeted Therapies for Advanced Non-Small Cell Lung Cancer: A Guide for Pulmonologists. <i>Current Respiratory Medicine Reviews</i> , 2020, 16, 5-10.	0.1	0
2185	Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	4
2186	CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS. <i>Siberian Journal of Oncology</i> , 2020, 19, 132-137.	0.1	0
2187	Immunotherapy for Lung Cancer��Improving Outcomes in Patients With Locally Advanced Non��Small Cell Lung Cancer With Immunotherapy. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 548-554.	1.0	2

#	ARTICLE	IF	CITATIONS
2188	Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK-Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100082.	0.6	3
2189	Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care. <i>Journal of Thoracic Disease</i> , 2014, 6, 1888-91.	0.6	0
2190	Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 32.	0.7	0
2191	Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements. <i>Journal of Thoracic Disease</i> , 2015, 7, 220-3.	0.6	3
2192	Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate? An update incorporating the DELTA trial data. <i>Journal of Thoracic Disease</i> , 2015, 7, 224-6.	0.6	2
2193	Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning. <i>Translational Lung Cancer Research</i> , 2015, 4, 649-52.	1.3	2
2194	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 704-12.	1.3	8
2195	Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 1667-1679.	0.0	10
2196	Prevalence of EGFR and ALK Mutations in Lung Adenocarcinomas in the Levant Area - a Prospective Analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 107-114.	0.5	9
2197	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. <i>Lung India</i> , 2017, 34, 405-408.	0.3	1
2198	Molecular Targets in Non-Small Cell Lung Cancer. <i>Ochsner Journal</i> , 2017, 17, 388-392.	0.5	20
2209	Cyclooxygenase inhibitors combined with deuterium-enriched water augment cytotoxicity in A549 lung cancer cell line via activation of apoptosis and MAPK pathways. <i>Iranian Journal of Basic Medical Sciences</i> , 2018, 21, 508-516.	1.0	6
2210	Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 1735-1738.	0.5	1
2212	Symptom Management Strategies for Patients Receiving Anaplastic Lymphoma Kinase Inhibitors for Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 729-735.	0.2	2
2213	Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 94-101.	0.2	10
2215	Palatine tonsillar metastasis of lung adenocarcinoma: an unusual immunohistochemical phenotype and a potential diagnostic pitfall. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 2288-2292.	0.5	1
2216	Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 3647-3655.	0.5	7
2220	Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. <i>Journal of Thoracic Disease</i> , 2020, 12, 5505-5516.	0.6	0

#	ARTICLE	IF	CITATIONS
2221	Efficacy and safety of crizotinib plus bevacizumab in positive non-small cell lung cancer: an open-label, single-arm, prospective observational study. American Journal of Translational Research (discontinued), 2021, 13, 1526-1534.	0.0	4
2224	Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer. Precision Cancer Medicine, 0, 5, 4-4.	1.8	1
2225	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, 52, 53-64.	0.6	0
2226	Recent advances in lung cancer genomics: Application in targeted therapy. Advances in Genetics, 2021, 108, 201-275.	0.8	5
2227	Severe Skin Toxicity Caused by Sequential Anti-PD-1 Antibody and Alectinib in Non-small-cell Lung Cancer: A Report of Two Cases and a Literature Review. Internal Medicine, 2022, 61, 1735-1738.	0.3	3
2228	Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: "The Light at the End of the Tunnel". Case Reports in Oncology, 2021, 14, 1616-1620.	0.3	0
2229	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 369-402.	0.1	5
2230	The need for speed in advanced non-small cell lung cancer: A population kinetics assessment. Cancer Medicine, 2021, 10, 9040-9046.	1.3	11
2232	Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review. International Journal of Molecular Sciences, 2021, 22, 12244.	1.8	2
2233	Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients. Medicina (Lithuania), 2021, 57, 1252.	0.8	5
2235	Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials. BMC Cancer, 2021, 21, 1278.	1.1	13
2236	Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib. Diagnostics, 2021, 11, 2170.	1.3	8
2237	Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. Oncotarget, 2021, 12, 2375-2387.	0.8	12
2238	The Impact of Core Tissues on Successful Next-Generation Sequencing Analysis of Specimens Obtained through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. Cancers, 2021, 13, 5879.	1.7	4
2239	Understanding Factors Associated With Anaplastic Lymphoma Kinase Testing Delays in Patients With Non-Small Cell Lung Cancer in a Large Real-World Oncology Database. Archives of Pathology and Laboratory Medicine, 2022, 146, 975-983.	1.2	3
2240	Effect of targeted therapy and immunotherapy on advanced non-small cell lung cancer outcomes in the real world. Cancer Medicine, 2022, 11, 86-93.	1.3	19
2241	Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS). ESMO Open, 2021, 6, 100315.	2.0	18
2242	Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China. Thoracic Cancer, 2021, , .	0.8	3

#	ARTICLE	IF	CITATIONS
2243	Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. <i>ESMO Open</i> , 2021, 6, 100319.	2.0	47
2244	Colonic polyp-rare site of metastasis from primary lung carcinoma: Clinical presentations and outcome. <i>Lung India</i> , 2021, 38, 581.	0.3	0
2245	Epidemiological, clinical profile, and treatment outcome of stage iv nonsquamous nonsmall cell lung cancer patients presenting to tertiary care hospital in North India. <i>Oncology Journal of India</i> , 2021, 5, 104.	0.1	0
2246	Tumors: Non-small Cell Lung Cancer. , 2021, , 5270-5279.		0
2247	ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data. <i>Oncologist</i> , 2022, 27, e76-e84.	1.9	3
2248	Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. <i>ESMO Open</i> , 2022, 7, 100342.	2.0	11
2249	The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor. <i>Translational Oncology</i> , 2022, 17, 101338.	1.7	21
2250	Lungenkarzinom: Mehr Optionen für Patienten im fortgeschrittenen Stadium. , , .		0
2251	Pulmonary pleomorphic carcinoma harboring epidermal growth factor receptor mutation: Response to afatinib. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 103.	0.2	1
2252	Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status. <i>Journal of Thoracic Disease</i> , 2020, 12, 5505-5516.	0.6	0
2253	Association between BRAF mutant classification and the efficacy of pemetrexed-based chemotherapy in Chinese advanced non- small cell lung cancer patients: a multicenter retrospective study. <i>Translational Cancer Research</i> , 2020, 9, 6039-6049.	0.4	1
2254	Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , .	0.1	3
2255	Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. <i>Cancers</i> , 2022, 14, 718.	1.7	5
2256	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 2022, 2022, CD013453.	1.5	18
2257	A Case of Advanced Non-Small-Cell Lung Cancer With Response to Alectinib and Favorable Quality of Life. <i>Cureus</i> , 2022, 14, e21170.	0.2	0
2259	ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. <i>Clinical Cancer Research</i> , 2022, 28, 2506-2516.	3.2	19
2260	Complications following novel therapies for non-small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
2261	Effect of Gefitinib Combined with Chemotherapy in Patients with Advanced NSCLC: A Retrospective Cohort Study. <i>International Journal of General Medicine</i> , 2022, Volume 15, 637-644.	0.8	2

#	ARTICLE	IF	CITATIONS
2262	Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer. <i>Cancer Reports</i> , 2022, , e1483.	0.6	2
2263	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 328-332.	0.5	4
2264	Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 780655.	1.3	12
2265	The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103602.	2.0	5
2266	The application of radiomics in predicting gene mutations in cancer. <i>European Radiology</i> , 2022, 32, 4014-4024.	2.3	30
2267	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	0.8	242
2268	Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 782682.	1.3	4
2269	Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2022, 17, 43-51.	1.7	11
2270	A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 2-6.	2.3	3
2271	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 37-44.	2.3	7
2272	Clinical characteristics of non-small cell lung cancer patients with <i>EGFR</i> mutations and <i>ALK&amp;ROS1</i> fusions. <i>Clinical Respiratory Journal</i> , 2022, 16, 216-225.	0.6	4
2273	Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). <i>Cancers</i> , 2022, 14, 769.	1.7	9
2274	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	3.4	2
2275	A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC. <i>Cancers</i> , 2022, 14, 779.	1.7	3
2276	Targeting un-MET needs in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 164, 56-68.	0.9	15
2277	A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer. <i>Lung Cancer</i> , 2022, 165, 34-42.	0.9	20
2278	ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). <i>Lung Cancer</i> , 2022, 165, 54-62.	0.9	6
2279	EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling. <i>Cellular Signalling</i> , 2022, 92, 110264.	1.7	13



#	ARTICLE	IF	CITATIONS
2280	Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. <i>Diagnostic Pathology</i> , 2022, 17, 27.	0.9	3
2281	c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. <i>BMC Medicine</i> , 2022, 20, 59.	2.3	3
2282	Podcast on the Management of Adverse Events Associated with Lorlatinib. <i>Advances in Therapy</i> , 2022, 39, 1447.	1.3	1
2283	Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103622.	2.0	6
2284	Molecular testing on serous effusion: An update. <i>CytoJournal</i> , 2021, 18, 35.	0.8	3
2285	Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. <i>Npj Precision Oncology</i> , 2021, 5, 100.	2.3	21
2290	Neurological complications of lung cancer. , 2022, , 243-276.		0
2291	Target therapy in cancer treatment. , 2022, , .		0
2292	A radiologist's guide to novel anticancer therapies in the era of precision medicine. <i>European Journal of Radiology Open</i> , 2022, 9, 100406.	0.7	2
2293	Imaging Biomarkers in Thoracic Oncology: Current Advances in the Use of Radiomics in Lung Cancer Patients and its Potential Use for Therapy Response Prediction and Monitoring. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2022, , .	0.7	0
2294	ROS1 fusion lung adenosquamous carcinoma patient with short-term clinical benefit after crizotinib treatment: a case report. <i>Annals of Translational Medicine</i> , 2022, 10, 157-157.	0.7	4
2295	Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 1184.	1.7	16
2296	Cancer cachexia as a determinant of efficacy of first-line pembrolizumab in patients with advanced non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2022, 16, 91.	0.4	7
2297	The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 1-6.	0.7	3
2298	A Retrospective Study of the Utility of the OncoPrint Dx Target Test in Clinical Practice. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 26-32.	0.0	2
2299	Assisting Multitargeted Ligand Affinity Prediction of Receptor Tyrosine Kinases Associated Nonsmall Cell Lung Cancer Treatment with Multitasking Principal Neighborhood Aggregation. <i>Molecules</i> , 2022, 27, 1226.	1.7	3
2300	Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2022, 12, 267.	1.1	4
2301	Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 772090.	1.1	3

#	ARTICLE	IF	CITATIONS
2302	Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC. <i>Cancer Management and Research</i> , 2022, Volume 14, 843-850.	0.9	8
2303	Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 762338.	1.3	0
2304	Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 646-662.	0.5	2
2305	Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 315-329.	1.3	17
2306	Palliative Systemic Therapy Given near the End of Life for Metastatic Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 1316-1325.	0.9	3
2307	Treatment selection with organoids in an EGFRm + TP53m stage IA1 patient with recurrence after radical surgery. <i>Journal of Thoracic Disease</i> , 2022, 14, 595-598.	0.6	0
2308	Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. <i>Diagnostics</i> , 2022, 12, 682.	1.3	2
2309	Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 83-93.	1.3	2
2310	Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a detail plateau in the survival curve of these patients?. <i>BMC Cancer</i> , 2022, 22, 323.	1.1	12
2311	A concise review on tyrosine kinase targeted cancer therapy. <i>Current Drug Therapy</i> , 2022, 17, .	0.2	1
2312	SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 703-711.	1.2	2
2313	A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 251-254.	1.0	0
2314	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1800-1808.	3.2	26
2315	Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100311.	0.6	2
2316	Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 276-283.	0.6	1
2317	Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	1
2318	Targeted therapy in lung cancer: Are we closing the gap in years of life lost?. <i>Cancer Medicine</i> , 2022, 11, 3417-3424.	1.3	7
2319	Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 858279.	1.6	11

#	ARTICLE	IF	CITATIONS
2320	Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. <i>ESMO Open</i> , 2022, 7, 100398.	2.0	7
2321	Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2022, 166, 170-177.	0.9	4
2322	Novel targeted therapies for advanced non-small lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 326-336.	0.8	9
2323	Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1170-1176.	1.0	7
2324	Targeting ALK Rearrangements in NSCLC: Current State of the Art. <i>Frontiers in Oncology</i> , 2022, 12, 863461.	1.3	15
2325	Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC. <i>Surgical Case Reports</i> , 2022, 8, 59.	0.2	1
2326	“The first ones now, will later be last” understanding the importance of historical context when reading ESMO-MCBS scores. <i>ESMO Open</i> , 2022, 7, 100413.	2.0	0
2327	Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study. <i>JTCVS Open</i> , 2022, 10, 370-381.	0.2	6
2328	Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. <i>European Journal of Cancer</i> , 2022, 166, 51-59.	1.3	14
2329	Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report. <i>Frontiers in Pharmacology</i> , 2021, 12, 809467.	1.6	3
2330	Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 739765.	1.3	6
2331	Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib. <i>Medicine (United States)</i> , 2021, 100, e27999.	0.4	1
2332	Efficacy of lorlatinib in the treatment of ALK-positive non-small cell lung cancer patients with progression on crizotinib: personal experience. <i>Meditinskiy Sovet</i> , 2021, , 62-67.	0.1	0
2333	Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment. <i>Cancers</i> , 2022, 14, 132.	1.7	3
2334	Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 3-16.	1.1	9
2335	Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5533-5542.	1.0	1
2337	A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatment. <i>Thoracic Cancer</i> , 2022, 13, 1558-1569.	0.8	5
2338	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 649-662.	4.9	15

#	ARTICLE	IF	CITATIONS
2340	Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations. <i>Cancer Research Communications</i> , 2022, 2, 277-285.	0.7	4
2341	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e577-e583.	1.8	0
2374	Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care. <i>American Journal of the Medical Sciences</i> , 2022, 364, 371-378.	0.4	2
2375	Protective autophagy decreases lorlatinib cytotoxicity through Foxo3a-dependent inhibition of apoptosis in NSCLC. <i>Cell Death Discovery</i> , 2022, 8, 221.	2.0	3
2376	Pulmonary embolism and bradycardia in a NSCLC patient treated with crizotinib for a rare mutation. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 211-217.	0.5	2
2398	Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. <i>Chinese Clinical Oncology</i> , 2015, 4, 37.	0.4	12
2399	Methodology of clinical trials in lung cancer. <i>Chinese Clinical Oncology</i> , 2015, 4, 44.	0.4	1
2401	Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?. <i>Lung India</i> , 2017, 34, 405.	0.3	3
2402	Clinical efficacy and safety of crizotinib and alectinib in ALK-positive non-small cell lung cancer treatment and predictive value of CEA and CA125 for treatment efficacy.. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13108-13116.	0.0	3
2403	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210927.	0.6	1
2404	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2022, 24, 1613-1646.	0.6	39
2405	Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 497-530.	2.3	530
2406	Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. <i>Science Advances</i> , 2022, 8, eabm6638.	4.7	17
2407	The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2nd/3rd-Generation ALK Tyrosine Kinase Inhibitors (TKIs). <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
2408	Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1495-1511.	1.2	9
2409	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1071-1083.	0.5	2
2410	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022, 12, 750.	1.1	13
2411	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514.	12.5	140

#	ARTICLE	IF	CITATIONS
2412	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor- $\beta$ 2 as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100576.	0.7	1
2413	Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
2414	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. <i>Cancers</i> , 2022, 14, 2202.	1.7	3
2416	Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase $\alpha$ -positive non $\alpha$ -small cell lung cancer. <i>Thoracic Cancer</i> , 2022, , .	0.8	2
2417	Principles of medical and oncological management of giant masses of the mediastinum: a narrative review. <i>Mediastinum</i> , 0, 6, 35-35.	0.6	2
2418	Special issue $\alpha$ “The advance of solid tumor research in China $\alpha$ ” Real $\alpha$ world clinical outcomes of alectinib for advanced non $\alpha$ -small $\alpha$ -cell lung cancer patients with $\langle$ sc $\rangle$ ALK $\langle$ /sc $\rangle$ fusion in China. <i>International Journal of Cancer</i> , 2022, , .	2.3	0
2419	Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. <i>Minerva Medica</i> , 2022, 113, 315-332.	0.3	3
2421	Alectinib versus crizotinib in $\langle$ sc $\rangle$ ALK $\langle$ /sc $\rangle$ $\alpha$ -positive advanced non $\alpha$ -small cell lung cancer and comparison of next $\alpha$ -generation $\langle$ sc $\rangle$ TKIs $\langle$ /sc $\rangle$ after crizotinib failure: Real $\alpha$ world evidence. <i>Cancer Medicine</i> , 2022, 11, 4491-4500.	1.3	7
2422	Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison. <i>Journal of Clinical Medicine</i> , 2022, 11, 2963.	1.0	3
2423	HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. <i>Lung Cancer</i> , 2022, 170, 1-10.	0.9	14
2424	Prevalence of highly actionable mutations among Indian patients with advanced non $\alpha$ -small cell lung cancer: A systematic review and meta $\alpha$ -analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 158-171.	0.7	0
2425	Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	0
2427	Evaluation of Lung Toxicity Related to the Treatment With Alectinib Using a Pharmacovigilance Database. <i>Anticancer Research</i> , 2022, 42, 3109-3116.	0.5	2
2428	Perioperative targeted therapy for oncogene-driven NSCLC. <i>Lung Cancer</i> , 2022, 172, 160-169.	0.9	15
2429	Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. <i>Current Medical Research and Opinion</i> , 2022, 38, 1369-1378.	0.9	0
2430	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	3
2432	ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise. , 2022, 19, .		0
2434	Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 376.	0.3	1

#	ARTICLE	IF	CITATIONS
2435	Modern treatment of ALK-positive non-small cell lung cancer. South Russian Journal of Cancer, 2022, 3, 41-51.	0.1	0
2436	Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget, 2022, 13, 812-827.	0.8	2
2437	Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
2438	Long-term disease control in a patient with ALK-positive non-small cell lung cancer. Meditsinskiy Sovet, 2022, , 172-177.	0.1	0
2439	Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer. Cancer Treatment Reviews, 2022, 109, 102430.	3.4	4
2440	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, , .	0.8	4
2441	Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncology, 0, , .	1.1	1
2442	EML4-ALK fusion gene in non-small cell lung cancer (Review). Oncology Letters, 2022, 24, .	0.8	20
2444	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer, 2022, 3, 710-722.	5.7	28
2445	ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance. Journal of Drug Targeting, 2022, 30, 845-857.	2.1	8
2446	ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario. Ecancermedalscience, 0, 16, .	0.6	2
2447	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	5.8	51
2448	Incidental discovery of acute myeloid leukemia during liquid biopsy of a lung cancer patient. Journal of Physical Education and Sports Management, 2022, 8, a006201.	0.5	2
2449	The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. The Showa University Journal of Medical Sciences, 2022, 34, 64-77.	0.1	0
2450	Ubenimex Combined with Pemetrexed Upregulates SOCS1 to Inhibit Lung Adenocarcinoma Progression via the JAK2-STAT3 Signaling Pathway. Disease Markers, 2022, 2022, 1-14.	0.6	0
2451	The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation. International Journal of Molecular Sciences, 2022, 23, 7322.	1.8	3
2452	State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan. International Journal of Molecular Sciences, 2022, 23, 7037.	1.8	5
2453	The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies. Journal of Thoracic Disease, 2022, 14, 2201-2212.	0.6	1

#	ARTICLE	IF	CITATIONS
2454	A pharmacological exploration of targeted drug therapy in non-small cell lung cancer. , 2022, 39, .		7
2455	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	0.6	8
2456	Treating advanced lung cancer in older veterans with comorbid conditions and frailty. Seminars in Oncology, 2022, , .	0.8	0
2457	Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. Clinical and Translational Oncology, 2022, 24, 2231-2240.	1.2	1
2458	Clinically-meaningful improvements in therapy for unresectable NSCLC. Expert Review of Anticancer Therapy, 2022, 22, 927-937.	1.1	6
2459	<i>KRAS</i> G12D mutation drives immune suppression and the primary resistance of antiâ€PDâ€1/PDâ€L1 immunotherapy in nonâ€small cell lung cancer. Cancer Communications, 2022, 42, 828-847.	3.7	29
2460	Synthesis, Î±-Glucosidase Inhibition, Anticancer, DFT and Molecular Docking Investigations of Pyrazole Hydrazone Derivatives. Polycyclic Aromatic Compounds, 2023, 43, 5021-5040.	1.4	11
2461	Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer. Lung Cancer, 2022, 171, 18-25.	0.9	2
2462	Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. Cancers, 2022, 14, 3452.	1.7	6
2463	Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations. Translational Oncology, 2022, 23, 101471.	1.7	3
2464	Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALKâ€Inhibitor-Naive ALK+ Nonâ€Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clinical Lung Cancer, 2022, 23, 720-730.	1.1	5
2465	Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer, 2022, 171, 103-114.	0.9	3
2466	Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	4
2467	Overexpression of 14-3-3Î¶ primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. Aging, 2022, 14, 5838-5854.	1.4	3
2468	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics, 2022, 12, 1799.	1.3	7
2469	Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clinical and Research Reports, 2022, 3, 100385.	0.6	3
2470	Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. Frontiers in Genetics, 0, 13, .	1.1	0
2471	Fibroblast growth factor receptor 3 overexpression mediates <sc>ALK</sc> inhibitor resistance in <sc>ALK</sc>-rearranged nonâ€small cell lung cancer. Cancer Science, 2022, 113, 3888-3900.	1.7	8

#	ARTICLE	IF	CITATIONS
2473	The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2474	Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
2475	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
2476	Panel Sequencing for Targeted Therapy Selection in Solid Tumors. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 309-323.	0.7	1
2477	Crizotinib attenuates cancer metastasis by inhibiting TGF $\beta$ <sup>2</sup> signaling in non-small cell lung cancer cells. <i>Experimental and Molecular Medicine</i> , 2022, 54, 1225-1235.	3.2	3
2478	Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
2479	QSAR, Molecular Docking, MD Simulation and MMGBSA Calculations Approaches to Recognize Concealed Pharmacophoric Features Requisite for the Optimization of ALK Tyrosine Kinase Inhibitors as Anticancer Leads. <i>Molecules</i> , 2022, 27, 4951.	1.7	9
2480	Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings. <i>South Asian Journal of Cancer</i> , 0, , .	0.2	1
2481	Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. <i>BMC Cancer</i> , 2022, 22, .	1.1	5
2482	Confirmation of lung adenocarcinoma as the primary cancer with detection of EML4-ALK rearrangement using next-generation sequencing: a case study. <i>Pathology Research and Practice</i> , 2022, 238, 154105.	1.0	1
2483	Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). <i>Lung Cancer</i> , 2022, 173, 83-93.	0.9	5
2484	Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. <i>Advanced Drug Delivery Reviews</i> , 2022, 190, 114525.	6.6	22
2485	Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling. <i>Toxicology in Vitro</i> , 2022, 85, 105471.	1.1	3
2486	Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211166.	1.4	3
2487	Translational Research in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2488	Targeted Therapies in Non-small Cell Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	1
2489	Genomic Alterations in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
2490	Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0



#	ARTICLE	IF	CITATIONS
2491	Combination of <sup>18</sup> F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Korean Journal of Radiology, 2022, 23, 921.	1.5	9
2492	Optimal Treatments for NSCLC Patients Harboring Primary or Acquired <i>MET</i> Amplification. Technology in Cancer Research and Treatment, 2022, 21, 153303382211284.	0.8	3
2493	Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report. Translational Cancer Research, 2022, 11, 2967-2972.	0.4	2
2494	Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments. Oncology Letters, 2022, 24, .	0.8	1
2495	Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report. Medicine (United States), 2022, 101, e30255.	0.4	0
2496	Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2023, 24, 40-50.	1.1	9
2497	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. Frontiers in Oncology, 0, 12, .	1.3	6
2498	ALK-positive locally advanced lung cancer in a patient who achieved long-term complete response with crizotinib: A case report. Experimental and Therapeutic Medicine, 2022, 24, .	0.8	1
2499	Non-small cell lung cancer in China. Cancer Communications, 2022, 42, 937-970.	3.7	129
2500	The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). Journal of Cancer Research and Clinical Oncology, 2023, 149, 4141-4148.	1.2	2
2501	<i>HER</i> inhibitors overcome lorlatinib resistance caused by <i>NRG1</i> / <i>HER3</i> activation in <i>ALK</i> -rearranged lung cancer. Cancer Science, 2023, 114, 164-173.	1.7	5
2502	Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment, 0, 9, 82-90.	0.2	0
2503	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. Cancers, 2022, 14, 4430.	1.7	7
2504	The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives. Cancers, 2022, 14, 4765.	1.7	10
2505	Image-Guided Biopsy. Advances in Clinical Radiology, 2022, 4, 13-24.	0.1	0
2506	Prediction of Resistance Mutations Against Upcoming Anaplastic Lymphoma Kinase Inhibitors. Targeted Oncology, 2022, 17, 695-707.	1.7	4
2507	Comparison of next-generation sequencing and cobas <i>EGFR</i> mutation test v2 in detecting <i>EGFR</i> mutations. Thoracic Cancer, 2022, 13, 3217-3224.	0.8	6
2508	Targeted therapy in oncology. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 222-228.	0.1	0

#	ARTICLE	IF	CITATIONS
2509	Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience. <i>Clinical Cancer Investigation Journal</i> , 2022, 11, 25-29.	0.2	1
2510	Emerging genetic biomarkers in lung adenocarcinoma. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211323.	0.7	1
2512	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
2515	Currently available molecular analyses for personalized tumor therapy (Review). <i>Biomedical Reports</i> , 2022, 17, .	0.9	3
2517	Landscape of the clinical development of China innovative anti-lung cancer drugs. , 2023, 1, 67-75.		2
2518	Biomarker-Targeted Therapies in Non-“Small Cell Lung Cancer: Current Status and Perspectives. <i>Cells</i> , 2022, 11, 3200.	1.8	15
2519	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
2520	Real-world ALK Testing Trends in Patients With Advanced Non-“Small-Cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2023, 24, e39-e49.	1.1	3
2521	Lorlatinib: new therapeutic options for ALK-positive patients. <i>Meditinskiy Sovet</i> , 0, , .	0.1	0
2522	Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. <i>Cancers</i> , 2022, 14, 4861.	1.7	1
2525	Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. <i>AboutOpen</i> , 0, 9, 92-104.	0.2	0
2526	Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. <i>Cancers</i> , 2022, 14, 5119.	1.7	0
2527	Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease. <i>Drugs in Context</i> , 0, 11, 1-16.	1.0	6
2528	Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2529	Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14324.	1.2	2
2530	The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. <i>Biochemical Pharmacology</i> , 2022, 205, 115294.	2.0	0
2531	Modeling the impact of novel systemic treatments on lung cancer screening benefits. <i>Cancer</i> , 2023, 129, 226-234.	2.0	1
2532	Drug Resistance in Lung Cancer. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
2533	Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing. <i>Cancer Research and Treatment</i> , 2023, 55, 488-497.	1.3	2
2534	MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13898.	1.8	9
2535	Regression of Lung Cancer in Mice by Intranasal Administration of SARS-CoV-2 Spike S1. <i>Cancers</i> , 2022, 14, 5648.	1.7	9
2536	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 906-920.	1.4	4
2537	Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study. <i>Acta Oncologica</i> , 2022, 61, 1354-1361.	0.8	2
2538	Octogenarians With Anaplastic Lymphoma Kinase-rearranged Non-small-cell Lung Cancer: A Case Series. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 711-715.	0.3	0
2539	Tyrosine-Kinase Inhibitors. , 2022, , 273-292.		0
2540	Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions. <i>Respiratory Medicine</i> , 2023, 206, 107093.	1.3	1
2541	Eficacia de los inhibidores de ALK en dos casos con evaluación positiva por inmunohistoquímica y negativa por FISH. , 2017, 22, .		0
2542	Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs). , 2024, , 915-946.		0
2543	Primary Signet-Ring Cell Carcinoma of the Lung: A Case Report: Diagnosis, Treatment and Literature Report. <i>Advances in Clinical Medicine</i> , 2022, 12, 10418-10422.	0.0	0
2544	Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2545	Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
2546	Is there a role for lung surgery in initially unresectable non-small cell lung cancer after tyrosine kinase inhibitor treatment?. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	0
2547	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. <i>Journal of Modern Oncology</i> , 2022, 24, 269-304.	0.1	2
2548	PI3K <sup>2</sup> inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer. <i>Molecular Oncology</i> , 2023, 17, 747-764.	2.1	2
2549	Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2550	Real-world treatment and prognostic factors for survival in ALK + non-small cell lung cancer ( NSCLC ) patients with brain metastases in China. <i>Thoracic Cancer</i> , 0, , .	0.8	1

#	ARTICLE	IF	CITATIONS
2551	Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit. <i>Annals of Oncology</i> , 2023, 34, 431-439.	0.6	7
2552	Validation of safety outcomes in routinely collected data: lessons learned from a multinational post-approval safety study. <i>Pharmacoepidemiology and Drug Safety</i> , 0, .	0.9	0
2553	Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors. <i>Cancers</i> , 2022, 14, 6101.	1.7	4
2554	Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors. <i>Cancer Management and Research</i> , 0, Volume 14, 3421-3435.	0.9	1
2555	Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. <i>Pulmonology</i> , 2023, 29, 478-485.	1.0	4
2556	An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 291-299.	0.9	1
2557	Current status and challenges of immunotherapy in ALK rearranged NSCLC. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
2558	Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	9
2559	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	8
2561	Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 29-41.	1.1	1
2562	Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations. <i>ESMO Open</i> , 2022, 7, 100742.	2.0	4
2563	Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. <i>Lancet Respiratory Medicine</i> , 2023, 11, 354-366.	5.2	43
2565	Unravelling the genetic links between Parkinson's disease and lung cancer. <i>Biological Chemistry</i> , 2023, 404, 551-567.	1.2	1
2566	Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country. <i>Cancer Management and Research</i> , 0, Volume 15, 31-41.	0.9	0
2567	Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
2568	At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 143-159.	12.5	29
2569	BRAF RNA is prognostic and widely expressed in lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2023, 12, 27-41.	1.3	2
2570	Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2023, 23, 900-921.	0.9	1

#	ARTICLE	IF	CITATIONS
2571	Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501). <i>Cancers</i> , 2023, 15, 204.	1.7	2
2572	Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort. <i>Translational Lung Cancer Research</i> , 2022, 11, 2495-2506.	1.3	1
2573	Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial. <i>Journal of Thoracic Disease</i> , 2022, 14, 4751-4762.	0.6	2
2574	Efficacy and safety of alectinib in ALK-positive non-small cell lung cancer and blood markers for prognosis and efficacy: a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 2521-2538.	1.3	2
2575	Autocrine <i>EGF</i> and <i>TGF-<math>\beta</math></i> promote primary and acquired resistance to <i>ALK</i> / <i>Met</i> kinase inhibitors in non-small cell lung cancer. <i>Pharmacology Research and Perspectives</i> , 2023, 11, .	1.1	2
2576	Targeting lung cancer brain metastases: a narrative review of emerging insights for anaplastic lymphoma kinase (ALK)-positive disease. <i>Translational Lung Cancer Research</i> , 2023, 12, 379-392.	1.3	2
2577	Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review. <i>Cardiology</i> , 2023, 148, 324-334.	0.6	1
2578	Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals <i>EGFR</i> Mutations to Be Associated With Longer Overall Survival. <i>JCO Precision Oncology</i> , 2023, , .	1.5	1
2579	Case Analysis of Cancer Patients Undergoing Genetic Testing in a General Hospital in Northern Shaanxi from 2017 to 2020. <i>Advances in Clinical Medicine</i> , 2023, 13, 1177-1184.	0.0	0
2580	Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 339-357.	0.6	118
2582	Efficacy of combined transbronchial lung cryobiopsy and conventional forceps biopsy for lung malignancies: a prospective cohort study. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
2583	Multiple cardiotoxicities during osimertinib therapy. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522311643.	0.5	1
2584	Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and <i>meta-analysis</i> . <i>Cancer Medicine</i> , 2023, 12, 13873-13884.	1.3	0
2585	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, , .	0.9	0
2586	The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report. <i>Lung Cancer</i> , 2023, 180, 107188.	0.9	2
2587	<i>ROS1</i> as a possible prognostic biomarker of cervical adenocarcinoma: An exploratory analysis with next-generation sequencing. <i>Gynecologic Oncology</i> , 2023, 171, 59-66.	0.6	2
2589	Clinically relevant fusion oncogenes: detection and practical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211441.	1.4	8
2590	Advances in Targeted Therapy Against Driver Mutations and Epigenetic Alterations in Non-Small Cell Lung Cancer. <i>Oncologie</i> , 2022, 24, 613-648.	0.2	8

#	ARTICLE	IF	CITATIONS
2591	Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2242.	1.8	5
2592	Precision Oncology: Grundlagen und Klassifikationen. <i>Springer Reference Medizin</i> , 2022, , 1-7.	0.0	0
2593	Extended Survival in Patients With Non-“Small-Cell Lung Cancer”-Associated Brain Metastases in the Modern Era. <i>Neurosurgery</i> , 2023, 93, 50-59.	0.6	1
2594	Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review. <i>Anti-Cancer Drugs</i> , 2023, 34, 699-706.	0.7	0
2595	Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. <i>Biomedicines</i> , 2023, 11, 448.	1.4	7
2596	Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-“small cell cancer: A systematic review and network meta-analysis. <i>Cancer</i> , 2023, 129, 1261-1275.	2.0	5
2597	Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. <i>Swiss Medical Weekly</i> , 2023, 153, 40039.	0.8	0
2598	Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. <i>Lung Cancer</i> , 2023, 178, 57-65.	0.9	1
2599	Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
2600	Renal cyst formation complicating ALK inhibitors. <i>Journal of Onco-Nephrology</i> , 0, , 239936932311513.	0.3	0
2601	The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC. <i>International Immunopharmacology</i> , 2023, 116, 109787.	1.7	1
2602	The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review. <i>Radiologia Medica</i> , 2023, 128, 316-329.	4.7	5
2604	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
2605	Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 16, 109-114.	1.0	2
2606	Rare molecular subtypes of lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 229-249.	12.5	20
2607	The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. <i>International Immunopharmacology</i> , 2023, 117, 109895.	1.7	3
2608	Kinome inhibition states and multiomics data enable prediction of cell viability in diverse cancer types. <i>PLoS Computational Biology</i> , 2023, 19, e1010888.	1.5	1
2609	Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement. <i>Cancer Imaging</i> , 2023, 23, .	1.2	0

#	ARTICLE	IF	CITATIONS
2610	Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT). <i>BMC Medicine</i> , 2023, 21, .	2.3	7
2611	Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	11
2612	LOREALAUS: Lorlatinib REAL-World AUSTRalian Experience in Advanced ALK-Rearranged NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100490.	0.6	0
2613	Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancerâ€”current status and future directions. <i>Translational Lung Cancer Research</i> , 2023, 12, 322-336.	1.3	1
2614	Optimal first-line treatment for metastatic ALK+ non-small cell lung cancerâ€”a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 369-378.	1.3	3
2615	Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations. <i>Translational Lung Cancer Research</i> , 2023, 12, 219-229.	1.3	1
2616	Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. <i>Frontiers of Medicine</i> , 2023, 17, 18-42.	1.5	8
2617	Real-World Data on EGFR and ALK Testing and TKI Usage in Norwayâ€”A Nation-Wide Population Study. <i>Cancers</i> , 2023, 15, 1505.	1.7	4
2618	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1276-1285.	0.6	0
2619	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103954.	2.0	3
2620	Asian Subgroup Analysis of the Randomized PhaseÂ³ CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100499.	0.6	1
2621	Multisystem ALK-positive histiocytosis: a multi-case study and literature review. <i>Orphanet Journal of Rare Diseases</i> , 2023, 18, .	1.2	4
2622	Efficacy and safety of anaplastic lymphoma kinase inhibitors for nonâ€”small cell lung cancer: A systematic review and network metaâ€”analysis. <i>Thoracic Cancer</i> , 2023, 14, 929-939.	0.8	3
2623	Mechanisms of cancer-associated thrombosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2023, 7, 100123.	1.0	4
2624	Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
2625	Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics. <i>Thyroid</i> , 2023, 33, 682-690.	2.4	6
2626	NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. <i>Diagnostics</i> , 2023, 13, 1117.	1.3	1
2627	Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
2628	Safety analysis of antineoplastic drugs for lung cancer: a retrospective analysis based on Shaanxi Province in Western China. <i>Expert Opinion on Drug Safety</i> , 2024, 23, 99-105.	1.0	1
2629	Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5821.	1.8	3
2630	Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. <i>Clinical Lung Cancer</i> , 2023, 24, 467-473.	1.1	2
2631	Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5858.	1.8	4
2632	ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report. <i>Cureus</i> , 2023, , .	0.2	0
2633	Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 837-856.	1.3	4
2634	Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	8
2635	Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC. <i>Discover Oncology</i> , 2023, 14, .	0.8	2
2636	New targeted therapies for non-small cell lung cancer. <i>Journal of the Korean Medical Association</i> , 2023, 66, 180-190.	0.1	0
2637	Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy — A retrospective planning study. <i>Physica Medica</i> , 2023, 108, 102559.	0.4	0
2638	Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2023, 12, 895-908.	1.3	1
2639	The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2023, , .	0.6	0
2640	lruplinalkib (WXâ€™0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer. <i>Investigational New Drugs</i> , 2023, 41, 254-266.	1.2	6
2641	The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages. <i>Cancers</i> , 2023, 15, 2250.	1.7	17
2642	Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
2643	Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	2
2644	Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults. <i>BMC Cancer</i> , 2023, 23, .	1.1	1
2645	CodeBreak 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code. <i>Lung Cancer: Targets and Therapy</i> , 0, Volume 14, 31-39.	1.3	0



#	ARTICLE	IF	CITATIONS
2646	Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer. <i>Diagnostic Cytopathology</i> , 2023, 51, 397-405.	0.5	0
2647	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceuticals</i> , 2023, 16, 614.	1.7	18
2656	Epigenetic therapy in lung cancer. , 2023, , 237-274.		0
2692	Evaluation des Nutzens. , 2023, , 37-179.		0
2694	The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation. <i>Methods in Molecular Biology</i> , 2023, , 145-163.	0.4	1
2697	Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer. , 2023, , .		0
2699	Precision Oncology: Grundlagen und Klassifikationen. <i>Springer Reference Medizin</i> , 2023, , 1321-1327.	0.0	0
2718	Diagnosis and treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer. , 2024, , 253-268.		0
2721	Insight into Intratumoral Heterogeneity Through Single CTC Sequencing and CDX Analysis. <i>Current Cancer Research</i> , 2023, , 301-325.	0.2	0
2731	Non-surgical Cancer Treatments. , 2023, , 131-147.		0
2746	What Is the Clinical Course of Pediatric Cancers?. , 2023, , 333-344.		0
2768	Veränderungen der Mukosa " verschiedene Lokalisationen. , 2023, , 129-177.		0
2776	Case report: Rare presentation of double primary malignancies of the lung and thyroid: a difficult diagnosis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0